Drug, bio-affecting and body treating compositions inventions 09/08

20080233046 - Trefoil factor 3 (tff3) as a target for anti-cancer therapy: The present invention is directed to methods of treating and preventing cancer, such as cancer characterized by differential expression of trefoil factor 3 (TFF3). The methods include administering to a patient an agent that modulates TFF3 activity or expression. The present invention is further directed to reducing the physiological effects... Agent: Novartis Vaccines And Diagnostics Inc.

20080233047 - Symmetric and asymmetric halogen-containing metallocarboranylporphyrins and uses thereof: The present invention is directed to low toxicity boronated compounds and methods for their use in the treatment, visualization, and diagnosis of tumors. More specifically, the present invention is directed to low toxicity halogenated, carborane-containing 5,10,15,20-tetraphenylporphyrin compounds and methods for their use particularly in boron neutron capture therapy (BNCT) and... Agent: Brookhaven Science Associates/ Brookhaven National Laboratory

20080233048 - Oral preparation useful in measurement capacity to metabolize pyridine: An object of the present invention is to provide an oral preparation that can be used to diagnose the existence or degree of pyridine metabolic capacity disorder, pyrimidine metabolic rate, etc., with high accuracy and with little variation due to individual differences. The oral preparation is prepared using a powder... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080233049 - Agents and methods for early diagnosis and monitoring of alzheimer's disease and other neurological disorders: This invention is in the fields of medicine and neurology, and relates to methods and agents for early diagnosis and monitoring of Alzheimer's disease and other neurological disorders. More particularly, the present invention provides the method for evaluating the health of central nervous system neurons in a human patient, comprising... Agent: Knobbe Martens Olson & Bear LLP

20080233052 - Contrast agents: The present invention relates to particles comprising cores of tungsten or tungsten in mixture with other metallic elements wherein said cores are coated and have an average size of at least 20 nm. Further, the invention relates to pharmaceuticals containing such particles, and to the use of such pharmaceuticals specifically... Agent: Ge Healthcare, Inc.

20080233050 - Diagnostic and therapeutic optical agents: Disclosed herein are compounds that may be characterized by some as cyanine and indocyanine dye bioconjugates. Compounds disclosed herein may be utilized (e.g., in the form of a pharmaceutically acceptable composition) in a number of medical procedures, such as in the visualization and detection of tumors.... Agent: Mallinckrodt Inc.

20080233051 - Nanoparticles for two-photon activated photodynamic therapy and imaging: The present invention provides organically modified silica (ORMOSIL) nanoparticles into which have been incorporated two-photon absorption dye molecules. The two photon absorption dye displays a unique aggregation induced fluorescence enhancement behavior. As a result ORMOSIL nanoparticles with high amounts of the dye can be prepared. These particles can be used... Agent: Hodgson Russ LLP The Guaranty Building

20080233053 - Method and device for ophthalmic administration of active pharmaceutical ingredients: Disclosed is the use of a mist of a pharmaceutical composition for ophthalmic delivery of a protein or peptide active pharmaceutical ingredient, a related method of treatment and a device useful in implementing the use and method. Disclosed is also the use of a mist for ophthalmic delivery of a... Agent: Martin D. Moynihan Prtsi

20080233054 - Dental anti-hypersensitivity composition and method: The present invention relates to compositions and methods for calcifying dental tissue, e.g., preventing or treating dental hypersensitivity. An oral composition of arginine bicarbonate and calcium carbonate promotes the formation of dentinal tubule plugs aided by combining calcium and phosphate in the fluid. In a specific example, an arginine bicarbonate/calcium... Agent: Darby & Darby P.C.

20080233055 - Flavored oral care strip: An oral care strip includes a substrate having a first side and a second side. An oral care substance is disposed on the first side and a flavor element is attached to the second side. The flavor element may be a dissolvable, edible, flavored film. A method for forming the... Agent: Warner Norcross & Judd LLP

20080233057 - Mild cleansing compositions: Mild cleansing compositions comprising anionic, nonionic and/or amphoteric surfactants, one or more dyes having a total color, and one or more encapsulated dyes, including microencapsulated dyes, in microcapsules prepared by coacervation, precipitation, polycondensation or other reaction of anionic and cationic components, which encapsulated dyes have a total color different from... Agent: Synnestvedt & Lechner LLP

20080233056 - Organoleptic compounds with enhanced properties: wherein a, b and c are integers independently selected from 0 and 1. Z is a member selected from a sterol, a tocopherol, a ubiquinol and derivatives or homologues thereof. Y1 and Y2 are hydrophilic moieties, which are members independently selected from polyethers, polyalcohols and derivatives thereof, and L1 and... Agent: Morgan, Lewis & Bockius LLP (sf)

20080233058 - Oral care compositions with film forming polymers: In various embodiments, such polymers comprise monomeric units such as acrylic acid, methacrylic acid, acrylates, and combinations thereof. In one embodiment, the film forming polymer comprises a copolymer of a first monomeric unit selected from the group consisting of acrylic acid, methacrylic acid, and combinations thereof, with a second monomeric... Agent: Colgate-palmolive Company

20080233062 - Cationic latex as a carrier for active ingredients and methods for making and using the same: This invention relates to the field of polymeric materials that can be used in combination with a wide variety of substrates, such as textiles, metal, cellulosic materials, plastics, and the like, and to the field of active agents including, for example, antimicrobial, antibacterial, and antifungal materials. This invention further relates... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080233060 - High spf transparent or translucent, cytoprotective, biodegradable, uv radiation resistant compositions: A composition comprising purified water using ozonation, ionization, or distillation or any combination thereof wherein alcohol may be substituted for, or combined with water at least one emollient including but not limited to chitosan, and aloe vera gel, individually or in any combination; an oil component with spf boosting agents... Agent: Guerry Leonard Grune

20080233059 - Process for the direct manufacture of polyglycerol polyricinoleate: A process for manufacturing polymers of glycerin and hydroxyl fatty acids, for example, polyglycerol polyricinoleates, which mix a polyglycerol with a hydroxyl fatty acid directly to form a reaction mixture, and then heat the reaction mixture to a temperature sufficient to cause it to polymerize through an esterification mechanism until... Agent: Stepan Company C/o Mcandrews Held & Malloy

20080233061 - Structured surfactant compositions: p

20080233063 - Lustrous and scratch-resistant nail varnish through addition of sol-gel systems: The present invention relates to, for example, a nail varnish additive, a nail varnish additive composition for improving at least one property of nail varnishes, the nail varnish additive composition being, in one embodiment, in the form of a sol-gel system; to a process for forming a nail varnish additive... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080233064 - High shine, stick-shaped comsmetic products: The present invention provides a cosmetic composition having a gloss of at least about 85 gloss units (gu), as well as sufficient shape retention properties for forming a stick-shaped cosmetic product. Specifically, the cosmetic composition contains: (a) a high viscosity oil component; (b) a medium viscosity oil component; (c) a... Agent: Mimi Yang

20080233065 - Stable cosmetic emulsion with polyamide gelling agent: The present invention relates to a gelled cosmetic emulsion comprising an oil phase, an aqueous phase and a gelling system which contains a polyamide resin containing a linking hetero-atom with a certain electronegativity in a sufficient amount to gel the emulsion, and a resin stabilizer containing an atom with a... Agent: The Estee Lauder Cos, Inc

20080233067 - Method of making enhanced efficacy antiperspirant actives: This invention comprises: (1) a wet grinding method for enhancing the activity of an aluminum or an aluminum/zirconium salt without the dilution and heating traditionally required wherein the enhancement is described as forming a salt wherein the amount of smaller aluminum species as represented by Peak 4+Peak 5 is increased... Agent: Colgate-palmolive Company

20080233066 - Transparent cosmetic or dermatological formulation: The invention relates to a clear, cosmetic and dermatological formulation having reduced stickiness, comprising at least one antiperspirant active ingredient and/or deodorant active ingredient, at least one α-hydroxycarboxylic acid and water.... Agent: Greenblum & Bernstein, P.L.C

20080233068 - Oxidative hair dyes and related topical compositions: An oxidative hair dye system comprises a hair dye, an organometallic compound and an oxidising agent. The organometallic compound is preferably an organotitanate compound, particularly a tetraalkyl titanate or a titanate chelate. Such compounds are also useful for enhancing the substantivity of topical compositions applied to the body, which comprise... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080233069 - Multi-purpose polymers, methods and compositions: Disclosed are multi-purpose polymers that are the polymerization product of a monomer mixture comprising at least one amino-substituted vinyl monomer; at least one nonionic vinyl monomer; at least one associative vinyl monomer; at least one semihydrophobic vinyl surfactant monomer; and, optionally, comprising one or more hydroxy-substituted nonionic vinyl monomer, crosslinking... Agent: Legal Department Lubrizol Advanced Materials, Inc

20080233072 - Process and kit-of-parts for improved hair conditioning after coloring, bleaching or perming: The present invention relates to the field of hair care. More specifically, the present invention relates to the conditioning of hair after it has been oxidised in a coloring, bleaching or perming treatment. Superior conditioning is obtained by providing a cationic polymer to the hair while it is subjected to... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080233071 - Pulverulent styling composition: A pulverulent composition comprising 50 to 95% by weight of an aqueous solvent, hydrophobicized silicon dioxide powder and at least one film-forming and/or setting polymer for the temporary shaping of keratin fibers and a corresponding pulverulent styling composition. Upon mechanical stress, the powder releases the solvent and the film-forming and/or... Agent: Paul & Paul

20080233070 - Hair treatment compositions: Aqueous hair treatment compositions which comprise a mono C14-C22 trimethylammonium surfactant, a di-(C20-C24) imidazoline quaternary surfactant, and a mono C12-C22 alkyl hydroxyethyl dimethylammonium surfactant provide improved hair conditioning benefits.... Agent: Unilever Patent Group

20080233074 - Composition and method for dry cow udder protection: A composition for dry cow udder protection includes a bimodal interpenetrating polymer system having both cationic and anionic functionalities and capable of forming a stable aqueous solution and ionic bonds between polar chains. The bimodal inter-penetrating polymer system, preferably, includes two acrylate copolymers, Polyacrylate-18 and Polyacrylate-19. The bimodal interpenetrating polymer... Agent: Edwin D. Schindler

20080233075 - Cosmetic composition for skin tightening: The present invention provides a topical composition that contains a water-soluble film-forming polymer, a bimodal copolymer comprising a first polymeric component with anionic functional groups and a second polymeric component with cationic functional groups, and one or more biological polymers that are derived from a source selected from the group... Agent: Mimi Yang

20080233077 - Cosmetic use of a particular copolymer as skin tensor in a cosmetic composition: The present invention relates to the cosmetic use, as a skin-tensioning agent in a cosmetic composition, of a copolymer comprising units derived from styrene and units derived from ethyl (meth)acrylate, in which the weight ratio between the units derived from styrene and the units derived from ethyl (meth)acrylate is greater... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080233076 - Process for stabilizing ascorbic acid compositions: The present invention relates to a process for inhibiting radical-induced damage to skin involving contacting the skin with a composition containing: a) ascorbic acid and/or a water soluble derivative thereof; b) at least one cinnamic acid derivative; c) water; d) at least one non-aqueous organic solvent; e) at least one... Agent: L'oreal Usa/ Patent Department

20080233073 - Ion binding polymers and uses thereof: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the... Agent: Senniger Powers LLP

20080233078 - Therapeutic polyesters and polyamides: Polymers (i.e. polyesters, polyamides, and polythioesters or a mixture thereof) which degrade hydrolytically into biologically active compounds are provided. Methods of producing these polymers, intermediates useful for preparing these polymers, and methods of using these polymers to deliver biologically active compounds to a host are also provided.... Agent: Viksnins Harris & Padys Pllp

20080233079 - Crosslinked amine polymers: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides polymeric and pharmaceutical compositions comprising crosslinked amine polymers. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment... Agent: Senniger Powers LLP (ilps)

20080233080 - Inulins, levans, fructans and other smaller-than-cellulose termite feeding attractants, and termite: The present invention discloses Resistance Management (RM) practices that are critical to safeguarding Bacillus thuringiensis as a natural resource and to sustaining genetically modified crops that express Bt toxins for managing ECB and WCRW. The methods involve blending seed transformed with a nucleic acid encoding a different pesticidal protein, where... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20080233084 - Interleukin-8 labelled via one or more site specifically conjugated hydrazinonicotinamide (hynic) moieties and its use in diagnosis of infection and inflammation: Interleukin-8, or an analog or derivative thereof, labelled via one or more hydrazinonicotinamide (HYNIC) moieties site-specifically conjugated to one or 5 more internal lysines and/or an N-terminal amino acid, for use in diagnosis of infection and inflammation.... Agent: Mallinckrodt Inc.

20080233083 - Methods and compositions for vaccination of animals with prrsv antigens with improved immunogenicity: Pigs challenged with hypoglycosylated variants of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) major surface protein GP5 exhibited increased production of PRRSV-neutralizing antibodies relative to the levels of neurtalizing antibodies produced by pigs immunized with wild type (wt) or glycosylated GP5. This invention provides for methods of obtaining improved immune... Agent: Thompson Coburn, LLP

20080233082 - Polymer with ability to signal the recruitment of vascular progenitor cells: The present invention provides polymeric compositions, devices, and methods for repair of vascular injury, particularly endothelial injury and impaired vascular repair, such as from intracranial aneurysms and carotid atherosclerosis. The invention particularly provides polymers incorporating signaling factors useful for recruiting circulating vascular progenitor cells. The polymers can be used alone... Agent: Alston & Bird LLP

20080233081 - Pro-angiogenic peptides: This present invention generally relates to peptides, compositions, treatment methods, and devices useful for the medical diagnosis and treatment of pathogenic disorders. More specifically, the invention relates to immunostimulatory peptides which can stimulate the production of therapeutically beneficial cytokines. The peptides of the invention can regulate the release of a... Agent: Schmeiser Olsen & Watts

20080233085 - Use of il-18bp isoforms for the treatment and/or prevention of neurological inflammatory diseases: The invention relates to the use of an IL18-BP isoform that does not bind to IL18, or of an agonist thereof, for treatment or prevention of a neurological and/or inflammatory disease. Preferred isoforms for use in the frame of the invention include IL-18BPb and IL-18BPd.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080233086 - Expression vectors for treating bacterial infections: The present invention is compositions and methods for producing anti-bacterial polypeptides, and for using those compositions and methods for treating diseases and conditions caused by a bacterial infection. More specifically, the compositions and methods include treating a gram-negative bacterium with a gram-positive host that produces a polypeptide effective against the... Agent: William J Bundren The Law Office Of William J Bundren

20080233090 - Method of treatment by administration of rna: A method of effecting a treatment response in a target tissue of a subject, comprising: administering to the subject isolated RNA comprising an RNA sequence extractable or extracted from a source tissue such that said treatment response is effected; wherein the RNA is isolated polyA positive RNA in substantially pure... Agent: Woodcock Washburn LLP

20080233089 - Modified cells expressing a protein that modulates activity of bhlh proteins, and uses thereof: The present invention relates to modified cells carrying a heterologous gene sequence encoding a protein, such as an Inhibitor of differentiation (Id) gene sequence that binds a basic helix-loop-helix (bHLH) protein to inhibit cell growth, differentiation and/or tumorigenesis of the modified cells. The modified cells are differentiated, proliferate and do... Agent: Mandel & Adriano

20080233092 - Methods and compositions for treating lactose intolerance: The invention provides methods and compositions for treating lactose intolerance. In embodiments, the invention provides methods and composition for decreasing symptoms of lactose intolerance by administering to an individual suffering from lactose intolerance increasing doses of lactose using a protocol such that at the end of treatment the individual's symptoms... Agent: Wilson Sonsini Goodrich & Rosati

20080233093 - Preventing and reducing biofilm formation and planktonic proliferation: The present invention relates to methods for preventing and/or reducing biofilm formation and/or planktonic proliferation with one or more selected bacteria strains or bacterial blends.... Agent: Novozymes North America, Inc.

20080233094 - Attenuated salmonella enterica serovar paratyphi a and uses thereof: The present invention is drawn to a live, attenuated S. Paratyphi A strain, a live, attenuated S. Paratyphi A strain comprising a stabilized plasmid expression system, and methods of using these strains.... Agent: Sughrue Mion, PLLC

20080233087 - Methods for identifying, isolating, and utilizing endocrine progenitor cells from adult human pancreata: The presence of the cell surface marker CD133 or the presence of a glycosylated form of the prominin-1 gene product on adult pancreatic cells is used to identify pancreatic endocrine progenitor cells, and useful in methods of isolation and enrichment. Isolated pancreatic endocrine progenitor cells can be used for cell... Agent: Pearl Cohen Zedek Latzer, LLP

20080233088 - Preparative regimen for engraftment, growth and differentiation of non-hematopoeitic cells in vivo after transplantation: The invention relates to methods of obtaining an expanded population of mammalian ex vivo cells and/or for treating a mammalian subject by (a) administering to a subject an effective amount of an agent that confers a growth disadvantage to at least a subset of endogenous cells at the site of... Agent: Townsend And Townsend And Crew LLP (varian)

20080233095 - Method for obtaining antigen-specific tr1 regulatory lymphocytes: The invention relates to a method for preparing antigen-specific Tr1 regulatory lymphocytes. The inventive method involves the use of artificial antigen-presenting cells, expressing a molecule from the HLA class II system and a human LFA-3 molecule and expressing none of the B7-1, B7-2, B7-H1, CD40, CD23 or ICAM-1 costimulation molecules.... Agent: Young & Thompson

20080233096 - Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels: A method of reducing extracellular brain glutamate levels. The method comprises administering to a subject in need thereof a therapeutically effective amount of an agent capable of reducing blood glutamate levels thereby reducing extracellular brain glutamate levels.... Agent: Martin D. Moynihan Prtsi, Inc.

20080233099 - Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels: A method of reducing extracellular brain glutamate levels. The method comprises administering to a subject in need thereof a therapeutically effective amount of an agent capable of reducing blood glutamate levels thereby reducing extracellular brain glutamate levels.... Agent: Martin D. Moynihan Prtsi, Inc.

20080233097 - Phosphorylation site of mitogen-activated protein kinases, modified proteins and applications: A new phosphorylation site of mitogen-activated kinase proteins (MAPK) has been found. Phosphorylated MAPKs in said phosphorylation site can be used as a diagnostic marker of pathologies mediated by MAPKs.... Agent: Intellectual Property / Technology Law

20080233098 - Rho family antagonists and their use to block inhibition of neurite outgrowth: The invention relates to an antagonist of one or more of Rho family members having ability to elicit neurite outgrowth from cultured neurons in an assay method which includes culturing neurons on a substrate that incorporates a growth-inhibiting amount of Rho family member and exposing the cultured neurons to a... Agent: Fish & Richardson P.C.

20080233100 - Targeted enzymes: The present invention provides targeted enzymes that bind to targets better than the corresponding pre-targeted enzymes bind the target under like conditions, methods of making targeted enzymes, methods of using targeted enzymes to treat diseases, and pharmaceutical compositions comprising targeted enzymes.... Agent: Danisco US Inc., Genencor Division

20080233101 - Rna-mediated epigenetic regulation of gene transcription: The invention provides a method of regulating transcription of a gene that is a target for an epigenetic regulator; a method of characterizing the transcriptional activity of such a gene; a method of screening for a chromosomal element (CE) for an epigenetic regulator of a target gene; an isolated complex... Agent: Beyer Weaver LLP

20080233102 - Drug therapy for celiac sprue: Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.... Agent: Bozicevic, Field & Francis LLP

20080233103 - Mycobacterial peptide deformylase: The present invention relates to the design of the Antisense-oligonucleotide complementary to the specific region of peptide deformylase gene from Mycobacterium tuberculosis. The use of this Antisense-oligonucleotide on mycobacterial culture inhibits the production of the peptide deformylase enzyme by hybridizing within the region, which is found to be responsible for... Agent: Harness, Dickey & Pierce, P.L.C

20080233091 - Use of probiotic bacteria in the treatment of infection: The invention relates to the live cultures of probiotic bacteria to treat infectious diseases in humans and animals. Food-grade or non-pathogenic cultures are used to treat localised infections.... Agent: Young & Thompson

20080233104 - Probiotic, lactic acid-producing bacteria and uses thereof: The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant... Agent: Ivor R. Elrifi Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20080233105 - Compositions and methods for preventing or treating a viral infection: The present invention is a composition for enhancing the immunogenicity of viral vaccine. The composition encompasses a viral vaccine in combination with at least one toll-like receptor and, in particular embodiments, an anti-CD40 antibody. The compositions of the instant invention find application in the prevention or treatment of a viral... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20080233111 - Human receptor proteins; related reagents and methods: Nucleic acids encoding mammalian, e.g., primate or rodent receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.... Agent: Dnax Research Inc. Legal Department

20080233110 - Intrabodies with defined framework that is stable in a reducing environment and applications thereof: A method for the isolation of CDRs in a defined framework that is stable and soluble in reducing environment is described as well as thus obtainable scFv. Starting from such scFv with defined framework a scFv library can be generated wherein the framework is conserved while at least one complementary... Agent: Marshall, Gerstein & Borun LLP

20080233106 - Markers for labour: The invention relates to markers which find use in the diagnosis of labour or pre-term labour, to assays comprising such markers, to methods of identifying therapeutic agents which can prolong pregnancy, using these markers and to methods of treatment of pre-term labour, methods of prolonging gestation, or methods of suppressing... Agent: Wolf Greenfield & Sacks, P.C.

20080233108 - Methods for detecting and inhibiting angiogenesis using antagonists: The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the... Agent: Townsend And Townsend And Crew, LLP

20080233107 - Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally sensitive transmembrane peptide: A polypeptide with a predominantly hydrophobic sequence long enough to span a membrane lipid bilayer as a transmembrane helix (TM) and comprising one or more dissociable groups inserts across a membrane spontaneously in a pH-dependant fashion placing one terminus inside cell. The polypeptide conjugated with various functional moieties delivers and... Agent: Gauthier & Connors, LLP

20080233109 - Transgenic mammal carrying ganp gene transferred thereinto and utilization thereof: It is an object of the present invention to provide a high affinity antibody effective as a diagnostic or therapeutic for various diseases; a transgenic mammal for producing the high affinity antibody; and a medicine comprising the high affinity antibody or a cell producing the high affinity antibody. According to... Agent: Birch Stewart Kolasch & Birch

20080233112 - Treatment of diseases: Methods of treatment of various non-demyelinating and demyelinating neural disorders are provided, comprising administering a serum composition obtained from a goat after challenge with an immunogen. Also provided are methods of treatment of certain autommune disorders using such a composition.... Agent: Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein

20080233115 - Anti-il-20 antibodies and binding partners and methods of using in inflammation: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-20 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. The present invention includes anti-IL-20 and anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-20 using... Agent: Zymogenetics, Inc. Intellectual Property Department

20080233116 - Human monoclonal antibodies to ctla-4: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within... Agent: Ropes & Gray LLP

20080233113 - Method of inhibiting complement activation with human anti-factor c3 antibodies and use thereof: A method of inhibiting complement activation mediated by C3b inhibitors in a subject includes administering a C3B inhibitor to the subject to inhibit at least one of C3b binding to factors B and properdin, inhibit C3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20080233114 - Novel fgf homologs: The present invention relates to polynucleotide and polypeptide molecules for zFGF5 a novel member of the FGF family. The polypeptides, and polynucleotides encoding them, are proliferative for muscle cells, in particular cardiac cells and may be used for remodeling cardiac tissue and improving cardiac function. The present invention also includes... Agent: Zymogenetics, Inc. Intellectual Property Department

20080233117 - Reducing tumor growth: This document provides methods and materials for reducing tumor growth in a mammal. For example, methods and materials for using PLVAP inhibitors to reduce tumor growth in a mammal (e.g., a human) are provided.... Agent: Fish & Richardson P.C.

20080233118 - Uses of antibody to m-csf: Methods of using M-CSF antibodies to treat macrophage-associated diseases including atherosclerosis and HIV are provided.... Agent: Marshall, Gerstein & Borun LLP

20080233120 - Anti-p53 antibodies: The present invention relates to nucleotide sequences which encode polypeptides of antibodies against the p53 protein in vertebrates, and to die polypeptides and antibodies (or fragments thereof) encoded by those nucleotide sequences. The invention also relates to nucleotide sequences and polypeptide sequences for use in the development of diagnostic and... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080233122 - Human monoclonal antibodies to ctla-4: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within... Agent: Ropes & Gray LLP

20080233121 - Therapeutic treatments based on administration of small rna fragments: This invention provides therapeutic treatments that prevent or ameliorate thrombocytopenia based on administration of small RNA fragments. More specifically, this invention provides an improved chemotherapeutic regimen that prevents or ameliorates bone marrow suppression and thrombocytopenia induced by anti-cancer drugs, wherein the chemotherapeutic regimen incorporates administration of small RNA fragments. Further,... Agent: Scully Scott Murphy & Presser, PC

20080233119 - Compositions and methods for treating inflammatory lung disease: The invention provides a method of modulating a T cell immune response by modulating DR3 function in the T cell, wherein the T cell response causes a symptom of inflammatory lung disease. The invention also provides a method of treating a reactive airway disease in an animal subject by administering... Agent: Darby & Darby P.C.

20080233125 - Compositions and methods for inhibiting squamous cell carcinoma: The present invention relates to compositions and methods for detecting and inhibiting squamous cell carcinoma using agents that target the laminin 5 alpha 3 G4-G5 domain.... Agent: Bozicevic, Field & Francis LLP Stanford University Office Of Technology Licensing

20080233124 - Compositions and methods for the therapy and diagnosis of ovarian cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group PLLC

20080233126 - G proteins, polynucleotides encoding the same and utilization thereof: A novel protein (Gm1) includes an amino acid sequence part having a high homology with a domain having a high homology with a GTP binding site and a GTPase site conserved among G protein α subunits and a trimer forming domain conserved among G protein α subunits. The Gm1 protein... Agent: Panitch Schwarze Belisario & Nadel LLP

20080233123 - Polypeptide from haemophilus influenzae: The invention provides BASB203 polypeptides and polynucleotides encoding BASB203 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.... Agent: Ratner & Prestia- Sb Division

20080233127 - Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors: The present invention relates to Imidazolopyrimidine Analogs, methods of making Imidazolopyrimidine Analogs, compositions comprising an Imidazolopyrimidine Analog, and methods for treating or preventing a PI3K-related disorder comprising administering to a subject in need thereof an effective amount of an Imidazolopyrimidine Analog. The invention also relates to methods for treating or... Agent: Wyeth Patent Law Group

20080233128 - Treatment of viral infections: A method of treating viral infections comprises administering to a patient a regimen that is able to temporarily reduce the number or functionality of the host cells which the virus uses for its reproduction in a controlled manner. Preferably, host cells are part of the immune system.... Agent: Millen, White, Zelano & Branigan, P.C.

20080233130 - Ligand that has binding specificity for il-4 and/or il-13: The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080233129 - Ligand that has binding specificity for il-4 and/or ll-13: The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080233134 - Antibodies that specifically bind to chemokine beta-4: The present invention relates to antibodies and related molecules that specifically bind to CK-B4. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including cancers, as well as immune system diseases and disorders including autoimmune disease, inflammatory disorders,... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080233133 - Humanized collagen antibodies and related methods: The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic... Agent: Wilson Sonsini Goodrich & Rosati

20080233132 - Multiple sclerosis therapy: The present invention relates to methods for treating multiple sclerosis by combining immunotherapy with myelin repair.... Agent: Wilson Sonsini Goodrich & Rosati

20080233131 - Vaccine: The invention provides a method for generating anti-CD4 auto-antibodies comprising administering to an individual an anti-CD4 antibody molecule which has a low affinity for native CD4 in said individual or a protein or peptide comprising a CD4-like epitope, wherein administration of said antibody molecule, protein or peptide results in the... Agent: Fulbright & Jaworski, LLP

20080233135 - Cobalamin taxane bioconjugates: The present invention is directed to methods and compositions including a taxane covalently bonded to the cobalt atom of a cobalamin. The composition can be delivered by any effective route, but is particularly useful as an oral anti-cancer or antiangiogenic compound. The anti-cancer/anti-angiogenic compound can be used in various chemotherapies... Agent: Thorpe North & Western, LLP.

20080233136 - Biologically active peptides: Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced therefrom are also disclosed.... Agent: EagleIPLimited

20080233138 - Coccidiosis poultry vaccine: This invention relates to novel Eimeria proteins with immunogenic properties as well as to DNA sequences encoding these proteins. These proteins can be administered to poultry thereby protecting the birds against coccidiosis. In addition the DNA encoding these proteins can be used for the preparation of a vector vaccine against... Agent: Intervet/schering-plough Animal Health Patent Department

20080233139 - Compositions and methods for the therapy and diagnosis of prostate cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The... Agent: Seed Intellectual Property Law Group PLLC

20080233137 - Compounds that block the c5a receptor and their use in therapy: The present invention relates to compounds that are able to prevent intramolecular contact of the N-terminal residues 10 to 18 of human C5aR with the extracellular loops thereof. More specifically the invention relates to compounds that are able to bind the aspartates in positions 10, 15 and 18 and the... Agent: Morrison & Foerster LLP

20080233140 - Therapeutic applications of activation of human antigen-presenting cells through dectin-1: The present invention includes compositions and methods for binding Dectin-1 on immune cells with anti-Dectin-1-specific antibodies or fragment thereof capable of activating the immune cells.... Agent: Chalker Flores, LLP

20080233141 - Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection: This invention provides compositions including a chimera of papillomavirus capsid polypeptide L2 and polypeptide including an immunotherapeutic epitope, and GST fusions thereof. The present invention also provides complexes comprising chimeras of papillomavirus L2 polypeptides non-covalently associated with papillomavirus L1 polypeptides, and GST fusions thereof. These compositions may be used to... Agent: Faegre & Benson LLP Patent Docketing

20080233142 - Use of penetration enhancers and barrier disruption methods to enhance the immune response of an antigen: A transcutaneous immunization system where the topical application of an adjuvant and an antigen or nucleic acid encoding for an antigen, to intact skin induces a systemic or mucosol antibody response. The immune response so elicited can be enhanced by physical or chemical skin penetration enhancement.... Agent: Morgan Lewis & Bockius LLP

20080233143 - Adjuvanting material: The present invention provides an adjuvanting material, the adjuvanting material comprising a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group. Further, the present invention provides an immunogenic composition comprising (a) a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating... Agent: Davis Wright Tremaine, LLP/seattle

20080233145 - Pharmaceutical compositions comprising old man's beard (usnea barbata) and st. john's wort (hypericum perforatum) and their use: Pharmaceutical compositions of Usnea barbata and the use thereof for the treatment of skin diseases are disclosed. A preferred composition is the combination with an extract of Hypericum perforatum. The extracts are obtained by supercritical high-pressure extraction with spring carbon-dioxide. A preferred form of preparation is the homogenization of 6%... Agent: Smith Patent Consulting Consulting, LLC

20080233144 - Use of the mushroom agaricus blazei murill for the production of medicaments suitable for treating infections and allergies: The present invention concerns the use of the mushroom Agaricus blazei Murill for producing a medication for combating or preventing bacterial and non-bacterial infections (e.g. parasites or virus) in a mammal as well as combating or preventing allergy in mammals. Such an infection may e.g. be caused by pneumococci and... Agent: Ronald R. Santucci Frommer Lawrence & Haug

20080233146 - Promoter gene, recombinant turkey herpesvirus having the novel promoter gene, and poultry vaccine including the recombinant herpes virus of turkey: Promoter genes that are derived from Marek's disease virus (MDV). These promoter genes can express two foreign genes when inserted in a recombinant turkey herpesvirus (HVT). A recombinant HVT having said novel promoter gene between two foreign genes. The poultry vaccine consisting of the recombinant turkey herpesvirus described in the... Agent: Kratz, Quintos & Hanson, LLP

20080233147 - Circovirus sequences associated with piglet weight loss disease (pwd): The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a... Agent: Bingham Mccutchen LLP

20080233148 - Method of producing virus: It is intended to provide a safe and efficient method of producing a virus which is free from animal-origin components in the whole process from culturing adhesive cells to producing the virus on an industrial scale by the cell culture. Namely, a method of producing a virus comprising: adhering adhesive... Agent: Edwards Angell Palmer & Dodge LLP

20080233149 - Use of erythropoietin for enhancing immune responses and for treatment of lymphoproliferative disorders: The present invention relates to the use of erythropoietin (EPO) for enhancing immune responses and for the treatment of lymphoproliferative disorders, excluding multiple myeloma. Accordingly to the invention EPO may be administered with a viral or bacterial vaccine.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080233150 - Respiratory syncytial virus-virus like particle (vlps): The present invention discloses and claims virus like particles (VLPs) that express and/or contains RSV proteins. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080233152 - Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat: This invention relates to novel compositions of borulinum toxin that are stabilized using HIV-TAT fragments or derivatives of HIV-TAT fragments. The composition can be administered for various therapeutic, aesthetic and/or cosmetic purposes. The invention also provides method for stabilizing botulinum toxin using HIV-TAT fragments or derivatives or HIV-TAT fragments.... Agent: King & Spalding

20080233151 - Use of non-antibacterial tetracycline analogs and formulations thereof for the treatment of bacterial exotoxins: The invention relates to methods for protecting and/or treating a mammal at risk of acquiring a condition associated with bacteria that produce a calmodulin exotoxin, a metalloproteinase exotoxin, or both, by administering a non-antibacterial tetracycline formulation.... Agent: Hoffmann & Baron, LLP

20080233153 - Vaccine compositions and adjuvant: The immune response of an animal to a target immunogen may be enhanced by use of a novel adjuvant which includes low concentrations of killed cells of Mycobacterium avium subspecies avium in combination with mineral oil. The adjuvant may be used in vaccine compositions for the immunization of an animal... Agent: Usda-ars-office Of Technology Transfer National Ctr For Agricultural Utilization Research

20080233154 - Vaccine composition: The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are improved by one or more genetic changes to the... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080233155 - Compositions for antigen-specific induction of tolerance: The invention relates to an immunogenic composition for sublingual, perlingual or oral administration, comprising at least an antigen and at least an adjuvant that is a bacterium selected from a Bifidobacterium and a lactic acid bacterium, and/or a combination of a corticosteroid with vitamin D3 or any metabolite or analog... Agent: Stites & Harbison PLLC

20080233157 - Inhibiting surface enhanced crystallization of amorphous pharmaceuticals with ultrathin coatings: The present invention provides surface-stabilized amorphous pharmaceuticals comprising an amorphous pharmaceutical substrate coated with a biocompatible immobilizing material. Amorphous pharmaceutical substrates that are prone to surface enhanced crystallization benefit from the present coatings. The coated amorphous pharmaceuticals of the present invention maintain their amorphous state and, therefore, their solubility over... Agent: Foley & Lardner LLP

20080233156 - Pharmaceutical compositions: Provided herein is a method of treating a condition in a host that is responsive to an agonist, the method comprising administering to the host a multi-layer pharmaceutical composition comprising the agonist and an antagonist thereof, wherein the agonist and antagonist are not in direct contact with one another in... Agent: Patrick J. Halloran, Ph.d., J.d

20080233158 - Two-coat makeup product, its uses, and makeup kit comprising the product: A cosmetic makeup product comprising at least two compositions, the first composition comprising a physiologically acceptable medium and the second composition comprising a mixture of at least one high molecular weight polymer having a weight-average molecular mass of greater than or equal to 200,000 g/mol and at least one low... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080233159 - Home-use insecticide: The present invention provides a home-use insecticide formulated as an insect knockdown agent and insect killing agent that contains a useful pyrethroid compound having superior residual efficacy. The home-use insecticide contains (d)-2-methyl-4-oxo-3-(2-propynyl)-2-cyclopenten-1-yl (d)-trans-2,2-dimethyl-3-(2,2-dichlorovinyl)cyclopropanecarboxylate as an active ingredient thereof.... Agent: Oliff & Berridge, PLC

20080233160 - Building board: The building board according to the present invention has a coat formed on the surface, and is characterized in that antimicrobial composite materials are included on the surface of the coat and a coat layer containing colloidal silica as a main component is formed, said antimicrobial composite materials being characterized... Agent: Birch Stewart Kolasch & Birch

20080233161 - Deposition products, composite materials and processes for the production thereof: A composite material comprising a substrate and a deposition product and the use of a deposition product for providing an antimicrobial effect. The substrate of the composite material is a medical device. Further, in each of the composite material and the use, the deposition product consists essentially of at least... Agent: Rodman Rodman

20080233162 - Fibrous 3-dimensional scaffold via electrospinning for tissue regeneration and method for preparing the same: The present invention relates to a fibrous 3-dimensional porous scaffold via electrospinning for tissue regeneration and a method for preparing the same. The fibrous porous scaffold for tissue regeneration of the present invention characteristically has a biomimetic structure established by using electrospinning which is efficient without wasting materials and simple... Agent: Jhk Law

20080233163 - Thiazole-based nitric oxide donors having acyl substuent(s) and uses thereof: Disclosed are novel NO-donating compounds, designed such that when NO is released from the compound a residue which is a naturally occurring metabolite is formed, and thus a development of tolerance to the compounds upon repetitive administration is prevented or decreased. Also disclosed are methods of preparing such NO-donating compounds,... Agent: Martin D. Moynihan Prtsi, Inc.

20080233169 - 4-aza-caprolactone-based polymeric compositions useful for the manufacture of biodegradable medical devices and as medical device coatings: N-substituted 4-aza-caprolactone biodegradable polymers, including derivatives thereof, useful for making implantable medical devices and coatings therefore are provided. The medical devices and coatings of the present invention can also be used for in situ controlled release drug delivery and are useful for treating or preventing medical conditions such as restenosis,... Agent: Medtronic Vascular, Inc.IPLegal Department

20080233168 - Medical devices and coatings therefore comprising biodegradable polymers with enhanced functionality: Biodegradable polymers useful for fabricating implantable medical devices and as coatings for medical devices are provided. The biodegradable polymers are biocompatible and can be tuned to provide optimum bioactive agent elution rates as well as degradation rates. Also provided are methods for making medical devices and medical device coatings using... Agent: Medtronic Vascular, Inc.IPLegal Department

20080233164 - Polymer for use in conduits, medical devices and biomedical surface modification: o

20080233166 - Systems and methods of coating a hybrid hemodialysis access graft or a hybrid femoral artery bypass graft in a mammal: Hybrid synthetic grafts and embodiments of systems and methods for producing hybrid vascular grafts that can yield implantable grafts that combine synthetic grafts with living cells. Embodiments of systems can include a pressure/flow loop subsystem having an external flow loop system coupled to a specimen holder, where the pressure/flow loop... Agent: Rene A. Vazquez

20080233165 - Time release calcium sulfate and growth factor matrix for bone augmentation: A bone-growth stimulating composition for forming a resorbable implant, methods for making such a composition and a corresponding putty/paste material. In some embodiments of the invention, such a material includes a plurality of particles having a predetermined size and comprising a first calcium sulfate compound, a resorbable polymer in a... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo Attn: Patent Intake Customer No. 35437

20080233167 - Urological medical devices for release of prostatically beneficial therapeutic agents: According to an aspect of the invention, urological medical devices are provided, which comprise a prostatically beneficial agent selected from alpha-adrenergic blockers, antispasmodic agents, anticholinergic/antimuscarinic agents, calcium channel blockers, anti-inflammatory agents, hormone-affecting agents, anti-cancer agents, and combinations thereof, among others. The urological medical devices are adapted for implantation or insertion... Agent: Mayer & Williams PC

20080233170 - Osteogenic proteins: Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors carrying sequences encoding these novel polypeptide chains and host cells transfected with these vectors; (4) methods... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP (formerly Kirkpatrick & Lockhart Nicholson Graham)

20080233171 - Extended therapeutic effect ocular implant treatments: Methods for treating ocular conditions by inserting an implant comprising an active agent into an ocular site of a patient thereby obtaining an amelioration of a symptom of the ocular condition (i.e. a therapeutic effect) for an extended period of time during which a therapeutic amount or a detectable amount... Agent: Stephen Donovan Allergan, Inc.

20080233172 - Extended therapeutic effect ocular implant treatments: Methods for treating ocular conditions by inserting an implant comprising an active agent into an ocular site of a patient thereby obtaining an amelioration of a symptom of the ocular condition (i.e. a therapeutic effect) for an extended period of time during which a therapeutic amount or a detectable amount... Agent: Stephen Donovan Allergan, Inc.

20080233173 - Extended therapeutic effect ocular implant treatments: Methods for treating ocular conditions by inserting an implant comprising an active agent into an ocular site of a patient thereby obtaining an amelioration of a symptom of the ocular condition (i.e. a therapeutic effect) for an extended period of time during which a therapeutic amount or a detectable amount... Agent: Stephen Donovan Allergan, Inc.

20080233174 - High dose film compositions and methods of preparation: This invention relates to films incorporating high amounts of pharmaceutical agents and methods for the preparation of the same. Moreover, the invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a... Agent: Hoffmann & Baron, LLP

20080233175 - Glucanases, nucleic acids encoding them and methods for making and using them: The invention relates to polypeptides having glucanase, e.g., endoglucanase, mannanase, xylanase activity or a combination of these activities, and polynucleotides encoding them. In one aspect, the glucanase activity is an endoglucanase activity (e.g., endo-1,4-beta-D-glucan 4-glucano hydrolase activity) and comprises hydrolysis of 1,4-beta-D-glycosidic linkages in cellulose, cellulose derivatives (e.g., carboxy methyl... Agent: Verenium C/o Mofo S.d.

20080233176 - Haemostatic composition and method: The invention relates to a composition comprising: (a) one or more aminoacids selected from glycine, proline and hydroxyproline; (b) a source of calcium ions; and (c) water. The invention also extends to a dry composition comprising the aforementioned components (a) and (b). The compositions of the invention are useful for... Agent: Knobbe Martens Olson & Bear LLP

20080233177 - Fibre-free transdermal therapeutic system and method for its production: A transdermal therapeutic system which is free of fibrous constituents, and a method for the production of such a transdermal therapeutic system A preparation containing active substance is applied by a printing method onto the pressure-sensitive adhesive layer of the transdermal therapeutic system.... Agent: D. Peter Hochberg Co. L.p.a.

20080233178 - Abuse resistant opioid transdermal delivery device containing opioid antagonist microspheres: The present invention provides abuse-resistant transdermal delivery devices containing an opioid agonist intended for analgesic purposes in pain patients.... Agent: Davidson, Davidson & Kappel, LLC

20080233180 - Transdermal patch and method for delivery of vitamin b12: The present invention is directed to compositions and devices for transdermally administering vitamin B12 to a subject. In one aspect, a vitamin B12 containing composition suitable for transdermal administration is provided in the form of a shelf stable transdermal delivery patch. Such patches contain vitamin B12 combined with selected penetration... Agent: Quarles & Brady LLP

20080233179 - Transdermal composition having enhanced color stability: A pharmaceutical composition for transdermal or transmucosal delivery of a pharmaceutical agent effective to treat a neurological disorder such as Parkinson's disease is disclosed. The composition contains an antioxidant, which provides color and chemical stability of the pharmaceutical agent. The antioxidant may also provide enhanced skin permeability of the agent.... Agent: Winston & Strawn LLP Patent Department

20080233181 - Nanoparticle adjuvants for sub-unit vaccines: The present invention relates to nanoparticle vaccine adjuvants comprised of a carrier, particularly polymerized lipids, having multiple copies of an antigen or combinations of different antigens displayed on the carrier. Such antigen-displaying nanoparticles may also display a targeting molecule on its surface in order to direct it to a specific... Agent: Nixon Peabody LLP - Patent Group

20080233182 - Organic compounds: The present invention relates to a method of protecting copper-sensitive compounds and/or compositions from decomposition.... Agent: Novartis Corporate Intellectual Property

20080233183 - Topical formulations having enhanced bioavailability: The present disclosure provides compositions suitable for delivering lipophilic bioactive agents. The compositions may be utilized to treat numerous diseases and conditions that would benefit from the application of a lipophilic bioactive agent.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20080233184 - Combination enzyme products: The present invention provides a unique package as well as methods packaging an enzyme portion and a substance portion. The package is bifurcated to maintain an enzyme separate from a primary substance until a predetermined set of environmental conditions is met. When the environmental conditions are met, the enzyme acts... Agent: Joseph P. Kincart, Esq.

20080233185 - Fumaric acid derivatives as nf-kappab inhibitor: The present invention relates to the use of one or more fumaric acid derivatives as NF-kappaB inhibitor. At the same time, the present invention relates to the use of the fumaric acid derivatives for preparing a pharmaceutical composition for treating diseases that may be influenced by NF-kappaB.... Agent: Biogen Idec / Finnegan Henderson, LLP

20080233186 - Dietary compositions and methods of enhancing lean body mass and exercise performance: Various compounds can be administered orally to humans or animals for the purpose of enhancing nitric oxide production. Enhancing nitric oxide production is beneficial for those looking to increase lean body mass or enhance exercise performance. Such administration can also be used for the purpose of enhancing nutrient transport for... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080233187 - Method of production of fine-crystalline mixture containing non-steroid anti-inflammatory drug, fine-crystalline mixture obtainable by this method and solid pharmaceutical composition containing this mixture: The invention concerns a method of production of a fine-crystalline mixture containing a non-steroid anti-inflammatory drug and an auxiliary substance, wherein a coarse-crystalline substance from the group of non-steroid anti-inflammatory drugs is dissolved in a solvent at an increased temperature, the solution is subsequently distributed at rapid chilling into a... Agent: Notaro And Michalos

20080233188 - Stable pharmaceutical compositions comprising a pyrimidine - sulfamide: The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof.... Agent: Dickstein Shapiro LLP

20080233189 - Pharmaceutical tablets comprising two or more unitary segments: Accurate means of dosing with a compressed, segmented pharmaceutical tablet, and tablettes formed from said tablets, is disclosed.... Agent: Hedman & Costigan P.C.

20080233190 - Segmented pharmaceutical dosage forms: A pharmaceutical tablet adapted for accurate division of a dose of a drug into two or more smaller doses, which tablet has two or more segments.... Agent: Accu-break Technologies, Inc.

20080233191 - Use of ranolazine for elevated brain-type natriuretic peptide: This invention is directed to the use of ranolazine to reduce the risk of adverse coronary events in a mammalian patient. Typically, the natriuretic peptide is associated with coronary disease, acute coronary syndrome, and/or diastolic dysfunction. Ranolazine may be administered to the patient as an intravenous solution or in an... Agent: Cv Therapeutics, Inc.

20080233192 - Tablets with improved dissolution profile: The present disclosure relates to tablets obtainable by compression of a mixture comprising at least 5% by weight of a diluent and granules which comprise a very slightly soluble drug, wherein the granules consist of a core of saccharose beads having (prior to coating) a mean particle size greater than... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080233194 - Dispersion for pulmonary delivery of a bioactive agent: Stabilized dispersions are provided for the delivery of a bioactive agent. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a liquid fluorochemical. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated,... Agent: Nektar Therapeutics

20080233193 - Oral antimicrobial pharmaceutical compositions: The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon.... Agent: Darby & Darby P.C.

20080233195 - Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth: The present invention concerns methods for stimulating the growth and repair of bone and cartilage using synthetic triterpenoids and tricyclic-bis-enones. Examples of suitable triterpenoids include CDDO, CDDO-Me, CDDO-Im, and CDDO-Ethylamide. Examples of tricyclic-bis-enones include TBE-31 and TBE-34.... Agent: Fulbright & Jaworski L.L.P.

20080233196 - Injectable sterile pharmaceutical composition with piperacillin sodium and tazobactam sodium as active principles: A sterile pharmaceutical composition having as its active principles piperacillin sodium and tazobactam sodium of substantially the same density, mixed with sodium bicarbonate. The mixture is soluble in water to give injectable reconstituted solutions having high stability with time.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080233198 - Method for delivering a peptide to a subject at a modulated rate via microcapsules of lactic-co-glycolic copolymer containing said peptide: Micro-capsules for the slow release of drugs, consisting of a lactic-co-glycolic copolymer to which a plasticiser has been incorporated and which contain a drug of pharmaceutical interested within them.... Agent: Ostrolenk Faber Gerb & Soffen

20080233197 - Pharmaceutical compositions: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from... Agent: Patrick J. Halloran, Ph.d., J.d

20080233199 - Coacervation process: Methods of forming compositions for the sustained release of water soluble active agents, including biologically active polypeptides and products produced by the process are described. Improved product characteristics and ease of scale-up can be achieved using a novel coacervation process wherein at least one coacervation agent is added to the... Agent: Elmore Patent Law Group, PC

20080233200 - Nanoparticles for protein drug delivery: The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery.... Agent: Hosheng Tu

20080233201 - Method for preparing calibrated biodegradable microspheres: The invention relates to a method for preparing monodispersed biodegradable microspheres consisting in a) preparing an emulsion containing at least one polymeric phase and at least one aqueous phase at a viscosity ratio between the dispersed polymeric phase and the aqueous phase ranging from 0.12 to 10, b) exposing the... Agent: Young & Thompson

20080233202 - Fungicidal compositions: The present invention relates to fungicidal compositions and particularly fungicidal compositions comprising anhydrous milk fat (AMF), soybean oil and/or coconut fat. The invention also relates to a fungicidal method employing a composition of the invention. The compositions and methods of the invention have applications in the management (prevention and control)... Agent: Jacobson Holman PLLC

20080233203 - Porous orthapedic materials coated with demineralized bone matrix: A biomaterial comprising a porous biocompatible structure and a demineralized bone extract coated onto into the pores of the biocompatible structure are provided. The biomaterial may also comprise a demineralized bone gelatin where the gelatin may be coated over the extract coating or mixed with the extract coating before being... Agent: Bose Mckinney & Evans LLP 2700 First Indiana Plaza

20080233204 - Anti-microbial paint films: ii) an anti-microbial substance, comprising a metal or metal compound deposited on a particulate inorganic material, in an effective amount to kill microbes or prevent their growth on the surface of the solid coating and wherein the paint film is free of metallic copper and zinc and their alloys.... Agent: Roetzel And Andress

20080233205 - Organic compound and metal ion synergistic disinfection and purification system and method of manufacture: A new, novel and useful disinfection and purification system comprised of organic compounds in synergistic action with selected metal ions and method of manufacture and use. One of the benefits that is derived from this system is the ability to quickly and easily treat a surface, fluid or medium for... Agent: Morgan, Lewis & Bockius LLP

20080233206 - Compositions and methods for anti-inflammatory treatments: The present invention relates to an improved method for treating a wide range of inflammatory disorders by administering a tetracycline compound together with an effective inhibitor of tetracycline absorption, such as polyvalent metals. Pharmaceutical compositions used in that method are also taught.... Agent: Frost Brown Todd, LLC

20080233207 - Injectable and infusable mercury compositions and methods for treating cancer: An aqueous solution suitable for injection into a mammal in need thereof includes an inorganic mercury (II) containing compound present in an amount between 0.1 nanomole and 50 millimoles Hg2+ where the solution is sufficiently stable such that there is no precipitation from the solution for at least thirty days... Agent: Gordon & Jacobson, P.C.

20080233208 - Use of erianin in preparing pharmaceutical for treating tumors: This invention relates to a use of the compound of formula (I), Erianin, in preparing pharmaceutical for treating tumors... Agent: Occhiuti Rohlicek & Tsao, LLP

20080233209 - Composition and method of use for the treatment of metabolic syndrome and inflammation: The present invention provides a method and composition for preventing, treating or managing Metabolic Syndrome. The composition contains brown marine vegetable extract containing an effective amount of fucoxanthin which is administered for preventing, treating or managing Metabolic Syndrome.... Agent: Kramer & Amado, P.C.

20080233210 - Co-biocidal formulation for polymeric materials: Polymeric materials containing at least one continuous phase man-made polymer and at least one biodegradable component are protected against microbial attack through the use a combination of a boron-containing compound and an organic biocide. Methods and compositions for preparing treated polymeric materials are provided. A shaped article comprising a continuous... Agent: Sheridan Ross PC

20080233211 - Combined preparation for treating sepsis: The present invention relates to a combined preparation comprising the active substance corticoid and a selenium-containing active substance. The combination of active substances leads to a clear reduction of the mortality rate of sepsis patients.... Agent: Leydig Voit & Mayer, Ltd

20080233212 - Use of exogenous gaseous nitric oxide in the treatment and disinfection of biofilms: The administration of gaseous nitric oxide as a biocidal moiety is proffered as a de novo treatment in the control and eradication of biofilms. The present invention relates to the use or methods of application of exogenous nitric oxide gas (gNO) as a stand alone biocidal agent or in cohort... Agent: Sidley Austin LLP

20080233213 - Hair sustaining formulation: A multi-dimensional hair sustaining formulation having a liquid transport agent that carries multi-ingredients to hair follicles in order to prevent Dihydrotestosterone (DHT) from attaching to receptor sites on the follicles of existing hair, hence promoting the growth of existing hair which otherwise would succumb to DHT attack.... Agent: Oktay Enterprises International

20080233216 - Composition comprising the extract of siegesbeckiae herba for preventing and treating arthritis and the use thereof: The extract of Siegesbeckiae herba of the present invention showed potent inhibitory effect on the dissociation of proteoglycan and type II collagen in chondrocyte and cartilage tissue and protecting effect on cartilage due to the inhibition of MMP-1, MMP-3 and MMP-13 activity and the restoring effect on cartilage tissue, the... Agent: Kirk Hahn

20080233215 - Excipient and an improved method for manufacturing extracted, evaporated, granulated botanical herb product: An excipient and a method for manufacturing concentrated Chinese herbs through using the excipient are provided. The manufacturing method includes the following steps: (a) providing a Chinese herb raw material; (b) obtaining an extract from the Chinese herb raw material; (c) collecting volatile oils in a separate bin, later reintroduced;... Agent: Connolly Bove Lodge & Hutz, LLP

20080233214 - Therapeutic compounds isolated from calomeria amaranthoides: The present invention relates to extracts and compounds which are isolated from Calomeria amaranthoides, and to derivatives and analogues of such compounds, which demonstrate cytotoxic activity against a variety of cell types exhibiting hyperproliferative cell division.... Agent: Quarles & Brady LLP

20080233217 - Composition comprising notoginseng radix extract for preventing and treating of arthritis as an effective ingredient: e

20080233218 - Methods for treating oral cancers with herbal compositions: The inventive subject matter relates to methods for treating oral cancers, comprising administration of a composition comprising therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger; and therapeutically effective amounts of hydroalcoholic extracts of holy basil, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, huzhang, Chinese goldthread, and... Agent: Nath & Associates

20080233219 - Composition for diet comprising plant essential oil as active ingredient, sheet type composition for diet comprising thereof, percutaneous pharmaceutical agent for diet comprising thereof, and method for producing thereof: The present invention provides a composition for diet comprising an essential oil adsorbent is coated with neroli oil to prepare an essential oil-coated particle, and then the particle is covered with a essential oil adsorbing and desorbing agent to prepare the carbon-coated particle (NR), the carbon-coated particle similarly prepared by... Agent: Kratz, Quintos & Hanson, LLP

20080233220 - Further medical use of a botanical drug or dietary supplement: The present invention relates to further medical uses for a botanical drug or dietary supplement consisting essentially of four botanical drug substances, optionally formulated with excipients. The botanical raw materials, botanical drug substances or botanical ingredients used are from a species of each of the genera (a) Silybum; (b) Astragalus... Agent: Dickinson Wright PLLC

20080233221 - Prostate cancer and benign prostatic hyperplasia treatments: The present invention provides methods of treating prostate cancer and benign prostatic hyperplasia using xanthohumol and/or a xanthohumol analog.... Agent: Klarquist Sparkman, LLP

20080233222 - Method of improving cardiovascular health: A nutritional supplement including β-cryptoxanthin is found to be effective at lowering blood pressure in mammals. β-cryptoxanthin therefore may be used to maintain cardiovascular health by lowering blood pressure, preventing high, elevated blood pressure and/or maintaining healthy blood pressure. Administration of β-cryptoxanthin in combination with safflower oil is particularly effective.... Agent: Davis, Brown, Koehn, Shors & Roberts, P.C. The Davis Brown Tower

20080233223 - Process for preparing extract from rhus verniciflua and pharmaceutical composition containing the same: The present invention provides a process for preparing an extract of Rhus verniciflua by using water and organic solvents to extract active ingredients, which comprises (a) adding water or a mixture of water and alcohol as the solvent to Rhus verniciflua to extract the soluble components, then filtering the resultant... Agent: Ipla P.A.

20080226546 - Kit for preparation of nano-targeted liposome drug in combined radionuclide therapy and chemotherapy: This invention is to manufacture a kit for preparation of nano-targeted liposome drugs in combined chemotherapy and radionuclide therapy. It is a kit consisting of three components: (1) A 10 ml vial A which contains BMEDA, gluconate acetate, SnCl2. (2) A 10 ml vial B which contains DSPC, cholesterol, DSPE-PEG,... Agent: Michael Lin

20080226547 - Alpha-emitting hydroxyapatite particles: The present invention provides Hydroxyapatite (HA) incorporating an alpha-emitting radionuclide or an in vivo generator for an alpha-emitting radionuclide. The invention further provides methods for the formation of such HA, pharmaceutical compositions comprising the HA and methods of medical treatment of cancerous or noncancerous disease including administering the HA or... Agent: Clark & Elbing LLP

20080226548 - Methods of applying ionization radiation for therapy of hiv infection: This invention provides methods for treating subjects infected with human immunodeficiency virus (HIV) which comprise administering to the subjects a radiolabeled antibody or agent effective to kill HIV infected cells, where the antibody or agent is specific for a HIV envelope glycoprotein. The invention also provides compositions and methods for... Agent: Amster, Rothstein & Ebenstein LLP

20080226549 - Breast cancer eradication program: A method of treating breast cancer that is at least partially ER+ is disclosed. The method comprises administering at a tumor site in a mammalian subject a pharmaceutically acceptable form of Fe(II) or Fe(III) in a suitable carrier. A four-part program aimed at eradicating breast cancer includes (a) local treatment... Agent: Winstead PC

20080226550 - Small technetium-99m and rhenium labeled agents and methods for imaging tumors: The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tumors, e.g., carcinomas, melanomas and other tumors. In another embodiment, the invention relates to methods of imaging tumors using radiolabeled metal complexes. Preferred radiolabeled complexes for imaging tumors... Agent: Edwards Angell Palmer & Dodge LLP

20080226551 - Transport molecules using reverse sequence hiv-tat polypeptides: This invention relates to novel transport molecules that comprise a polypeptide comprising amino acid residues arranged in a sequence that is the reverse-sequence of basic portion of the HIV-TAT protein. The novel transport polypeptides are useful for transmembrane or intracellular delivery of cargo molecules, non-limiting examples of which include polypeptides... Agent: King & Spalding

20080226552 - Automated radiolabelling method: The present invention provides an automated method for the preparation of 123I-labelled radiopharmaceutical compositions, together with disposable cassettes for use in the method. The use of an automated synthesizer apparatus in the preparation of 123I-labelled radiopharmaceuticals is also described. Also described is the use of cassettes of the present invention... Agent: Ge Healthcare, Inc.

20080226553 - Cell-based rna interference and related methods and compositions: This invention provides, among other things, methods for performing RNA interference in stem cells and methods for using stem cells in vivo.... Agent: Ropes & Gray LLP

20080226557 - Luciferins: Novel luciferins, methods of making luciferins, and uses of the same are disclosed.... Agent: Fish & Richardson PC

20080226558 - Mesoderm and definitive endoderm cell populations: The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy.... Agent: Crowell & Moring LLP Intellectual Property Group

20080226555 - Method for the use of [11c] carbon monoxide in labeling synthesis of 11c-labelled esters and acids by sensitized photo-induced free radical: Methods and reagents for photo-initiated carbonylation with carbon-isotope labeled carbon monoxide using alkyl/aryl iodides with alcohols or water treated by photosensitizers are provided. The resultant carbon-isotope labeled esters and acids, and pharmaceutical acceptable salts and solvates are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits... Agent: Ge Healthcare, Inc.

20080226554 - Methods for detecting markers associated with endometrial disease or phase: Methods for detecting endometrial diseases or an endometrium phase in a subject are described comprising measuring endometrial markers or polynucleotides encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for endometrial diseases, and kits for carrying out the methods of the invention.... Agent: Howson And Howson

20080226556 - Removal promoters and inhibitor for apoptosis cells in vivo: The present invention is to provide a removal promoter for apoptotic cells which is capable of immediately removing apoptotic cells in vivo by macrophages, or a removal inhibitor which inhibits the removal of apoptotic cells in vivo by macrophages. A removal promoter for apoptotic cells in vivo containing the milk... Agent: Foley And Lardner LLP Suite 500

20080226559 - Benztropine compounds and uses thereof: Disclosed are benztropine analogs having the formula (I) in which Ar is a C6-C20 monocyclic aryl group or a C10-C20>bicyclic aryl group or a heteroaryl, heterocyclic, or arylheterocyclic group having 2 to 12 carbon atoms and one or more heteroatoms selected from the group consisting of N, O, S, P,... Agent: Leydig, Voit & Mayer, Ltd.

20080226560 - Compositions and methods to prevent cancer with cupredoxins: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The cargo compound may be a nucleic acid and specifically a DNA, RNA or anti-sense. The invention... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20080226561 - Therapeutic use of anti-tf-antigen antibody: The invention is related to administration of monoclonal antibody JAA-F11 to an individual for inhibition of metastasis and/or inhibition of growth of cells which express TF—Ag, or for detection of tumors or metastatic foci which express TF—Ag. For inhibition of metastasis or inhibition of growth of cells expressing TF—Ag, the... Agent: Hodgson Russ LLP The Guaranty Building

20080226562 - Biocompatible fluorescent metal oxide nanoparticles: The invention relates to highly fluorescent metal oxide nanoparticles to which biomolecules and other compounds can be chemically linked to form biocompatible, stable optical imaging agents for in vitro and in vivo applications. The fluorescent metal oxide nanoparticles may also be used for magnetic resonance imaging (MRI), thus providing a... Agent: Goodwin Procter LLP Patent Administrator

20080226563 - Non-invasive localization of a light-emitting conjugate in a mammal: Methods and compositions for detecting and localizing light originating from a mammal are disclosed. Also disclosed are methods for targeting light emission to selected regions, as well as for tracking entities within the mammal. In addition, animal models for disease states are disclosed, as are methods for localizing and tracking... Agent: Robins & Pasternak

20080226564 - Respiratory dispersion for metered dose inhalers: A respiratory dispersion is provided for the pulmonary delivery of at least two bioactive agents. The dispersion comprises a propellant suspension medium having dispersed therein a plurality of perforated microstructures, wherein the two bioactive agents are incorporated into individual perforated microstructures.... Agent: Janah & Associates A Professional Corp

20080226565 - Anticariogenic proteins & peptides & saccharides: This Invention discloses new proteins, peptides and saccharides that have anticarogenic capabilities and that are characterized by the presence of one or more components that have the ability to form a complex with calcium ions: such as epsilon-polylysine that is conjugated with one or more bisphosphonyl-, biscarboxyl-, or 3-hydroxy-phthalate-groups or... Agent: Clark & Elbing LLP

20080226566 - Use of poorly water-soluble calcium salts and/or the composites thereof: The use of a composition containing at least one not easily water-soluble calcium salt and/or the composite material thereof, to protect and/or therapeutically treat and/or preventively treat teeth and/or bones in case of damage or prevent damage resulting from external influences, especially biological, chemical, physical, and/or microbiological influences, particularly to... Agent: Paul & Paul

20080226567 - Tooth whitening products: A tooth whitening product is provided. The tooth whitening product includes a material sized to cover at least a portion of the front surface of a plurality of teeth. A thin layer of a tooth whitening composition is disposed on the material. The whitening composition contains a peroxide active with... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080226570 - Cosmetic treatment for body-modelling with sun protection and modelling kit: The invention relates to a method for body shaping by means of a sun-protection agent and a corresponding cosmetic product. The inventive method consists in pre-treating by means of a preliminary product containing a caffeine, algae extract, pineapple extract, radical scavenger, copper gluconate, silylpropionic acid and a melanin-stimulating amino acid-containing... Agent: Akerman Senterfitt

20080226569 - Polyurethane dispersions for use in personal care products: e

20080226568 - Synergistic preservative systems and their use in topical compositions: A synergistic preservative system having an oil-miscible glycol and an enzymatic composition. The synergistic preservative system demonstrates enhanced anti-fungal, anti-bacterial, and anti-microbial efficacy and is free of formaldehyde donors, parabens, ethanols, and isothiazolinones.... Agent: Charles N.j. Ruggiero Ohlandt , Greeley, Ruggiero & Perle, L.L.P.

20080226571 - Compositions and methods to effect enhanced photoprotection against uv a and uv b induced damage of human skin: A composition based on labdane-diterpenoids that provides better photo protection against both UV A and UV B radiations in the HaCaT human keratinocyte cell lines is disclosed. The composition comprises 8,13-epoxy-1α,6β,7β,9α-tetrahydroxylabd-14-en-11-one alone and in combination with 6β-acetoxy-8,13-epoxy-1α,7β,9α-trihydroxylabd-14-en-11-one and/or 7β-acetoxy-8,13-epoxy-1α,6β,9α-trihydroxylabd-14-en-11-one. The composition protects the cells of the skin from harmful UV... Agent: Sabinsa Corporation

20080226572 - Cosmetic emulsion containing silicone compounds: The present invention mainly relates to a cosmetic kit for make-up or non therapeutic care of keratinous substance(s) comprising at least two compositions and containing at least one compound X and at least one compound Y, compounds X and Y being capable of reacting together and at least one of... Agent: Oliff & Berridge, PLC

20080226573 - Covalently bonding nail primer: The present invention relates generally to the field of primers and adhesion promoters. More specifically, the primer of the present invention is comprised of one or more multi-carbonylated methacrylates. In a preferred embodiment, a non-ketone polar solvent is also employee. The resulting composition eliminates primer related discoloration of artificial nail... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20080226574 - Line of cosmetic compositions: The present invention relates to a line of cosmetic compositions comprising at least two compositions each comprising a cosmetically-acceptable medium and at least one multilayer interference pigment, each composition providing coverage that is greater than or equal to 25, the respective multilayer interference pigments of the various compositions being selected... Agent: Oliff & Berridge, PLC

20080226577 - Cosmetic product comprising silicone compounds and an amphiphilic polymer: The present invention relates to a cosmetic kit that can be used for the care and/or make-up of keratinous substance(s), comprising at least two compositions that are different and are packaged separately with at least one of the compositions being of the emulsion type and comprising at least one amphiphilic... Agent: Oliff & Berridge, PLC

20080226578 - Cosmetic compositions comprising polymers comprising complementary chemical functional groups: Cosmetic compositions comprising at least two polymers comprising complementary chemical functional groups, capable of forming a coat on a keratin material, such as hair, a cosmetic process comprising the use of these polymers on the keratin material, such as the hair, and also their use for producing a coat on... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080226575 - Long-lasting cosmetic composition, method for using, and process for making: There is a cosmetic composition that has an anhydrous gel phase having a gellant and an organic solvent, an aqueous phase having a hydrophilic film former and water, and a wax phase having a wax and a hydrophilized lanolin derivative. The anhydrous gel phase, the aqueous phase, and the wax... Agent: Avon Products, Inc.

20080226576 - Hair shaping compositions comprising at least one silicone and at least one alkoxysilane having solubilizing functional groups: Disclosed herein is a method for preventing the deterioration of the feel of the hair upon repeated application of a hair shaping composition comprising at least one alkoxysilane having at least one solubilizing functional group, wherein the method comprises applying to the hair said shaping composition wherein said composition further... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080226580 - Biodegradable oil absorbing film: An object of the present invention is to provide products composed of a biodegradable raw material(s). The present invention provides a biodegradable oil absorbing film containing polyhydroxyalkanoate.... Agent: Birch Stewart Kolasch & Birch

20080226581 - Composition comprising a monomer compound exhibiting an optical property, method making use of said composition, a monomer compound and a polymer containing said monomer compound and the use thereof: The invention relates to a cosmetic or pharmaceutical composition comprising, in a physiologically acceptable medium, at least one type of polymer containing at least one type of novel monomer compound exhibiting optical properties. Said invention also relates to a cosmetic method for making up or treating keratinous materials, in particular... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080226582 - Composition for improving atopic dermatological diseases comprising magnolol and honokiol: Disclosed is a composition for improving atopic dermatological diseases comprising magnolol, honokiol or the combination thereof.... Agent: O'keefe, Egan, Peterman & Enders LLP

20080226579 - Novel resinate complex of s-clopidogrel and production method thereof: The present invention is a novel resinate complex of (+)-clopidogrel optical isomer, wherein the (+)-clopidogrel isomer is bounded to a water-soluble cation exchange resin having sulfonic acid groups. The novel resinate complex has recognized some advantages in that (1) its chemical structure is stable, and (2) it can be formulated... Agent: Sughrue Mion, PLLC

20080226583 - Therapeutic polyesters and polyamides: Polymers (i.e. polyesters, polyamides, and polythioesters or a mixture thereof) which degrade hydrolytically into biologically active compounds are provided. Methods of producing these polymers, intermediates useful for preparing these polymers, and methods of using these polymers to deliver biologically active compounds to a host are also provided.... Agent: Viksnins Harris & Padys Pllp

20080226584 - Antimicrobial and antistatic polymers and methods of using such polymers on various substrates: The present invention relates to a substrate having one or more antimicrobial or antistatic properties. Such properties are imparted by applying a coating or film formed from a cationically-charged polymer composition. The polymer composition includes a noncationic ethylenically unsaturated monomer and an ethylenically unsaturated monomer capable of providing a cationic... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080226585 - Method for treating surfaces with copolymers: The present invention relates to a method for treating at least a surface of a substrate containing labile hydrogen atoms to confer to it cytotoxic properties or cell-adhesion properties, characterized in that it comprises at least a step consisting of exposing, within a liquid medium, said substrate or a surface... Agent: Oliff & Berridge, PLC

20080226587 - Methods and compositions for immunomodulation: Compositions for immunomodulation that include acylated peptide antigens recognized by CD1c-restricted T cells, and methods of using the compositions, are provided herein.... Agent: Fish & Richardson PC

20080226589 - Compositions and methods of use of phorbol esters: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like HIV and AIDS, or the development of neoplasms in a mammalian subject. The methods... Agent: Black Lowe & Graham PLLC

20080226590 - Compounds for the treatment of hepatitis c: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080226591 - Compounds for the treatment of hepatitis c: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080226592 - Compounds for the treatment of hepatitis c: The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080226593 - Compounds for the treatment of hepatitis c: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080226588 - Treating melanoma with bis(thiohydrazide amides): Disclosed herein are methods of treating lentigo maligna, superficial spreading malignant melanoma, acral lentiginous malignant melanoma or nodular malignant melanoma with bis(thio-hydrazide amides) represented by a formula selected from structural formulas (i)-(ix) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these bis(thio-hydrazide amides) and compositions comprising these bis(thiohydrazide)amides and one... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080226594 - Culturing circular ssdna viruses for the production of vaccines: The present invention relates to the use of interferon in the in vitro cultivation of animal circular ssDNA virus such as Porcine Circovirus 2 or human TT virus in an animal cell line. Increased titres of animal circular ssDNA virus are obtained by one or more of the following conditions:... Agent: Clark & Elbing LLP

20080226595 - Treatment of inflammatory diseases using placental stem cells: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.... Agent: Jones Day

20080226596 - Therapeutic compositions and methods useful in treating hepatitis: The invention encompasses therapeutic compositions containing a pentavalent antimonial composition. The pentavalent antimonial can be sodium stibogluconate and pentamidine and biological equivalents of said compounds. The therapeutic composition of this embodiment contains an effective amount of pentavalent antimonial that can be used in treating infectious diseases. The types of diseases... Agent: Morgan Lewis & Bockius LLP

20080226597 - Evolved interferon-alpha polypeptides: The present invention provides evolved interferon-alpha polypeptides, and conjugates thereof, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of... Agent: Maxygen, Inc. Intellectual Property Department

20080226600 - Adeno-associated viruses and uses thereof: The invention provides an isolated and purified DNA molecule comprising at least one DNA segment, a biologically active subunit or variant thereof, of a circular intermediate of adeno-associated virus, which DNA segment confers increased episomal stability, persistence or abundance of the isolated DNA molecule in a host cell. The invention... Agent: Schwegman, Lundberg & Woessner, P.A.

20080226598 - Compositions and methods for generating an immune response utilizing alphavirus-based vector systems: Methods are provided for generating immune responses utilizing alphavirus-based vector systems.... Agent: Novartis Vaccines And Diagnostics Inc.

20080226601 - Herpes virus-based compositions and methods of use in the prenatal and perinatal periods: Disclosed are compositions and methods for reducing the severity of a birth defect in a mammal by exposing the mammal (e.g., in utero) to a herpes virus amplicon particle comprising a cis element-flanked transgene and a sequence encoding a transposase. Upon expression, the transposase inserts the transgene into the genome... Agent: Fish & Richardson P.C.

20080226599 - Methods of treatment involving p21/cip1: The onset ratios and pathological conditions of collagen-induced arthritis and adjuvant arthritis in model mice and rats, respectively, were successfully ameliorated by topically expressing the cyclin-dependent kinase inhibitors p16INK4a and p21Cip1 p in articular tissues using adenoviral vectors. In the synovial cells of CDKI-transduced mice, expression of inflammatory cytokines was... Agent: Fish & Richardson PC

20080226602 - Reoviruses having modified sequences: The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.... Agent: Fish & Richardson P.C.

20080226610 - Compositions and methods for elimination of unwanted cells: Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium... Agent: Fish & Richardson P.C.

20080226612 - Compositions of cells enriched for combinations of various stem and progenitor cell populations, methods of use thereof and methods of private banking thereof: The present disclosure covers compositions and method for the preparation and use of mixtures of adult stem/progenitor cell populations recovered and enriched from specific tissues with very limited attempts for their purification. Such mixtures of cell populations have improved therapeutic effectiveness in the treatment of certain diseases and tissue regeneration... Agent: Dr. Mark M. Friedman C/o Bill Polkinghorn - Discovery Dispatch

20080226611 - Gene therapy using tgf-beta: The subject invention is related to a cell-mediated gene therapy treatment for orthopedic disease using a member belonging to the transforming growth factor-β (TGF-β) superfamily. TGF-β gene therapy as a new treatment method for degenerative arthritis is demonstrated. After transfection of TGF-β cDNA expression vectors into fibroblasts (NIH 3T3-TGF-β1), the... Agent: Joseph Hyosuk Kim Jhk Law

20080226613 - Prognosis, diagnosis and treatment of bone marrow derived stem cell associated cancer: The present invention is based on the unexpected discovery that the loss of cells in inflamed tissue during chronic inflammation leads to the influx and long-term re-population of the tissue with bone marrow derived stem cells, and that it is these stem cells that are the primary source of metaplasia... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080226603 - Prebiotic: Carbohydrates, in particular mannose containing carbohydrates, are used as a promotor of cell growth. Specifically, polysaccharide hydrolysates are shown to have superior efficacy in promoting the growth of cells, synbiotic foods, prebiotics and pharmaceutical compositions containing mannose containing carbohydrates and polysaccharide hydrolysates described.... Agent: Ked & Associates, LLP

20080226614 - Eukaryotic based synergistic formulation for gastro-intestinal disorders: The present invention describes a eukaryotic based synergistic formulation for gastro-intestinal disorders comprising eukaryolics and adjuncts selected from pharmaceutically and or physiologically acceptable components. The invention also describes the manner in which the eukaryolics are isolated from tropical fruits , The medium used for growing them and the method used... Agent: Reed Smith LLP

20080226606 - Compositions and methods for the therapy and diagnosis of prostate cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The... Agent: Seed Intellectual Property Law Group PLLC

20080226607 - Compositions and methods for the therapy and diagnosis of prostate cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The... Agent: Seed Intellectual Property Law Group PLLC

20080226605 - Methods and compositions facilitating entry of compounds into cells: Disclosed are methods and compositions for facilitating entry of compounds to cells. In some forms, the compositions comprise one or more aminoglycosides and one or more lipids. The disclosed compositions can also comprise one or more compounds or compositions. It was discovered that the disclosed compositions increase the efficiency of... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20080226608 - Methods of isolating and using enriched subpopulations of bone marrow progenitors for the treatment of diabetes: Enriched subpopulations of bone marrow progenitors are obtained according to methods that involve the staining of bone marrow cells and the identification of bone marrow progenitors within the stained cell population having specific intracellular fluorescence or orthogonal light scatter properties. Enriched subpopulations of the described progenitors may be used to... Agent: Senniger Powers LLP (wshu)

20080226609 - Transplantation of glial restricted precursor-derived astrocytes for promotion of axon growth: Provided herein are compositions and methods for the treatment of central nervous system (CNS) lesions comprising administration of glial restricted precursor (GRP) derived astrocytes (GDAs).... Agent: Fish & Richardson P.C.

20080226615 - Vectors having both isoforms of beta-hexosaminidase and uses of the same: Disclosed are compositions and methods related to delivering a nucleic acid to the central nervous system.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20080226616 - Emulsifier combination for cosmetics: The present invention relates to a cosmetic preparation containing an emulsifier combination of polyacrylic acid salts, acrylate/C10-30 alkyl acrylate crosspolymer and carrageenan and the use of the cosmetic preparation.... Agent: Greenblum & Bernstein, P.L.C

20080226617 - Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation: The present invention provides an isolated and substantially purified recombinant human arginase having sufficiently high enzymatic activity and stability to maintain Adequate Arginine Depletion in a patient. The present invention also provides a pharmaceutical composition comprising the modified invention enzyme and method for treatment of diseases using the pharmaceutical composition.... Agent: EagleIPLimited

20080226586 - Chemokine beta-15: The present invention concerns a member of the human chemokine CC protein family. In particular, isolated nucleic acid molecules are provided encoding the chemokine β-15 protein. Chemokine β-15 polypeptides are also provided. The invention further concerns diagnostic methods for detecting thymus disorders and therapeutic methods for modulating bone marrow cell... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080226604 - Methods for treating ischemic tissue: Compositions and methods for treating ischemic tissue are provided herein.... Agent: Dechert LLP

20080226621 - Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent... Agent: Genentech, Inc.

20080226619 - Anti-muc1 alpha/beta antibodies: The present invention provides antibodies that simultaneously bind the α- and β-subunits of an intact MUC1 protein, and methods for making and using such antibodies.... Agent: Townsend And Townsend And Crew, LLP

20080226624 - Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect: The present invention relates to a combined treatment of cancer using a urokinase inhibitor and a cytotoxic or a cytostatic agent.... Agent: Mcdermott Will & Emery LLP

20080226620 - Compositions and methods for the therapy and diagnosis of prostate cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The... Agent: Seed Intellectual Property Law Group PLLC

20080226622 - Hif inhibitors: HIF-1 inhibitors and methods of use thereof are provided.... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20080226618 - Hydantoin derivatives useful as antibacterial agents: F

20080226623 - Stabilized protein crystals, formulations comprising them and methods of making them: This invention relates to methods for the stabilization, storage and delivery of biologically active macromolecules, such as proteins, peptides and nucleic acids. In particular, this invention relates to protein or nucleic acid crystals, formulations and compositions comprising them. Methods are provided for the crystallization of proteins and nucleic acids and... Agent: Ropes & Gray LLP

20080226625 - Stable non- aqueous single phase viscous vehicles and formulations utlizing such vehicles: This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The... Agent: Intarcia Therapeutics, Inc. Attn: Barbara G. Mcclung

20080226629 - Anti-vegf antibodies: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.... Agent: Genentech, Inc.

20080226628 - Cdr-grafted anti-tissue factor antibodies and methods of use thereof: The present invention provides CDR-grated antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also... Agent: Philip S. Johnson Johnson & Johnson

20080226627 - Hn-33 compositions and methods: This application is based, inter alia, on the discovery of a binding interaction between the Hn-33 hemagglutinin polypeptide of the type A Clostridium botulinum neurotoxin complex and synaptosomal proteins, including synaptotagmin II (Syt II). Methods of screening for compounds that modulate, e.g., increase or decrease, this interaction are provided. Also... Agent: Fish & Richardson PC

20080226626 - Immunoregulatory antibodies and uses thereof: A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20080226631 - Methods of modulating cytokine activity; related reagents: Provided are methods of modulating cytokine activity, e.g., for the purpose of treating inflammation of the airways and lung. Also provided are reagents for use in screening for agonists or antagonists of IL-19 or IL-24.... Agent: Dnax Research Inc. Legal Department

20080226630 - Recombinant antibodies for treatment of respiratory syncytial virus infections: Disclosed are novel polyclonal antibodies, which target respiratory syncytial virus (RSV), as well as novel high affinity antibody molecules reactive with RSV. The polyclonal antibodies may comprise antibody molecules which are reactive with both RSV protein F and RSV protein G, and preferably the polyclonal antibodies target a variety of... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080226632 - Amphiregulin antibodies and their use to treat cancer and psoriasis: The present invention is directed to anti-AR antibodies, preferably humanized monoclonal antibodies having the amino acid sequences disclosed herein. The present invention includes a pharmaceutical composition comprising such antibodies. The present invention includes a method of inhibiting cancer cell growth comprising administering such antibodies into a subject. The present invention... Agent: Pdl Biopharma, Inc. Attn: Legal Department

20080226635 - Antibodies against insulin-like growth factor i receptor and uses thereof: An antibody binding to IGF-IR and being glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is between 20% and 50%, has improved properties in antitumor therapy.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080226633 - Compositions and methods for the therapy and diagnosis of ovarian cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group PLLC

20080226636 - Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes: A purified polypeptide, designated ULIP6, comprising the amino acid sequence SEQ ID No. 2 or an epitopic fragment of said polypeptide, comprising the sequence SEQ ID No. 4, is provided along with its nucleic acid sequences. In addition, antibodies to the polypeptide and methods of diagnosing paraneoplastic neurological syndromes and/or... Agent: Stites & Harbison PLLC

20080226634 - Tes7 and antibodies that bind thereto: The invention provides the identification and characterization of disease and cancer-associated antigen, TES7. The invention also provides a family of monoclonal antibodies that bind to antigen TES7, methods of diagnosing and treating various human cancers and diseases that express TES7.... Agent: Morrison & Foerster LLP

20080226640 - C1q related protein: This invention relates to a novel protein, termed INSP162, herein identified as a secreted protein containing c1q and collagen domains and to the use of this protein and nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment of disease.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080226643 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group PLLC

20080226642 - Compositions and methods for the therapy and diagnosis of ovarian cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group PLLC

20080226637 - Haemophilus influenzae basb206 gene and protein: This invention relates to polynucleotides, (herein referred to as “BASB206 polynucleotide(s)”), polypeptides encoded by them (referred to herein as “BASB206” or “BASB206 polypeptide(s)”), recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including vaccines against bacterial infections. In... Agent: Ratner & Prestia- Sb Division

20080226639 - Heparin binding peptide: The invention relates to new peptide fragments capable of stimulating neurite outgrowth, stimulating of cell survival, stimulating neural plasticity associated with memory and learning, and modulating cell motility. The biological activity of the peptide fragments is associated with their capability of binding and activating a neurotrophin receptor of the Trk... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080226645 - Methods and compositions for assessment and treatment of asthma: The present invention provides methods and compositions for the assessment and treatment of asthma and other inflammatory diseases, particularly those mediated by interleukin-13 (IL-13). The present invention also provides arrays comprising markers for asthma as well as IL-13 responsiveness. The markers of the present invention can be used in methods... Agent: Wyeth Patent Law Group

20080226638 - Modifier of organelle metabolism: Provided herein are methods for the treatment of metabolism disorders by delivering a therapeutically effective amount of a modulator of a SOUP1 polypeptide. The invention also relates to a nucleic acid molecule encoding a polypeptide contributing to membrane stability and/or function of organelles.... Agent: Sutherland Asbill & Brennan LLP

20080226647 - Monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon: The invention relates to a monoclonal antibody directed against the human interferon class I receptor (IFN-R) characterized by the following properties: it recognizes the extracellular domain of the human IFN-R, and it has a neutralizing capacity against the biological properties of the human type I-IFN. It further concerns their use... Agent: Baker Botts L.L.P.

20080226644 - Novel cancer associated protein: The present invention relates to a novel polypeptide (BCMP 101) compositions comprising the polypeptide, including vaccines, and antibodies that are immunospecific for the polypeptide. The use of the polypeptide in the diagnosis, prophylaxis and treatment of cancer, in particular breast cancer is also provided.... Agent: Klauber & Jackson

20080226641 - Outer surface proteins, their genes, and their use: According to the present invention, a series of genes are identified in Group B Streptococcus, the products of which may be located on the outer surface of the organism. The genes, or functional fragments thereof, may be useful in the preparation of therapeutics, e.g. vaccines for the immunization of a... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080226646 - Use of biomolecular targets in the treatment and visualization of tumors: The present invention relates to the use of a protein that is differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as a biomolecular target for tumor treatment therapies. The protein is also expressed in tissues from adenocarcinoma, non-melanoma, and renal carcinoma cells. Immunotherapeutic and immunoimaging... Agent: Lahive & Cockfield, LLP/medarex Floor 30, Suite 3000

20080226651 - Compounds capable of inhibiting hiv-1 infection: This invention provides an antibody capable of specifically inhibiting the fusion of an HIV-1 envelope glycoprotein+ cell with an appropriate CD4+ cell without cross reacting with the HIV-1 envelope glycoprotein or CD4 and capable of inhibiting infection by one or more strains of HIV-1. This antibody is then used to... Agent: John P. White Cooper & Dunham LLP

20080226650 - Cotinine neutralizing antibody: The present application discloses monoclonal antibody against cotinine and nicotine.... Agent: Jhk Law

20080226649 - Cpg-like nucleic acids and methods of use thereof: Immunostimulatory compositions described as CpG-like nucleic acids are provided, including nucleic acids having immunostimulatory characteristics of CpG nucleic acid, despite certain substitutions of C, G, or C and G of the CpG dinucleotide. The substitutions can include, among others, exchange of methylated C for C, inosine for G, and ZpY... Agent: Wolf Greenfield & Sacks, P.C.

20080226648 - Methods for treating stress and affecting biological immune systems: The subject invention provides materials and methods for treating stress and/or augmenting immune response. More specifically, the present invention provides methods for the treatment and/or prevention of stress-related physiological responses; the alleviation of stress-related symptoms; as well as the prevention or delay in development of stress-related complications. The present invention... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080226652 - Binding molecules capable of neutralizing rabies virus and uses thereof: Provided are binding molecules that specifically bind to rabies virus and are capable of neutralizing the virus. Further provided are nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis,... Agent: Trask Britt

20080226653 - Inhibition of platelet aggregation: The present invention relates generally to the field of hyperglycemia-induced complications. More particularly, it concerns methods and compositions for the treatment and prevention of microvascular complications associated with diabetes. In one embodiment, the present invention provides a method of inhibiting hyperglycemia-induced platelet activation in a subject by administering to the... Agent: Fulbright & Jaworski L.L.P.

20080226654 - Uses of mammalian cytokine; related reagents: Provided are methods of treatment for bone disorders related to bone deposition and resorption dysfunction. These bone disorders may be the result of inflammation, cancers, etc. Provided are methods of using agonists or antagonists of a cytokine molecule.... Agent: Dnax Research Inc. Legal Department

20080226655 - Kallikrein-inhibitor therapies: Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.... Agent: Lowrie, Lando & Anastasi, LLP

20080226656 - Rg1 antibodies and uses thereof: The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.... Agent: Mandel & Adriano

20080226657 - Monomethylvaline compounds capable of conjugation to ligands: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.... Agent: Townsend And Townsend And Crew LLP

20080226658 - Targeting of glycoprotein therapeutics: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080226659 - Methods of treatment using anti-erbb antibody-maytansinoid conjugates: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-maytansinoid conjugates.... Agent: Heller Ehrman LLP

20080226662 - Dendritic cell co-stimulatory molecules: A novel costimulatory protein molecule, B7-DC, which is a member of the B7 family, is described as is DNA coding therefor and expression vectors comprising this DNA. B7-DC protein, fragments, fusion polypeptides/proteins and other functional derivatives, and transformed cells expressing B7-DC are useful in vaccine compositions and methods. Compositions and... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080226660 - Optimized expression of hpv 58 l1 in yeast: Synthetic DNA molecules encoding the HPV 52 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV 52 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. In alternative embodiments of the invention, the nucleotide sequence of the synthetic molecule is altered... Agent: Merck And Co., Inc

20080226661 - Phage screening assay: The present invention relates to a method for identifying an agent for potential use in a vaccine. The present invention also provides agents identified by this method for use in a vaccine. The present further describes peptides of the pathogen Mycoplasma for use as a vaccine to treat or present... Agent: Myers Bigel Sibley & Sajovec

20080226663 - Pine cone extracts and uses thereof: A method of producing a pine cone extract and the pine cone extract produced there from, wherein the pine cone extract is useful in increasing the effects of nucleic acid vaccines and medicaments; and useful in the production of phenotypically immature and/or mature dendritic and/or fibrocyte cells.... Agent: Howrey LLP - Dc

20080226664 - Colon cancer antigen panel: The invention provides methods, compositions and kits for inducing and/or enhancing an immune response in a subject. The invention in some aspects includes polypeptide and nucleic acid molecules that induce and/or enhance an immune response. In some aspects of the invention, the polypeptide and/or nucleic acid molecules of the invention... Agent: Wolf Greenfield & Sacks, P.C.

20080226665 - Epha2 t-cell epitopes and uses therefor: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify... Agent: Jones Day

20080226666 - Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof: The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the... Agent: Anne M. Rosenblum, Esq.

20080226667 - Innate immune system-directed vaccines: The present invention provides novel vaccines, methods for the production of such vaccines and methods of using such vaccines. The novel vaccines of the present invention combine both of the signals necessary to activate native T-cells—a specific antigen and the co-stimulatory signal—leading to a robust and specific T-cell immune response.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080226668 - Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes: The present invention regards methods and formulations for the treatment of diabetes and the prevention of autoimmune diabetes. The invention includes the administration of human recombinant GAD65 protein in a pharmaceutically acceptable adjuvant.... Agent: Roger A. Gilcrest

20080226670 - Canine combination vaccines: This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper... Agent: Pharmacia & Upjohn

20080226669 - Multivalent pcv2 immunogenic compositions and methods of producing such compositions: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence... Agent: Tracey S. Truitt Erickson & Kleypas, L.L.C.

20080226671 - Vaccines for mycoplasma bovis and methods of use: The invention of novel, effective vaccines against Mycoplasma. bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joint infections, keratoconjunctivitis and middle ear infections. The novel vaccines also lessen the effect of... Agent: Kenyon & Kenyon LLP

20080226672 - Adjuvant systems and vaccines: An adjuvant composition comprising monophosphoryl lipid A or a derivative of monophposphoryl lipid A adsorbed onto an aluminium salt particle.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080226673 - Subunit vaccine against respiratory syncytial virus infection: The present invention relates generally to methods of treating or preventing RSV infections, and more specifically, to compositions, and the use thereof, comprising one or more RSV G protein immunogen or fragment thereof capable of eliciting protective immunity without eliciting an immunopathological response or eliciting a reduced immunopathological response.... Agent: Glaxosmithkline Corporated Intellectual Property - Uw2220

20080226674 - Composition having antitumor effect: The present invention is intended to provide a pharmaceutical composition for delivering a chemotherapeutic, preferably an anticancer drug, into cells or into a living organism, using a viral envelope vector, and provides a pharmaceutical composition comprising a chemotherapeutic encapsulated in, or used in combination with, a viral envelope vector having... Agent: Banner & Witcoff, Ltd.

20080226675 - Recombinant vector and use in gene therapy: A recombinant vector for delivering A3G genes into human cells comprising (i) a gene expression block including an A3G gene selected from a wild type A3G gene represented by SEQ ID NO: 1 and a mutant A3G gene and (ii) a group of elements from a modified lentiviral vector including... Agent: Yuan Qing Jiang

20080226676 - Multivalent avian influenza vaccines and methods: The present invention provides vaccine compositions comprising at least two strains of avian influenza virus, wherein one of the strains has an H5 hemagglutinin subtype and the other strain has an H7 hemagglutinin subtype, and wherein at least one of the strains has an N4 neuraminidase subtype and neither strain... Agent: Wyeth Patent Law Group

20080226677 - Recombinant virus vector for gene transfer into lymphoid cells: A recombinant herpesvirus, a method for producing the recombinant herpesvirus, and a pharmaceutical composition comprising the recombinant herpesvirus, are provided with a method for producing a recombinant herpesvirus using a BAC vector sequence. In addition, a vector comprising a herpesvirus genomic gene and a BAC vector sequence, a cell comprising... Agent: Perkins Coie LLP

20080226678 - Compositions for immunizing against mycobacterium: A method for generating a T cell immune response in a host involving administering a vectored vaccine comprising a non-replicating or replication impaired viral vector expressing the translation product of a mycobacterial antigen 85A gene. Vectored vaccines and uses thereof are also provided. Also provided is a method of inducing... Agent: Brooks Kushman P.C.

20080226679 - Novel surface exposed proteins from chlamydia pneumoniae: The invention relates to the identification of members of a gene family from the human respiratory pathogen Chlamydia pneumoniae, encoding surface exposed membrane proteins of a size of approximately 89-101 kDa, preferably about 89.6-100.3 kDa and about 56.1 kDa. The invention relates to the novel DNA sequences, the deduced amino... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080226681 - Highly active glycoproteins-process conditions and an efficient method for their production: The present invention relates to highly active glycoproteins with specific sialylation degrees, a pharmaceutical composition for use in diagnosis or therapy comprising the glycoproteins, a method for the determination of highly active glycoproteins and of the conditions for their production, a method for producing the highly active glycoproteins, and a... Agent: Norris, Mclaughlin & Marcus, P.A.

20080226682 - Immunoactive compositions for improved oral delivery of vaccines and therapeutic agents: The present invention concerns methods and compositions for improved oral delivery of bioactive agents, such as vaccines. In preferred embodiments, the compositions comprise at least one lectin, saponin, polyunsaturated fatty acid and/or isoflavone. In further embodiments, the compositions may further comprise at least one protease inhibitor, buffer and/or surfactant. In... Agent: Faegre & Benson LLP Patent Docketing

20080226680 - Method and composition for delivery of medicants to animals: According to the present invention, a vaccine or pharmaceutical-containing composition is applied to the muzzle area of the animal, which will then naturally use its tongue to clean itself. This behavior will cause the animal to deposit applied composition to the mucosa of the nasal and oral cavities, thus meeting... Agent: Husch Blackwell Sanders LLP

20080226683 - Pharmaceutical composition including clinoptilolite: The invention is for a method of potentiating clinoptilolite, the method including the steps of: providing fresh or spent clinoptilolite; exposing the clinoptilolite to a saline solution having a sodium ion content of about 10% to liberate impurities from the clinoptilolite; and drying the washed clinoptilolite fraction to render a... Agent: Grossman, Tucker, Perreault & Pfleger, PLLC

20080226684 - Method and process for the production of multi-coated recognitive and releasing systems: The present invention includes compositions, methods, systems and kits for the controlled delivery of an active agent within a polymeric network upon the binding of a molecule that decreases the structural integrity of the polymeric network at one or more micro- or nanovacuoles.... Agent: Chalker Flores, LLP

20080226685 - Product and method for controlling flying insects: Insect control articles and methods of controlling insects comprising a cellulosic based substrate or matrix having a specified surface area impregnated and/or dosed with a vapour active pyrethroid in a carrier solvent, such that the vapour active pyrethroid is emanated into the environment at a rate of at least approximately... Agent: Merchant & Gould PC

20080226687 - Drug delivery and method having coated microprojections incorporating vasoconstrictors: A device and method are provided for percutaneous transdermal delivery of a biologically active agent. The coating formulation containing the biologically active agent and a vasoconstrictor is applied to the skin piercing elements using known coating techniques and then dried. The device is applied to the skin of a living... Agent: Edwards Angell Palmer & Dodge LLP

20080226686 - Generation of nitric oxide in situ at substrate/blood interfaces and reproducible nitric oxide sensor for detecting nitrosothiols: A material includes a surface and a reactive agent that is located at the surface of the material, covalently attached to a backbone of the material, and/or located within the material. The reactive agent has nitrite reductase activity, nitrate reductase activity, and/or nitrosothiol reductase activity. The reactive agent also converts... Agent: Julia Church Dierker Dierker & Associates, P.C.

20080226691 - Bone cement compositions having fiber-reinforcement and/or increased flowability: The present invention relates in general to implantable compositions, and method for preparing same, containing a calcium salt-containing component, optionally demineralized bone, a plurality of discrete fibers, optionally a flow additive, and optionally continuous reinforcing fibers or an array of organized fibers in the form of mesh. Advantageously, the discrete... Agent: Schwegman, Lundberg & Woessner / Synthes

20080226688 - Ceramic composition for filling bone defects: The invention is directed toward a sterile formable implant composition for application to a bone defect site comprising bioactive glass particles in an aqueous carrier solution, the bioactive glass particles being added to a viscous carrier at a concentration ranging from about 68% to about 76% (w/w), the carrier comprising... Agent: Jones Day

20080226690 - Heparosan-based biomaterials and coatings and methods of production and use thereof: The presently claimed and disclosed invention relates to biomaterial compositions that include an isolated heparosan polymer. The presently claimed and disclosed invention also relates to kits containing such biomaterial compositions, as well as to methods of producing such biomaterial compositions. The presently claimed and disclosed invention further relates to methods... Agent: Dunlap Codding, P.C.

20080226689 - Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles: This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The... Agent: Intarcia Therapeutics, Inc. Attn: Barbara G. Mcclung

20080226692 - Cultured cell sheet, production method thereof, and application method thereof: The problem to be solved by the present invention is to provide a cultured cell sheet that expresses phenotypes of the chondroid tissue. The problems can be solved by producing the cultured cell sheet in which cells are cultured on a surface of a cell culture support that is coated... Agent: Nixon & Vanderhye, PC

20080226693 - Apparatus and method for making a polymeric structure: The apparatus and method for preparing a polymeric structure from which a number of medical devices may be constructed is described. The structures are preferably formed from bioabsorbable materials using low temperature fabrication processes, whereby drugs or other bio-active agents are incorporated into or onto the device and degradation of... Agent: Philip S. Johnson Johnson & Johnson

20080226694 - Method for introducing superhydrophobic articles into the human body: An article to be inserted into the human body has a superhydrophobic surface. The superhydrophobic surface is coated with a water soluble thin but durable protective coat. One positioned inside the body the coating is rapidly dissolved by the blood or other fluids and exposes the superhydrophobic surface. To coat... Agent: Daniel Gelbart

20080226695 - Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom: The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film.... Agent: Hoffmann & Baron, LLP

20080226696 - Methods of improving learning abilities of aged companion animals: The present invention provides methods of improving learning ability of aged companion animals (such as aged dogs) by administering an effective amount of a carnitine and an effective amount of a lipoic acid. Also provided are kits and animal treats for improving learning ability of aged companion animals comprising effective... Agent: Morrison & Foerster LLP

20080226698 - Amorphous drug transdermal systems, manufacturing methods, and stabilization: The present invention refers to a transdermal delivery device comprising a backing layer, an adhesive matrix layer comprising a supersaturated concentration of an active agent substantially in amorphous form within the adhesive matrix, and a release liner. The present invention also refers to a method of preparing an adhesive matrix... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080226697 - Patch for external use with elevated content of absorption promoter in pressure-sensitive adhesive base: A pressure-sensitive adhesive composition for transdermal absorption which contains a drug and a transdermal absorption promoter for the drug, characterized by further containing polyvinylpyrrolidone so as to stabilize the transdermal absorption promoter contained in the adhesive composition. Thus, the transdermal absorption promoter can be prevented from vaporization or degradation and... Agent: Licata & Tyrrell P.C.

20080226703 - Human growth hormone patch formulations: The invention encompasses a transdermal patch formulation comprising hGH, at least one sugar, one amino acid or polyol, and a buffer, wherein the buffer maintains the pH of the formulation in the range of about 5 to about 9 and the formulation does not contain both glycine and mannitol.... Agent: Winston & Strawn LLP Patent Department

20080226700 - Medicated gauze: The present invention relates to a medicated gauze containing as active ingredient, aliantoin, a Centella Asiatica extract and, optionally, an Urtica dioica extract.... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080226701 - Medicated patches: An athletic head gear having a hard outer shell, at least one soft inner padding cushioning the head of a user from the hard outer shell, and a medicated patch including an adhesive layer contacting the soft inner padding, and a medicated layer for contacting the user's skin, where the... Agent: Katten Muchin Rosenman LLP

20080226699 - Method and system for rapid transdermal administration: Invention relates to a method for transdermal delivery of a topically applied physiologically active agent comprising: providing a micro-projection apparatus comprising an array of microprojections (3) extending from a substrate; applying the array of micro-projections to an area of skin to form an array of microscopic holes therein; and contacting... Agent: Foley And Lardner LLP Suite 500

20080226702 - Transdermal delivery form disposal systems and methods: The extraction and use of residual opioids from transdermal dosage forms can be reduced by placement and fixation of used dosage forms onto a surface. The used dosage form can be fixed to the surface such that it cannot be removed without at least partially destroying the matrix containing the... Agent: Ip Group Of Dla Piper US LLP

20080226705 - Gel delivery system for oral administration of medicaments: The invention relates to a swallowable delivery device fabricated from a composition including a hydrated polymeric matrix with gelatinous consistency, one or more active ingredients, and optionally one or more stiffening agent. The delivery device is of a size and shape amenable to swallowing with enhanced solubility and controlled release... Agent: Moore & Van Allen PLLC

20080226704 - Method of producing coated fine particles: The present invention provides a method of producing coated fine particles in which core fine particles is coated with a coating layer, which comprises the steps of preparing a liquid (liquid A) containing a polar organic solvent in which core fine particles are dispersed and a component constituting a coating... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080226709 - Phospholipid membrane preparation: The present invention aims at providing a phospholipid membrane preparation wherein an antigen or an allergen is bound onto the surface of a phospholipid membrane comprising a phospholipid containing an acyl group or a hydrocarbon group having 10 to 12 carbon atoms, and a stabilizer of a phospholipid membrane. The... Agent: Leydig Voit & Mayer, Ltd

20080226708 - Silicone vesicles containing actives: Processes are disclosed for preparing silicone vesicle compositions and emulsions containing silicone vesicles, the compositions prepared therefrom, and formulated personal and healthcare products containing the silicone vesicles and emulsions compositions.... Agent: Dow Corning Corporation Co1232

20080226706 - Use of repeat sequence protein polymers in personal care compositions: The present invention provides personal care compositions, and more particularly, personal care compositions comprising a bioactively effective amount of a repeat sequence protein polymer. In some particularly preferred embodiments, the present invention provides personal care compositions comprising an effective amount of at least one fragment of a repeat sequence protein... Agent: Kamrin T. Macknight Genencor International, Inc.

20080226707 - Wnt compositions and methods of use thereof: Methods and compositions are provided for the therapeutic use of Wnt proteins, where the Wnt protein is inserted in the non-aqueous phase of a lipid structure. In some embodiments the Wnt protein is presented in its active conformation on an outer liposome membrane or micelle. Pharmaceutical compositions of the present... Agent: Bozicevic, Field & Francis LLP

20080226710 - Ubiquinol and alpha lipoic acid compositions: The present invention is directed to compositions and methods of delivery of CoQ that is reduced in the presence of lipoic acid and, optionally a fatty acid and/or optionally in a monoterpene. The compositions that include the reduced CoQ can be formulated in soft gel capsules.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080226711 - Pharmaceutical compositions of duloxetine: The present invention relates to solid oral pharmaceutical compositions of duloxetine, process for preparing such compositions and method of using such compositions. Preferably, the invention relates to a delayed release composition of duloxetine comprising a core comprising duloxetine, optional separating coat and an enteric coat.... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20080226712 - Oral administration form for pyridin-2-ylmethylsulfinyl-1h benzimidazoles: The invention relates to an oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles and their salts, which comprises the active compound together with tablet disintegrants and is provided with a film coating customary per se for sustained-release compositions.... Agent: Nath & Associates PLLC

20080226716 - Amino acid conjugates providing for sustained systemic concentration of gaba analogues: Compounds that provide for sustained systemic concentrations of GABA analogs following oral administration to animals are disclosed. Pharmaceutical compositions including, and methods using, such compounds are also disclosed.... Agent: Buchanan, Ingersoll & Rooney PC

20080226713 - Controlled release pharmaceutical compositions of tolperisone for oral administration: The invention relates to a tolperisone-containing pharmaceutical preparation with controllable active-substance release for oral administration, characterised in that the active substance tolperisone and/or a pharmaceutical salt thereof is embedded in a pharmaceutically compatible material. By selecting the pharmaceutically compatible materials in the preparation and accordingly in the coating of a... Agent: Roberta L. Robins Robins & Pasternak

20080226714 - Sustained-release tablet formulations of piperazine-piperidine antagonists and agonists of the 5-ht1a receptor having enhanced intestinal dissolution: The present invention relates to sustained-release tablet formulations of piperazine-piperidine compounds, which can be useful in treating central nervous system disorders; to processes for their preparation; and to methods of using them.... Agent: Wilmerhale/wyeth

20080226715 - Therapeutic compositions and methods: The present invention provides compositions, methods and kits for treating, preventing or reducing the risk of developing a CNS disorder. In general, the invention involves utilizing caffeine for preventing or alleviating pathological symptoms of a CNS disorder, such as headache, epilepsy, pain, Parkinson's disease, psychiatric disorders such as anxiety, bipolar... Agent: Wilson Sonsini Goodrich & Rosati

20080226718 - Indole and azaindole derivatives for the treatment of inflammatory and autoimmune diseases: The use is described of compounds of formula (I) wherein A is chosen from a phenyl or a heterocyclic ring with 5 or 6 members containing up to two heteroatoms chosen from nitrogen, oxygen and sulfur, X and Y represent carbon or nitrogen, and R1-R6 are as described in the... Agent: Squire, Sanders & Dempsey L.L.P.

20080226717 - Sublingual coated tablet: The present invention relates to a sublingual coated tablet and to a method for the preparation thereof. The tablet includes a core devoid of a pharmaceutically active substance, and a coating including at least one active substance. The preferred active substance is an opioid analgesic.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20080226719 - Combination of rosiglitazone and donepezil for improvement of cognitive function: Disclosed is a pharmaceutical composition comprising both rosiglitazone or a pharmaceutically acceptable salt thereof and donepezil or a pharmaceutically acceptable salt thereof which is of use in the treatment or prophylaxis of Alzheimer's disease or other dementias and mild cognitive impairment. Also disclosed is an oral dosage forms comprising rosiglitazone... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080226720 - Wound healing composition: The present invention relates to compositions and methods for tissue regeneration, particularly for treating skin lesions such as wounds. In one aspect, the invention provides a wound healing composition comprising living cells such as fibroblasts within a support matrix such as fibrin, in which the cells have a wound healing... Agent: Clark & Elbing LLP

20080226722 - Gel composition comprising charged polymers: Aqueous gel compositions are disclosed which are useful as drug carriers for controlled delivery applications, such as for parenteral depot formulations. The gels comprise ionically charged microparticles, and preferably mixtures of oppositely charged microparticles. The microparticles can be loaded with active compounds, such as therapeutic peptides and proteins. The gels... Agent: Morrison & Foerster LLP

20080226723 - Loadable polymeric particles for therapeutic use in erectile dysfunction and methods of preparing and using the same: Particles are provided for use in restorative procedures to treat erectile dysfunction. The particles include poly[bis(trifluoroethoxy)phosphazene] and/or derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such... Agent: Sutherland Asbill & Brennan LLP

20080226725 - New and advantageous hydrogel composition: New hydrogel, including a hydrogel containing cationic BSA is included in a vaccine to stimulate the immune system to increase the potency of the vaccine.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080226721 - Porous bodies and method of production thereof: Porous bodies which are soluble or dispersible in non-aqueous media comprising a three dimensional open-cell lattice containing (a) 10 to 70% by weight of a polymeric material which is soluble in water immiscible non-aqueous media and (b) 30 to 90% by weight of a surfactant, said porous bodies having an... Agent: Unilever Patent Group

20080226724 - Prevention of hydrogel viscosity loss: The present invention comprises methods and compositions for decreasing or preventing viscosity loss in hydrogels.... Agent: Quine Intellectual Property Law Group, P.C.

20080226726 - 3d-cardiac tissue engineering for the cell therapy of heart failure: A pharmaceutical composition comprising biodegradable gel-based matrix, at least one active agent and stem cells able to differentiate into cardiac tissue under the form of a patch, for the treatment of heart failure due to myocardial infarction is disclosed.... Agent: Young & Thompson

20080226728 - Antimicrobial nanoparticulate additives forming non-leachable sustained antimicrobial polymeric compositions: The present invention provides a particle comprising at least one aliphatic polymer having anti-microbially active quaternary ammonium groups chemically bound thereto. The particle of the invention may be used to inhibit populations of microorganisms and biofilms. Also provided are methods for the preparation of such particles and uses thereof for... Agent: Nath & Associates

20080226734 - Combination of a narcotic and non-narcotic analgesic: The present invention is directed to a formulation comprising a narcotic analgesic and a non-narcotic analgesic, methods of use and methods of preparing thereof.... Agent: Fox Rothschild, LLP Elan Pharma International Limited

20080226736 - Inhalatory pharmaceutical compositions in form of dry powders, solutions or suspensions obtained from the same and process for their preparation: Inhalatory pharmaceutical composition comprising a drug, a soluble excipient and a surfactant, characterized by: said soluble excipient is present in an amount between 10% and less than 100% by weight; —the weight ratio between said surfactant and said drug is between 0.01 and 10; —the particle size of at least... Agent: Connolly Bove Lodge & Hutz LLP

20080226732 - Nanoparticulate compositions of angiogenesis inhibitors: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner

20080226730 - Particles for inhalation having rapid release properties: The invention generally relates to formulations having particles comprising phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled insulin formulations are disclosed. Improved formulations comprising DPPC, insulin and sodium citrate which are useful in the treatment of diabetes are disclosed. Also, the invention relates to a... Agent: Elmore Patent Law Group, PC

20080226731 - Pharmaceutical compositions comprising i matinib and a release retardant: Sustained release pharmaceutical compositions that contain imatinib or a pharmaceutically acceptable salt thereof. The pharmaceutical compositions further contain a release retardant, for example a water soluble, a water swellable and/or a water insoluble polymer. The present invention also features a particularly useful process of making such sustained release pharmaceutical compositions... Agent: Novartis Corporate Intellectual Property

20080226735 - Rare earth metal compositions for treating hyperphosphatemia and related methods: Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the... Agent: Morrison & Foerster LLP

20080226733 - Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals: The present invention relates to spatially arranging a plurality of particles in a device for the oral delivery of a pharmaceutical. In particular, the plurality of particles is utilized for the oral delivery of a pharmaceutical to a subject via the drinking device.... Agent: Kv Pharmaceutical Company

20080226729 - Stable powder formulations of alum-adsorbed vaccines: The present invention is directed to methods for preparing a stable powder formulation of an alum-adsorbed vaccine. The methods comprise atomizing a liquid formulation comprising an immunogen adsorbed onto an aluminum adjuvant to produce an atomized formulation, freezing the atomized formulation to produce frozen particles, and drying the frozen particles... Agent: David W. Highet, Vp & ChiefIPCounsel Becton, Dickinson And Company

20080226737 - Use of calcitonin for the treatment of ra: The present invention relates to a novel use of calcitonin in rheumatoid arthritis, and to methods of treating and/or preventing rheumatoid arthritis and conditions associated therewith in mammals, particularly humans. In particular, a method is provided of preventing or/and treating rheumatoid arthritis in a patient in need thereof comprising administering... Agent: Novartis Corporate Intellectual Property

20080226727 - Water-in-silicone oil emulsion for use as a sunscreen product: A water-in-silicone oil emulsion contains (i) in the range from 0.1 to 25% by weight of particles of metal oxide having a median particle volume diameter in dispersion in the range from 18 to 32 nm, (ii) 5 to 60% by weight of silicone oil, and (iii) greater than 20%... Agent: Mayer, Brown, Rowe & Maw LLP

20080226738 - Sustained-released pellet formulation of alpha1-receptor antagonist and process for the preparation thereof: A sustained-release pellet formulation comprising: a pellet core comprising an α1-receptor antagonist, a pellet-forming substance and a pharmaceutically acceptable excipient and a coating layer comprising an enteric coating substance and a water-insoluble polymer, which is coated on said pellet core maintains a therapeutically effective drug level in the blood for... Agent: Sughrue Mion, PLLC

20080226739 - Hierarchically self-assembling linear-dendritic hybrid polymers for delivery of biologically active agents: A linear-dendritic hybrid polymer for encapsulating biologically active materials. The hybrid polymer includes a ligand for a predetermined target, a dendron, and a polyethylene glycol (PEG) chain linking the ligand to the dendron.... Agent: Choate, Hall & Stewart LLP

20080226740 - Marine algal extracts comprising marine algal polysaccharides of low degree polymerizaton, and the preparation processes and uses thereof: Disclosed herein are marine algal extracts containing marine algal polysaccharides of low degree polymerization, and nanoparticles fabricated from the extracts. Preparation processes and applications of the marine algal extracts and the nanoparticles are also disclosed.... Agent: Birch Stewart Kolasch & Birch

20080226742 - Compositions for drug delivery: Substantially non-porous polymeric microparticles comprising a hydrophobic polymer and a plasticizer, and containing therein a bioactive or bioinactive agent.... Agent: Dr. Reddy's Laboratories, Inc.

20080226741 - Cross-linked polymer particles: Biodegradable cross-linked particles, as well as related compositions and methods, are disclosed.... Agent: Fish & Richardson PC

20080226743 - Agent for photodynamic therapy containing porous silicon and method of quantitative measurement of reactive oxygen species produced therefrom: The present invention relates to an agent for photodynamic therapy (PDT) containing porous silicon (PSi) and a method of quantitative measurement of reactive oxygen species (ROS) produced therefrom. Particularly, it is expected that the present invention will contribute to the development of cancer treatment without side effects by suggesting PSi,... Agent: Greenlee Winner And Sullivan P C

20080226744 - Dietary supplement and related method: A composition including a unique combination of fruits, vegetables, herbs, and optionally vitamins, minerals and specialty ingredients. The composition can include a fruit ingredient, a vegetable ingredient and an herbal ingredient, wherein the fruit ingredient is at least one of pomegranate and citrus bioflavonoids, wherein the vegetable ingredient, is at... Agent: Warner, Norcross & Judd In Re: Alticor Inc.

20080226745 - Products containing highly unsaturated fatty acids for use by women during stages of preconception, pregnancy and lactation/post-partum: A method and product for improving maternal and child health through nutrition. Omega-6 fatty acid and/or omega-3 fatty acid are provided to a woman and/or child prior to, during and/or after pregnancy to improve the health of the woman and her child. The ratios of the omega-6 and omega-3 fatty... Agent: Sheridan Ross P.C.

20080226746 - Nutritional supplement for women: A nutritional supplement comprising a variety of vitamins and minerals is described. A nutritional supplement comprising between about 1 mg and about 5 mg of vitamin B1, between about 2 mg and about 8 mg of vitamin B2, between about 7 mg and about 30 mg of vitamin B6, between... Agent: Maldjian & Fallon LLC

20080226747 - Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same: The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.... Agent: Seed Intellectual Property Law Group PLLC

20080226748 - Stabilized chlorine dioxide and hypochlorous acid in a liquid biocide: A liquid biocide containing stabilized chlorine dioxide and hypochlorous acid for various uses, including use as a teat dip or dairy animals. The stable, prophylactic biocide consists essentially of 0.10-20.0% by weight of a chlorite salt, 0.1-3.0% by weight of an acid, 0.10-2.0% by weight of an alkaline agent, and... Agent: Andrus, Sceales, Starke & Sawall, LLP

20080226749 - Pharmaceutical composition for inhibiting the syndrome of snoring and preparation thereof: The present invention discloses a pharmaceutical composition for inhibiting a snore symptom, which comprises medicinal material of Uncaria rhynchophylla. The above pharmaceutical composition of the present invention also comprises medicinal materials of Uncaria rhynchophylla, Ephedra, Prunus armeniaca, and Glycyrrhiza uralensis.... Agent: Bacon & Thomas, PLLC

20080226750 - Methods, compositions and articles of manufacture for treating shock and other adverse conditions: The present invention concerns the use of active compounds for inducing apnea and treating shock, in addition to enhancing the survivability of a subject. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving these effects.... Agent: Fulbright & Jaworski L.L.P.

20080226751 - Pharmaceutical composition containing nitrate source and an acidifying agent for treating skin ischaemia: The use of acidified nitrate as an agent to produce local production of nitrate oxide at the skin surface is described in the treatment of peripheral ischaemia and associated conditions. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the... Agent: Osha Liang L.L.P.

20080226752 - Kits of hydralazine compounds and isosorbide dinitrate and/or isosorbide mononitrate: The present invention provides methods of treating and preventing mortality associated with heart failure in an African American patient with hypertension and improving oxygen consumption, quality of life and exercise tolerance by administering a therapeutically effective amount of at least one hydralazine compound and at least one of isosorbide dinitrate... Agent: Wilmerhale/dc

20080226755 - Composition to enhance the bioavailability of curcumin: A composition for enhanced bioavailability of curcumin including purified curcuminoid and purified essential oil of turmeric. A method to prepare a composition for enhanced bioavailability of curcumin having purified curcuminoid and purified essential oil of turmeric.... Agent: Jyoti C. Iyer, Esq.

20080226754 - Method for treatment of cartilage disorders with centella extract: The invention is a method for the treatment of mammalian articular cartilage disorders, inflammatory joint disease, trauma-related cartilage injuries, and degenerative disc disease. The method involves treating the affected area with a composition containing a therapeutically effective dose of Centella extract. The composition is delivered locally by parenteral administration to... Agent: Roberts Mlotkowski Safran & Cole, P.C.

20080226753 - Method of reducing insect resistant pests in transgenic crops: The present invention discloses Resistance Management (RM) practices that are critical to safeguarding Bacillus thuringiensis as a natural resource and to sustaining genetically modified crops that express Bt toxins for managing ECB and WCRW. The methods involve blending seed transformed with a nucleic acid encoding a different pesticidal protein, where... Agent: Mckee, Voorhees & Sease, P.L.C Attn: Pioneer Hi-bred

20080226756 - Compositions comprising a c-glycoside compound: e

20080226757 - Use of a ginkgo complexes for the enhancement of cognitive functions and the alleviation of mental fatigue: The invention is directed to the use of Ginkgo complexed with phosphatidylserine for the manufacture of a medicament or a dietary supplement for the enhancement of cognitive function and mental fatigue, i.e. to improve the factors related therewith such as to improve the speed of memory and memory quality, to... Agent: Young & Thompson

20080226758 - Lipoxygenase and cyclooxygenase inhibition: The present invention relates to methods, compositions and their constituents for inhibiting 5-Lipoxygenase (5-LO), 15-Lipoxygenase (15-LO), cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), in living organisms. More particularly, the present invention relates to methods and compositions involving the inhibition of 5-Lipoxygenase (5-LO), 15-Lipoxygenase (15-LO), cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), using processed Morinda... Agent: Kirton And Mcconkie

20080226760 - Antimicrobial composition and use thereof: This invention relates to compositions with broad antimicrobial activity against bacteria, fungi, and protozoans. The compositions and methods of the present invention can be used in the prevention and treatment of pathogenic processes in people and animals by any administration method (oral, topical, or parenteral), as a performance improver in... Agent: Darby & Darby P.C.

20080226759 - System for treating addictions: A system for treating addictions includes genetic testing to determine the presence of allelic variants of genes shown to be associated with impulsive/addictive behaviors and a tailored rehabilitation regimen of specific physical exercise, special diet and particular dietary supplements to optimize the way mood elevation is achieved in the patient.... Agent: Belasco, Jacobs & Townsley LLP Howard Hughes Center

20080219920 - Chimeric, human and humanized anti-csap monoclonal antibodies: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.... Agent: Immunomedics, Inc.

20080219919 - Cytotoxicity mediation of cells evidencing surface expression of cd44: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a... Agent: Mchale & Slavin, P.a.

20080219922 - Alzheimer's disease imaging agents: This invention provides compounds and methods of imaging amyloid deposits using radiolabeled compounds. This invention also provides a method of inhibiting the aggregation of amyloid proteins to form amyloid plaques or deposits, a method of determining a therapeutic compound's ability to inhibit aggregation of amyloid protein, and a method of... Agent: Greenlee Winner And Sullivan P C

20080219921 - Novel technetium and rhenium complexes.: Novel radioactive technetium and rhenium complexes comprising tripodal ligands are provided by the present invention. In particular, Tc(I) complexes are provided by the present invention. Novel ligands suitable for the formation of the technetium and rhenium complexes of the invention are also provided, as well as radiopharmaceutical compositions comprising said... Agent: Ge Healthcare, Inc.

20080219923 - Method and kit for the production of particles labelled with rhenium-188: Rhenium-188 labeled particles are produced by suspending particles of an organic polymer or a biopolymer in a solution wherein the solution contains a water-soluble tin-II salt and a Re-188 perrhenate salt with a radioactivity of 1,000 MBq to 60,000 MBq and wherein the solution has initially a pH value of... Agent: Gudrun E. Huckett Draudt

20080219927 - Adenosine derivative formulations for medical imaging: A stable composition useful for myocardial perfusion imaging contains one or more 2-alkynyladenosine derivatives; and a solvent which is made up of water and hydroxypropyl-β-cyclodextrin.... Agent: Williams Mullen

20080219925 - Delta opioid receptor protein: Recombinant forms of isolated and purified delta opioid receptors and methods to screen for compounds interactive with delta opioid receptors are described.... Agent: Morrison & Foerster LLP

20080219924 - Imaging, diagnosis and treatment of disease: The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascular endothelium.... Agent: Wolf Greenfield & Sacks, P.c.

20080219928 - Measuring gastrointestinal parameters: The present application relates to methods for determining gastric residual volumes and amounts of dietary formula in gastric contents using measurements of soluble solids concentrations in gastric contents, and in some embodiments, a concentrate having a relatively high concentration of soluble solids. The methods can be used for measuring gastric... Agent: Whyte Hirschboeck Dudek S C

20080219929 - Neurofibrillary labels: A method for determining the Braak stage of neurofibrillary degeneration associated with a tauopathy in a subject having neurofibrillary degeneration is disclosed. The method comprises the steps of (i) administering to the subject a conjugated, chelated or detectable chemical group-associated ligand that labels aggregated paired helical filament (PHF) tau protein... Agent: Foley And Lardner LLP Suite 500

20080219926 - Sers molecular probe for diagnostics and therapy and methods of use thereof: An oligonucleotide-based SERS molecular probe (SMP) includes a nanoparticle having at least a metal component, and at least one pin loop, the pin loop including a loop sequence complementary to at least one target sequence, a first stem attached to one end of the loop sequence, a second stem attached... Agent: Akerman Senterfitt

20080219931 - Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies: The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or Formula (II) or structures 1-45 and imaging the patient. After said imaging, at least one anti-amyloid agent is administered to said patient.... Agent: Foley And Lardner LLP Suite 500

20080219930 - Method for the evaluation of dengue virus therapeutic agents: The inventive subject matter relates to a method for evaluating potential compounds and vaccines for the prevention or treatment of dengue virus infection. The method utilizes pigs as an animal model for the evaluation of test vaccine or drug compounds. The breeds that can be utilized and in the inventive... Agent: Naval Medical Research Center Attn: (code 00l)

20080219932 - Magnetic resonance spectroscopy of breast biopsy to determine pathology, vascularization and nodal involvement: Robust classification methods analyse magnetic resonance spectroscopy (MRS) data (spectra) of fine needle aspirates taken from breast tumours. The resultant data when compared with the histopathology and clinical criteria provide computerized classification-based diagnosis and prognosis with a very high degree of accuracy and reliability. Diagnostic correlation performed between the spectra... Agent: Cooper & Dunham, LLP

20080219933 - Fluorescence-mediated molecular tomography: This invention relates to a fluorescence-mediated molecular tomographic imaging system, designed to detect near-infrared fluorescence activation in deep tissues. The system can use targeted fluorescent molecular probes or highly sensitive activatable fluorescence molecular probes. Such probes add molecular specificity and yield high fluorescence contrast, to allow early detection and molecular... Agent: Fish & Richardson Pc

20080219934 - Anionic, ampholytic copolymers for low-voc-compositions: The present invention provides cosmetic compositions containing a copolymer obtainable by the copolymerization of at least one methacrylic acid ester, methacrylic acid, acrylic acid, optionally at least one compound containing amino groups and polymerizable by free radical polymerization, and optionally other olefinically unsaturated compounds polymerizable by free radical polymerization. The... Agent: Connolly Bove Lodge & Hutz LLP

20080219935 - Phase transitive breath care products: Disclosed herein is a breath freshener whose phase is changed depending on the condition of use. A breath freshener of W/O emulsion phase comprises a monoglyceride as a main base, a polymer, an effective component for breath freshening, and a solvent. A breath freshener of solution phase comprises a monoglyceride... Agent: Birch Stewart Kolasch & Birch

20080219936 - Skin depigmenting compositions comprising adapalene, at least one depigmenting agent and at least one anti-inflammatory agent: Depigmenting compositions for the skin, comprise, formulated into a physiologically acceptable medium, adapalene, at least one depigmenting agent and at least one anti-inflammatory agent, and to the pharmaceutical/cosmetic applications thereof.... Agent: Buchanan, Ingersoll & Rooney Pc

20080219938 - Spf compositions: A composition comprising; water purified using ozonation, ionization, or distillation or any combination thereof wherein alcohol may be substituted for, or combined with water; at least one emollient including but not limited to chitosan, and aloe vera gel, individually or in any combination; an oil component with spf boosting agents... Agent: Guerry Leonard Grune

20080219939 - Sunblock formulations: Disclosed is a sunblock composition providing ultraviolet radiation protective agents that can be used in various compositions or formulations, specifically those of a higher SPF value that utilize micronized zinc dioxide, micronized titanium oxide, glass microspheres, glycerin and/or aloe, a carrier oil, and an emulsifier. The emulsifier is selected from... Agent: Guerry Leonard Grune

20080219937 - Use of at least one 2-alkyl furan, as depigmenting or lightening active principle: The invention concerns the cosmetic use of at least one 2-alkyl furan, as depigmenting active principle, in a depigmenting composition, as well as the associated cosmetic treatment method. The invention also concerns the use of at least one 2-alkyl furan for preparing an active drug as depigmenting agent. The invention... Agent: Faegre & Benson LLP Patent Docketing

20080219940 - Colored cosmetic composition having soft focus effect: Colored cosmetic compositions include, in a physiologically acceptable medium, a filler and a coloring agent, the coloring agent having a transparency and/or being present in a quantity such that presence of the coloring agent with the filler in the composition confers a saturation C* of greater than or equal to... Agent: Oliff & Berridge, Plc

20080219941 - Compositions and methods for removing hair styling aids: Disclosed are compositions for solubilizing and/or removing a hair styling aid composition from hair. The compositions comprise at least one active solvent, wherein the active solvent is a glycol or an ester; and a carrier composition comprising a liquid vehicle. Also disclosed are methods for solubilizing and/or removing hair styling... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20080219942 - Hair treatment composition: An improved hair treatment composition that strengthens cellulosic fiber found in the composition of hair, that eliminates the degradation of hair, and that provides for skin protection from the adverse reaction of caustic alkaline preparations found in professional hair products that are used in the bleaching and strengthening hair. The... Agent: Powell Law Associates, Llc Marvin J. Powell, Esquire

20080219943 - Composition for coating keratin fibres comprising a block polymer and a semicrystalline polymer: A subject of the invention is a composition for coating keratin fibres comprising a cosmetically acceptable medium, a block polymer, and at least one semicrystalline polymer. A subject of the invention is also the use of such a composition for obtaining a makeup for the keratin fibres, in particular the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080219944 - Polymer based antifouling coating: A coating composition comprising (i) at least one resin powder and (ii) at least one component selected from the group consisting of a metal compound, biocide and fluoropolymers. In particular, one antifouling composition that can be used on underwater stationary structures that sit in highly fouling environments comprises polyethylene as... Agent: Dilworth & Barrese, LLP

20080219945 - Pheromones and method of preventing infestation of contarinia nasturtii: The present invention relates to pheromone mixture comprising 2,9 diacetoxyundecane, 2,10-diacetoxyundecane and 2-acetoxyundecane, as a racemate or, biologically active stereoisomers thereof, as well as a method for monitoring and/or mating disruption of swede midge, Contarinia nasturtii, in Brassica vegetables, in particular Brussels sprouts, cauliflower and broccoli.... Agent: Gauthier & Connors, LLP

20080219946 - Therapeutic agent and method for ovulation disorder caused by luteinized unruptured follicle: A therapeutic agent for ovulation disorder of the present invention is characterized in comprising Granulocyte colony-stimulating factor; and that the ovulation disorder is caused by Luteinized Unruptured Follicle.... Agent: Fitch, Even, Tabin & Flannery

20080219949 - Methods for treating brain cancer using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6 dioxo(3-piperidyl))-isoindoline-1,3-dione: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or... Agent: Jones Day

20080219948 - Methods for treatment of behcet's disease using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or... Agent: Jones Day

20080219947 - Single chain trimers and uses therefor: Single chain trimer (SCT) molecules are disclosed, comprising an MHC antigen peptide sequence, a β2-microglobulin sequence and a full-length MHC class I heavy chain sequence, joined by linker sequences. Further described are nucleic acids encoding single chain trimers. Methods for expansion of antigen-specific T cell populations using single chain trimer... Agent: Sonnenschein Nath & Rosenthal LLP

20080219950 - Derivatives of growth hormone and related proteins: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in... Agent: Sheridan Ross Pc

20080219951 - Stabilization of biologically active proteins with mixtures of polysaccharides and amino acid based compounds: The invention provides heat stable aqueous solutions or gels comprising a biologically active protein and a stabilizing effective amount of a mixture of a polysaccharide and an amino acid based compound. The invention also discloses stabilized solutions or gels suitable for use in an implantable drug delivery device at body... Agent: Battelle Memorial Institute

20080219952 - Process for the preparation of glycosylated interferon beta: The present invention relates to a process for the production of interferon beta, and to an interferon beta composition having a unique glycosylation pattern.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080219953 - Cosmid dna constructs and methods of making and using same: Methods of inducing immune responses in individuals against a pathogen are disclosed. Methods of treating individuals susceptible to or suffering from a disease associated with a genetic defect which results in the non-production or under production of a protein or the production of a non-functioning or partially functioning protein are... Agent: Pepper Hamilton LLP

20080219954 - Method for rapid screening of bacterial transformants and novel simian adenovirus proteins: Chimpanzee serotype C68 proteins, peptides, and polypeptide are provided. Also provided are novel adenoviruses derived from these proteins, as well as compositions containing these proteins and methods of using same for immunization and therapy. Further, a rapid method for screening recombinant transformants using a visually detectable method is described.... Agent: Howson And Howson

20080219959 - Support having nanostructured titanium dioxide film and uses thereof: The present invention relates to supports for bioassays and the use thereof in cell culturing and in cell-based methods and assays. More precisely, the invention provides solid materials coated with films of nanostructured titanium dioxide suitable for the immobilisation of viruses and for cell-adhesion. The nanostructured TiO<SUB>2</SUB> film-coated support of... Agent: St. Onge Steward Johnston & Reens, Llc

20080219960 - Novel efficient production process for capsular polysaccharides of pathogenic grampositive bacteria by heterologous expression and secretion of complex polysaccharides in non-pathogenic, non-invasive gram-positive bacteria: The current invention provides methods and means for heterologous expression, production and/or secretion of complex capsular polysaccharides in non-pathogenic, non-invasive Gram-positive bacteria. The invention in particular provides non-pathogenic, non-invasive Gram-positive bacteria capable of expression and/or secretion of heterologous, complex polysaccharides from a pathogenic bacterial species. Such bacteria and polysaccharides produced... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080219961 - Method for stabilising pharmaceutical administration forms comprising microorganisms: The invention relates to a method for stabilising solid pharmaceutical administration forms which comprises at least one species of microorganism, and to a pack comprising packaging and a solid pharmaceutical administration form which comprises at least one species of microorganism.... Agent: Millen, White, Zelano & Branigan, P.c.

20080219956 - Hla homozygous cells and methods of use thereof: The present invention provides methods of generating a mammalian cell that is homozygous at a locus of interest, as well as cells made by the method. The present invention further provides methods of using the cells.... Agent: Bozicevic, Field & Francis LLP

20080219958 - Method for inducing an anti-tumor and anti-cachexia immune response in mammals: The invention relates to inducing an immune response toward tumor associated antigens and in particular to the administration of high molecular weight isolates of autologous urine either alone, with adjuvants, or with antigen presenting cells. The antigen presenting cells have been cocultured with isolates of autologous urine. The invention can... Agent: Knobbe Martens Olson & Bear LLP

20080219957 - Method of deriving mesenchymal stem cells: We disclose a method comprising: (a) providing an embryonic stem (ES) cell; and (b) establishing a progenitor cell line from the embryonic stem cell; in which the progenitor cell line is selected based on its ability to self-renew. Preferably, the method selects against somatic cells based on their inability to... Agent: Cohen & Grigsby, P.c.

20080219955 - Method of producing purified neural stem cells and related methods of treating a patient: The present invention provides a method of producing purified neural stem cells, comprising harvesting fluid containing neural stem cells from cerebrospinal fluid surrounding the spinal cord of an individual, isolating the neural stem cells from the fluid, culturing the neural stem cells in a culture medium effective to induce proliferation... Agent: Eckert Seamans Cherin & Mellott

20080219963 - Composition containing micronutrients with improved anti-oxidant activity and the use thereof: Compositions in fine powder form that can be obtained by means of a dry co-grinding process of an at least ternary mixture consisting of an active substance, a carrier and at least one auxiliary co-grinding substance, wherein the active substance is constituted by one or more micronutrient substances with particular... Agent: Connolly Bove Lodge & Hutz LLP

20080219962 - Method to enhance the bone formation activity of bmp by runx2 acetylation: The present invention relates to a method to enhance the activity of Runx2, a major target protein of Bone Mophogenetic Protein (BMP), by Runx2 acetylation, more precisely, a method to activate BMP-mediated bone formation pathway by protecting Runx2 from ubiquitination, indicating that Runx2 is protected from degradation by the increase... Agent: Lucas & Mercanti, LLP

20080219964 - Methods and products for enhancing energy and nutrition in human beings: Methods for increasing energy in men and women include ingesting internally, twice a day, products that include, for women, multivitamins, multiminerals, high-calcium bone support products, high-ORAC super food products, and enzymes, and, for men, multivitamins, multiminerals, prostate support products, high-ORAC super food products, and enzymes.... Agent: Wagner, Anderson & Bright, LLP

20080219965 - Phytase variants: The present invention relates to phytase variants, their preparation and uses, which phytase variants, when aligned according to FIG. 1, are amended as compared to a model phytase in at least one of a number of positions. Preferred model phytases are basidiomycete and ascomycete phytases, such as Peniophora phytase and... Agent: Novozymes North America, Inc.

20080219966 - Methods of treating pervasive development disorders: A therapeutic method for treating an individual diagnosed with PDD pervasive developmental disorder comprises determining the efficacy of digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering digestive enzymes to the individual based on the determination of the measure... Agent: Kristina M. Grasso Kristina M. Grasso, Esq. Pllc

20080219969 - Concentrate of chikungunya-specific immunoglobulins as a medicinal product: The invention concerns a new medicinal product for the treatment of chikungunya, i.e a concentrate of chikungunya-specific immunoglobulins, as well as its process of preparation.... Agent: Cermak Kenealy & Vaidya LLP

20080219971 - Human anti-cd100 antibodies: Compositions and methods are provided for treating diseases associated with CD100, including certain types of cancers, autoimmune diseases, inflammatory diseases including central nervous system (CNS) and peripheral nervous system (PNS) inflammatory diseases, transplant rejections, and invasive angiogenesis. Compositions include anti-CD100 antibodies capable of binding to a soluble human CD100 antigen... Agent: Alston & Bird LLP

20080219970 - Identification and molecular characterisation of proteins, expressed in the ixodes ricinus salivary glands: The invention relates to a new polynucleotide which encodes a polypeptide expressed in the salivary glands of ticks, more particularly the Ixodes ricinus arthropod tick, during the slow-feeding phase of the blood meal have. The polynucleotide and related polypeptide may be used in different constructions and for different applications which... Agent: Knobbe Martens Olson & Bear LLP

20080219973 - Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix: A pharmaceutical composition having an inhibitory effect on the overproduction and the accumulation of extracellular matrix, said composition comprising as an active ingredient a compound that inhibits the biological activity of galectin-3, which pharmaceutical composition can serve as a therapeutic or preventive agent for glomerular nephritis, diabetic nephropathy or tissue... Agent: Sughrue Mion, Pllc

20080219972 - Prostatic acid phosphatase (pap) materials and methods of use thereof in the prophylactic and therapeutic treatment of prostate cancer: A nucleic acid molecule comprising at least one nucleotide sequence encoding SEQ ID NO: 14, 15, 19, 41, or a sequence that is at least about 95% identical thereto; a composition comprising same and a method of administering same to induce an immune response; a polypeptide consisting of SEQ ID... Agent: Larcher & Chao LLP

20080219967 - Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases: Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.... Agent: Lahive & Cockfield, LLP / Biogen Idec Floor 30, Suite 3000

20080219968 - Sos1 inhibitors: Inhibitors of human Sos1, including antisense oligonucleotides, methods, and compositions specific for human Sos1, are provided. Methods of using the compositions for modulating Sos1 expression and for regulating cell growth, particularly tumor cell growth, are also provided.... Agent: Novartis Vaccines And Diagnostics Inc.

20080219977 - Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer: h

20080219976 - Methods and compositions for treatment and prevention of staphylococcal infections: The invention features methods and compositions for treatment or prevention of infection by, or disease caused by infection with, Staphylococcus spp., particularly S. aureus. The treatment is effected by providing to the infection target a n amount of antibody, or antibody binding fragment, which binds specifically to RNAIII activating protein... Agent: Jagtiani + Guttag

20080219974 - Optimized antibodies that target hm1.24: The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one modification relative to a parent antibody that alters affinity to an FcγR or alters effector function as compared... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20080219975 - Vegfr3 inhibitors: The present invention relates to the use of some of the macrocyclic quinazoline derivatives described in PCT publication WO2004/105765 as inhibitors of VEGFR3 mediated biological activities, especially those activities which are mediated by VEGFR3 ligands VEGF-C and/or VEGF-D.... Agent: Philip S. Johnson Johnson & Johnson

20080219978 - Soluble fcgammaria and related methods: Disclosed are soluble FcγRIA polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble FcγRIA polypeptides.... Agent: Zymogenetics, Inc. Intellectual Property Department

20080219979 - Methods of using il-17 receptor a antibodies: The present invention relates to IL-17 Receptor A antigen binding proteins, such as antibodies, and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation.... Agent: Amgen Inc. Law Department

20080219980 - Bi-specific complexes for targeting cells involved in allergic-type reactions, compositions and uses thereof: Disclosed are bi-specific complexes aimed at inhibiting mast cells, eosinophils and/or basophils, and thus, at inhibiting allergy-type reactions. In particular, said complexes are best exemplified by bi-specific antibodies, which bind to two targets present in the same cell. One target is the inhibitory receptor IRp60. The second target is a... Agent: Martin D. Moynihan Prtsi

20080219982 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group Pllc

20080219981 - Diagnostic kit for solid cancer and medicament for solid cancer therapy: The present invention provides novel solid cancer antigenic proteins, and diagnostic kits for solid cancer and therapeutic agents for solid cancer based on the antigenic proteins. Specifically, the present invention provides a human solid cancer antigenic polypeptide having an amino acid sequence selected from the group consisting of SEQ ID... Agent: Birch Stewart Kolasch & Birch

20080219983 - Antagonists of factor viii interaction with low-density lipoprotein receptor related protein: The present invention concerns the use of peptides derived from and antibodies generated against Factor VIII and the inhibition of Factor VIII interaction with LRP. Furthermore, the present invention concerns a method to inhibit LRP interaction with Factor VIII as well as a method to decrease Factor VIII degradation and/or... Agent: Townsend And Townsend And Crew, LLP

20080219989 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group Pllc

20080219990 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group Pllc

20080219991 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group Pllc

20080219988 - Compositions and methods for the therapy and diagnosis of prostate cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The... Agent: Seed Intellectual Property Law Group Pllc

20080219993 - Human rgr oncogene and truncated transcripts thereof detected in t cell malignancies, antibodies to the encoded polypeptides and methods of use: Naturally-occurring variants of human Rgr oncogene protein, in particular, abnormally truncated variants found in T cell malignancies, as well as the human Rgr protein are encompassed by the present invention. Also included are antibodies thereto and nucleic acid molecules encoding human Rgr protein and naturally-occurring variants thereof. The present invention... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080219984 - Nogo receptor-mediated blockade of axonal growth: Disclosed are NgR proteins and biologically active Nogo (ligand) protein fragments. Also disclosed are compositions and methods for modulating the expression or activity of the Nogo and NgR protein. Also disclosed are peptides which block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20080219987 - Novel phosphorylated phosphatase cdc25b sequences, antibodies directed against said sequences and uses thereof: A peptide sequence includes a fragment of at least 10 amino acids derived from the following SEQ ID NO:1: DRKMEVEELSpPLALGRFSL SEQ ID NO:1 wherein the serine residue in position 10 is phosphorylated, the above-mentioned fragment containing the phosphorylated serine residue. A polyclonal or monoclonal antibody capable of identifying a peptide... Agent: Young & Thompson

20080219992 - Pancreatic cancer secreted targets and uses thereof: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAST) and antibodies binds to PCAST. The present invention provides that PCAST is used as... Agent: Celera, An Applera Business Unit

20080219986 - Polynucleotides and polypeptides basb033 from neisseria meningitidis and their uses: The invention provides BASB033 polypeptides and polynucleotides encoding BASB033 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.... Agent: Ratner & Prestia- Sb Division

20080219985 - Prok2 antagonists and methods of use: The present invention provides methods of using PROK2 and PROK1 antagonist, including monoclonal antibodies to treat inflammation, angiogenesis, and cancer.... Agent: Zymogenetics, Inc. Intellectual Property Department

20080219995 - Il-32 monoclonal antibodies and uses thereof: The present invention provides monoclonal antibodies specific for interleukin-32 (IL-32, previously referred to as “natural killer cell transcript 4” or “NK4”) and hybridomas secreting monoclonal antibodies specific for IL-32. Also provided are diagnostic methods and kits (e.g., ELISA, Western blot, etc.) which utilize monoclonal antibodies specific for IL-32.... Agent: Fulbright & Jaworski L.l.p.

20080219994 - Modified bouganin proteins, cytotoxins and methods and uses thereof: The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate... Agent: Dann, Dorfman, Herrell & Skillman

20080219996 - Molecular markers associated with bone metastasis: This invention relates generally to the modulation of expression levels of bone sialoprotein (BSP) in tumors, especially a non-small cell lung cancer tumor, as an indicator of progression to bone metastasis.... Agent: Novartis Corporate Intellectual Property

20080219997 - Her-2 binding antagonists: There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO. 1 or SEQ ID NO:12, wherein the polypeptide... Agent: Davis Wright Tremaine, LLP/seattle

20080219998 - Anti-thrombotic agents: The present invention embodies: methods; compounds, their pharmaceutically acceptable analogs, isomer, salts, hydrates, solvates and prodrug derivatives, and pharmaceutically acceptable compositions thereof that have particular biological properties; devices; diagnostic and other assays; and the uses of such methods, compounds, devices and assays. Common throughout these embodiments is specific selective reduction... Agent: Stoel Rives LLP

20080219999 - Immunoadhesin for the prevention of rhinovirus infection: The immunoadhesions of the present invention are useful in treating rhinovirus infections. The immunoadhesions contain a chimeric ICAM molecule and may optionally also contain J chain and secretory compounds. The chimeric ICAM molecule is a fusion protein that has a rhinovirus receptor protein linked to an immunoglobulin protein. This invention... Agent: Morrison & Foerster LLP

20080220001 - Ca ix-specific inhibitors: e

20080220000 - Methods for generating improved immune reponse: This application relates to a method for generating an improved immune response in a host. The method involves the step of administering a vectored vaccine in the presence of an agent that impairs Treg cell function.... Agent: Woodcock Washburn LLP

20080220003 - C5a receptor antagonists: The present invention is related to a compound, preferably a C5a receptor antagonist, having the following structure, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21 and R22 are individually and independently selected from the group comprising H,... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080220005 - Comb polymers: The present invention provides a process for producing a comb polymer comprising the steps of: a) providing: (i) (w+z) molar equivalents of a monomer; (ii) one molar equivalent of an initiator compound of formula (IX), wherein B3 represents a halogen, B2 represents H or a halogen, Y1 represents a group... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080220002 - Modified transferin-antibody fusion proteins: Modified fission proteins of transferrin and therapeutic proteins or peptides, preferably antibody variable regions, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.... Agent: Pharmacia Corporation Global Patent Department

20080220004 - Use of vegf inhibitors for treatment of eye disorders: Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.... Agent: Regeneron Pharmaceuticals, Inc

20080220006 - Method for modulating inflammatory responses: The present invention is a method for inhibiting Treg cell functional activities by blocking Treg cell-mediated mast cell activation. It has been found IL-9 produced by Treg cells activates mast cells, which in turn mediate an amplification loop critical for graft tolerance and immune responses to tumors. Thus, a method... Agent: Licata & Tyrrell P.c.

20080220007 - Ehrlichia canis genes and vaccines: This invention provides the sequence of 5,299 nucleotides from the E. canis genome. There are four proteins, ProA, ProB, MmpA, and a cytochrome oxidase homolog, as well as a partial lipoprotein signal peptidase homolog at the carboxy terminus, coded for in this cloned fragment. The antigenic properties of these proteins... Agent: Marjama Muldoon Blasiak & Sullivan LLP

20080220008 - Mutated hiv nef for modulating immunity: Described is the use of a mutation of at least one amino acid in the immunosuppressive domain of a HIV or SIV accessory protein, for modulating the immunosuppressive property of the protein.... Agent: Young & Thompson

20080220009 - Rodent hepatitis b virus core proteins as vaccine platforms and methods of thereof: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.... Agent: Medlen & Carroll, LLP

20080220010 - Immunogenic compositions for streptococcus agalactiae: This application relates to Group B Streptococcus (“GBS”) vaccines comprising combinations of GBS polypeptide antigens where the polypeptides contribute to the immunological response in a recipient. Preferably, the compositions of the invention comprise a combination of two or more GBS antigens, wherein said combination includes GBS 80 or a fragment... Agent: Novartis Vaccines And Diagnostics Inc.

20080220011 - Use of flagellin in tumor immunotherapy: The invention provides a fusion protein comprising a flagellin adjuvant and a tumor antigen. Also provided are compositions comprising a flagellin adjuvant and a tumor antigen. The invention further provides pharmaceutical formulations and methods for inducing an immune response against a tumor antigen and methods of treating a tumor in... Agent: Myers Bigel Sibley & Sajovec

20080220012 - Therapeutic compositions that alter the immune response: The invention is therapeutic methods and compositions that alter the immunogenicity of the host.... Agent: Ropes & Gray LLP

20080220013 - Diagnostic method for brain damage-related disorders: A brain damage-related disorder is diagnosed in a subject by detecting at least one polypeptide, or a variant or mutant thereof, in a sample of body fluid taken from the subject, wherein the polypeptide is one for which the level is either increased or decreased in cerebrospinal fluid from deceased... Agent: Arent Fox LLP

20080220015 - Method of modulating neutralizing antibodies formation in mammals, and uses thereof in gene therapy, animal trangenesis and in functional inactivation of endogenous proteins: Disclosed is a method of modulating neutralizing antibodies formation against a heterologous protein. The method may be used to induce tolerance of the immune system towards the protein, such tolerance being useful to allow long-term gene therapy or transgene expression. The method may also be used to provide an animal... Agent: Buchanan, Ingersoll & Rooney Pc

20080220014 - Recombinant viral-based malaria vaccines: The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Novel codon-optimized circumsporozoite genes are... Agent: Trask Britt

20080220016 - Method of treating and preventing infectious diseases via creation of a modified viral particle with immunogenic properties: The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious organism, thereby reducing the infectivity... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080220017 - Method of treating and preventing infectious diseases via creation of a modified viral particle with immunogenic properties: The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious organism, thereby reducing the infectivity... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080220018 - Vaccine composition for vaccinating dogs against canine infectious respiratory disease(cird): A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against Streptococcus equi sub species zooepidemicus in a dog, (b) an agent capable of raising an immune response against Mycoplasma cynos in a dog, and (c) an agent capable... Agent: Knobbe Martens Olson & Bear LLP

20080220019 - Nucleic acid construct containing fulllength genome of human hepatitis c virus, recombinant fulllength virus genome-replicating cells having the nucleic acid construct transferred thereinto and method of producing hepatitis c virus particle: The present invention provides a method for replicating efficiently an RNA containing fulllength HCV genomic sequence and a method for producing HCV virus particles containing fulllength HCV replicon RNA or fulllength HCV genomic RNA by using a cell culture system. Further, the present invention relates to a method for producing... Agent: Birch Stewart Kolasch & Birch

20080220021 - Topical botulinum toxin compositions for the treatment of hyperhidrosis: The use of a topical botulinum toxin composition is disclosed for the treatment of a disorder amenable to treatment by botulinum toxin. The disorder may comprise the symptoms associated with hyperhidrosis. The topical botulinum toxin composition comprises phospholipid micelles, one or more primary stabilizers, and one or more skin penetration... Agent: Heenan Blaikie LLP

20080220020 - Transdermal botulinum toxin compositions: Pharmaceutical compositions for transdermal administration of neurotoxins to a patient include a neurotoxin, such as a botulinum toxin, and an enhancing agent that facilitates absorption of the neurotoxin through the skin of the patient and does not eliminate the bioactivity associated with the neurotoxin. The pharmaceutical compositions are topically applied... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20080220022 - Salmonella vaccine: The present invention relates to the field of vaccination against Salmonella in animals, particularly avian animals. The present invention also encompasses kits and uses of Salmonella immunogenic compositions or vaccines. The present invention further relates to methods and compositions comprising at least one primo-administration of an attenuated immunogenic composition or... Agent: Judy Jarecki-black Ph.d., J.d.

20080220023 - Antifungal vaccines with saccharomyces cerevisiae: Methods and formulations for vaccinating induce in mammals that are vaccinated protective immunity against diseases caused by fungi. The vaccines include a yeast, such as Saccharomyces cerevisiae, as an active agent for delivery orally or by injection. Parenteral delivery of the vaccine can occur by one injection or multiple time... Agent: Patterson & Sheridan, L.l.p.

20080220024 - Antifungal vaccines with saccharomyces cerevisiae: Methods and formulations for vaccinating induce in mammals that are vaccinated protective immunity against diseases caused by fungi. The vaccines include a yeast, such as Saccharomyces cerevisiae, as an active agent for delivery orally or by injection. Parenteral delivery of the vaccine can occur by one injection or multiple time... Agent: Patterson & Sheridan, L.l.p.

20080220025 - Treating tumors using implants comprising combinations of allogeneic cells: This invention provides methods and compositions for treating tumors. The cell population is made up of alloactivated lymphocytes from the patient or from one or more third-party donors that are alloactivated in a mixed lymphocyte culture. It can be placed into the tumor bed, or combined with tumor-associated antigen for... Agent: Bozicevic, Field & Francis LLP

20080220028 - Archaeal polar lipid aggregates for administration to animals: The invention provides non-replicating compositions, and methods for the delivery of these compositions containing pharmaceuticals, biologically relevant molecules, and/or antigens to the host, by administration via a mucosal route such as the intranasal. This invention provides non-replicating vaccine compositions and methods for the delivery of antigens in these vaccine compositions... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080220027 - Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and... Agent: Ropes & Gray LLP

20080220026 - Mesoporous material compositions and methods of their use for improving the appearance of biological surfaces: The present invention relates to compositions and methods for treating and improving the aesthetic appearance of a biological surface by altering the optical properties of the biological surface, thereby resulting in a natural appearance. The compositions of the invention may be topically applied to the biological surface, including but not... Agent: Charles J. Zeller, Esq. Avon Products Inc.

20080220033 - Cosmetic ingredient and cosmetic composition containing the same: The invention provides a cosmetic ingredient and cosmetic compositions containing the same that exhibit skin protection/recovery properties and which are suitable for use in various cosmetic forms, such as skin care cosmetics, makeup cosmetics and skin cleansing agents. The cosmetic ingredient and cosmetic compositions containing the same include spherical sulfated... Agent: Hogan & Hartson LLP Ip Group, Columbia Square

20080220031 - Dermocosmetic preparations: The invention furthermore relates to the use of said compounds in dermocosmetic formulations and the use of the dermocosmetics according to the invention for reducing skin or hair damage caused by free radicals. The invention furthermore relates to the use of the compounds according to the invention for increasing the... Agent: Connolly Bove Lodge & Hutz, LLP

20080220029 - Fast-dissolving/disintegrating film preparation having high proportion of active: The invention provides a fast-dissolving or fast-disintegrating film preparation having a high proportion (i.e., at least about 40%) of active agent(s) and related methods for its preparation. In one embodiment, the active agent is a pharmaceutical and the film comprises between about 10% and about 40% pullulan as a primary... Agent: Philip S. Johnson Johnson & Johnson

20080220030 - Nanoparticles comprising chitosan and cyclodextrin: This invention relates to a system comprising nanoparticles designed for the release of biologically active molecules, where the nanoparticles comprise a) at least 40% by weight of chitosan or a derivative thereof and b) less than 60% by weight of a cyclodextrin or a derivative thereof, where both components a)... Agent: Intellectual Property / Technology Law

20080220032 - Oral care layer and related method of manufacture: An oral care composition including a hydrophilic, aliphatic, polyether-based thermoplastic polyurethane, a glycol polymer, and a poly(N-vinyl lactam). These components form a tacky film having a thickness of about 1 mils to about 50 mils. A whitening agent, such as a peroxide, can be absorbed into the tacky film, and... Agent: Warner Norcross & Judd LLP

20080220034 - Antiadhesive polymers for prevention of adhesion of microorganisms to textiles and for prevention of laundry odor: Textile treatment agents and/or capsules comprising a polymer having antiadhesive action against microorganisms which adhere to a textile substrate, methods of treating textile substrates therewith and the textile so treated, wherein the polymer comprises a polymeric structural element selected from the group consisting of polyesters, polysaccharides, polyethers, polyurethanes, polyureas, polyamides,... Agent: Connolly Bove Lodge & Hutz LLP

20080220035 - Training spray: A composition for deterring a domestic pet from intruding upon a designated area. The composition includes a citrus oil, foaming and wetting agents in an aqueous carrier. The composition is particularly effective when applied in the form of a mist or spray deterring a cat from scratching furniture or related... Agent: Degosits & Noah LLP

20080220036 - Antimicrobial packaging material: An antimicrobial packaging material for food stuffs containing from 0.05% to 1.5% by weight of a natural essential oil. The oil can be selected from primarily linalool and/or methylchavicol, but also from one or more of citral, geraniol, methyl cinnamate, methyl eugenol, 1,8-cineole, trans-a-bergamotene, carvacrol and thymol blended with one... Agent: Connolly Bove Lodge & Hutz LLP

20080220037 - Biphosphonic compounds for preventing or limiting fixing of macromolecules, microorganisms and biofilm on solid, in particular metal or mineral surfaces: The invention concerns biphosphonic compounds of formula (I); microbiological anti-contamination compositions containing same, and their use for preventing or limiting fixing of macromolecules, micro-organisms and biofilm on solid surfaces, such as metal or mineral surfaces.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080220038 - Nematicidal compositions and methods of using them: There is disclosed method of killing nematodes comprising the step of applying an effective amount of a nematicidal composition comprising a terpene component and compositions suitable for use in the method. The terpene component is preferably in association with water, either as a solution or a suspension. An excipient may... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20080220042 - Biomolecule-linked biomimetic scaffolds: The invention provides a composition comprising a nanofiber polymer in which the fibers of the nanofiber polymer are aligned, and a molecule is covalently attached, either directly or through a linker, to the nanofiber polymer. This molecule is capable of either covalently or non-covalently attaching to a member selected from... Agent: Morgan, Lewis & Bockius LLP (sf)

20080220044 - Cancellous construct with support ring for repair of osteochondral defects: The invention is directed toward an osteochondral repair assembly comprising a shaped allograft construct comprising an unbalanced barbell-shaped cylindrical cancellous bone primary member formed with a mineralized cylindrical base section having a smaller diameter cylindrical stem leading to a second cylindrical section which is demineralized. A mineralized ring-shaped support member... Agent: Greenberg Traurig, LLP

20080220041 - Medical devices having improved performance: In accordance with various aspects of the invention, implantable and insertable medical devices are provided, which contain one or more polymeric regions. In one aspect, the polymeric regions comprise (a) a block copolymer that comprises a polyaromatic block and a polyalkene block admixed with (b) a sulfonated high Tg polymer.... Agent: Mayer & Williams Pc

20080220040 - Nitric oxide donating medical devices and methods of making same: Disclosed are implantable medical devices comprising nitric oxide (NO) donating polymers comprising polymer backbones having at least one cyclic amine disposed thereon. Methods are further disclosed for providing nitric oxide-donating polymers.... Agent: Medtronic Vascular, Inc. Ip Legal Department

20080220043 - Repair of larynx, trachea, and other fibrocartilaginous tissues: Provided herein are methods and devices for inducing the formation of functional replacement nonarticular cartilage tissues and ligament tissues. These methods and devices involve the use of osteogenic proteins, and are useful in repairing defects in the larynx, trachea, interarticular menisci, intervertebral discs, ear, nose, ribs and other fibrocartilaginous tissues... Agent: Ropes & Gray LLP

20080220045 - Self-setting polymeric cyanoacrylate composites: Self-setting, absorbable bioactive polycyanoacrylate-based composites include at least one inorganic phosphate salt or a combination of at least one inorganic phosphate salt and calcium silicate in a cyanoacrylate matrix. The composites can be reinforced with single- or multicomponent absorbable, warp-knitted mesh, thus producing a broad range of absorbable, bioactive biomaterials... Agent: Leigh P. Gregory

20080220039 - Thin film medical devices manufactured on application specific core shapes: A method for creating three-dimensional, unitary, thin film medical devices for implantation within a human subject is provided, along with a method for creating pores within such thin film devices. Using known sputtering methods, a film material is implanted on a core or combination of cores having an advanced threedimensional... Agent: Philip S. Johnson Johnson & Johnson

20080220047 - Low-swelling biocompatible hydrogels: Some aspects of the present disclosure relate to a surgical treatment for treating a tissue inside a vertebral column by forming a low-swelling biodegradable hydrogel in situ adherent to a tissue inside the vertebral column and substantially exterior to a theca in the vertebral column.... Agent: Tyco Healthcare Group Lp

20080220048 - Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore: Nitric Oxide (NO)-releasing polymers useful as implantable medical devices and coatings therefore are provided. Specifically the implantable medical devices and/or coatings comprise NO-releasing biodegradable polymers derived from [1,4]oxazepan-7-one and its derivatives. The medical devices and coatings of the present invention can also be used for in situ controlled release delivery... Agent: Medtronic Vascular, Inc. Ip Legal Department

20080220046 - Terpolymers for controlled release of bioactive agents from implantable medical devices: Disclosed herein are implantable medical devices comprising controlled release terpolymers and at least one drug releasable from said terpolymers coating. The terpolymers of the present invention are comprised of acrylate and/or vinyl monomers.... Agent: Medtronic Vascular, Inc. Ip Legal Department

20080220049 - Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins: The present disclosure relates to novel sustained-release intraocular drug delivery systems and improvements in the treatment of retinopathies. In particular, fibronectin scaffold domain proteins that selectively inhibit VEGFR-2 are contemplated.... Agent: Ropes & Gray LLP

20080220050 - Compositions for gingival retraction and other methods: At least one clay, at least one glass filler, and at least one astringent agent are formulated with water into a paste for injection in dental and medical applications. In one embodiment, the paste is used to treat and/or widen a gingival sulcus. The paste is readily rinsed off the... Agent: Wood, Herron & Evans, LLP

20080220052 - Body weight gain inhibitor: The invention provides a body weight gain inhibitor, a fat amount gain inhibitor, a medicament for prevention and/or treatment of obesity, a food composition having inhibitory effect on body weight gain and a food composition having inhibitory effect on fat amount gain, each containing ε-polylysine or a salt thereof. In... Agent: Hogan & Hartson LLP Ip Group, Columbia Square

20080220051 - Powdery sterol compositions containing colloid-forming agents: Compositions in powder form of sterols, stanols, and esters thereof, and natural macromolecular colloid formers are disclosed. A process of making the compositions is also disclosed. The suitability of incorporation of the compositions in powder form in food products, for example beverages and milk products, is also disclosed.... Agent: Cognis Corporation Patent Department

20080220054 - Modulation of drug release rate from electrospun fibers: Disclosed are co-electrospun polymeric fibers comprising polymers comprising pharmaceutically active agents and/or biologically active agents and capable of release at a combined release rate. Also disclosed are processes for preparing polymeric fibers capable of release at a combined release rate. Also disclosed are processes of modulating delivery rate of pharmaceutically... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20080220053 - Process for the preparation of two and three dimensional polymer scaffolds: A process for the preparation of polymer scaffolds containing a pharmacologically and/or biologically active protein molecule involving the following steps: neutralisation of the scaffold with a basic substance or a buffer solution; drying the scaffold; imbibition of the scaffold with a predefined quantity of a pharmacologically and/or biologically active protein... Agent: Ladas & Parry LLP

20080220055 - Therapeutic composition with enhanced endothelium targeting: A composition that includes nanoparticles with binding affinity for platelets, and methods for using this composition to treat vascular disease are disclosed.... Agent: Squire, Sanders & Dempsey LLP

20080220057 - Therapeutic compounds and methods of use: Compounds and methods useful for chemopreventative treatment of diseases such as cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis.... Agent: Fulbright & Jaworski L.l.p.

20080220056 - Treatment for liver disease: The present invention is based on the finding that the artificial induction of hepatic stellate cell (HSC) apoptosis in vivo can promote the resolution of liver fibrosis. Thus, the present invention provides methods for treating liver disease in a subject involving administration of an inducer of apoptosis which is capable... Agent: Nixon & Vanderhye, Pc

20080220058 - Method and composition for improving hair growth: A method and composition for improving human hair, having a composition of neutraceuticals that include Eclipta, chlorophyll, and an absorption enhancer, in which the absorption enhancer is selected from the group consisting of bioperine and phosphatidyl choline and Eclipta is included in an amount between 0.1 and 60 parts admixed... Agent: Mitchell A. Stein, Esq. Stein Law, P.c.

20080220060 - Gastroretentive formulations and manufacturing process thereof: The present invention concerns gastroretentive formulation comprising an active substance granulated with a mixture of a weak gelling agent, a strong gelling agent, and a gas generating agent and process for manufacturing said formulation.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20080220059 - Method and composition for improving hair growth: The invention relates to a pharmaceutical preparation for oral administration comprising N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide or its hydrates and/or solvates, as well as an acid, a method for its production as well as the use of this preparation for the treatment and/or prophylaxis of diseases which are caused by herpes viruses, in particular... Agent: Morrison & Foerster LLP

20080220061 - System for manufacturing controlled release dosage forms, such as zero-order release profile dosage form manufactured by three-dimensional printing: The present invention includes controlled release dosage forms and methods of designing and manufacturing dosage forms to obtain specific release profiles, for example, zero-order release profiles, escalating release profiles or decreasing release profiles. The dosage forms of the present invention can include spatial variation of API concentration in the dosage... Agent: Innovar, Llc

20080220063 - Biologic-chemical fungicide compositions and methods of use: The present invention is directed to biologic-chemical fungicide compositions (BCFs) that include one or more chemical fungicides, and microorganisms including gram-positive and/or gram-negative bacteria and yeast. Any chemical fungicide or combination of fungicides can be used. The BCFs typically also include an optional nutrient component in an amount sufficient to... Agent: The Clorox Company

20080220062 - Sustained release of agents for localized pain management: The invention relates to the treatment of localized pain by providing sustained release of an agent suitable for treating pain, methods for preparing and administering the agent, and methods of formulating and administering the agent as a pharmaceutical preparation. The agent can be locally administered to reduce systemic concentrations of... Agent: Ropes & Gray LLP

20080220064 - Extended release matrix formulations of morphine: The present invention provides extended-release matrix formulations comprising a therapeutically effective amount of morphine or salt thereof, one or more hydrophilic controlled release polymers and one or more pharmaceutically acceptable excipients. The formulations provide extended release of morphine or salt thereof over a specified period of time after oral administration... Agent: Jayadeep R. Deshmukh, Esq. Ranbaxy Inc.

20080220066 - Anti-viral topical gel formulations containing a diuretic such as furosemide and/or a cardiac glycoside such as digoxin: An anti-viral topical gel formulation comprising at least one loop diuretic and/or cardiac glycoside in a gel carrier medium, said formulation capable of transdermal delivery of the said diuretic and/or glycoside.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20080220065 - Compositions for treating foot odor and methods of use thereof: A composition and method of use thereof for treating foot odor caused by microbial organisms, wherein cupric polyatomic salt is utilized as the active ingredient, preferably in combination with a dispersal agent, and wherein healthy tissue is promoted and foot odor is eliminated.... Agent: Myers & Kaplan Intellectual Property Law, L.l.c.

20080220067 - Antimicrobial adhesive system: An adhesive composition having dispersed therein a broad spectrum antimicrobial agent for use in medical applications, such as an adhesive for surgical drapes, wound dressings and tapes, is provided. The adhesive is composed of acrylic polymers, tackifiers and a preferred antimicrobial agent, diiodomethyl-p-tolylsulfone. The subject adhesive composition may be formulated... Agent: Nawrocki, Rooney & Sivertson Suite 401, Broadway Place East

20080220068 - Treatment and prevention of excessive scarring: A pharmaceutical composition comprised of a hydration agent and an anesthetic can be used to treat excessive scarring conditions, such as keloid and hypertrophic scars.... Agent: Foley And Lardner LLP Suite 500

20080220076 - Active agent formulations, methods of making, and methods of use: Active agent compositions comprising active agent particles having an effective average particle size of less than 2000 nm, wherein the compositions comprise a particle sequestrant are disclosed. Compositions having an effective average particle size of less than 2000 nm, wherein the compositions comprise no added surfactants, phospholipids, or combinations thereof,... Agent: Cantor Colburn, LLP

20080220071 - Aqueous suspensions of poorly water-soluble and water-insoluble active ingredients and drying powder produced therefrom: Aqueous suspensions comprising: (a) at least one sparingly water-soluble or water-insoluble active agent in the form of nanoparticulate particles; (b) at least one whey component selected from the group consisting of whey proteins, whey protein hydrolysates, and mixtures thereof; and (c) at least one sucrose fatty acid ester having an... Agent: Connolly Bove Lodge & Hutz, LLP

20080220072 - Biologic modulations with nanoparticles: Certain aspects of the invention relate to the use of small particles in biological systems, including the delivery of biologically active agents to cells or tissues using nanoparticles of less than about 200 nm in approximate diameter. Embodiments include collection of particles having a bioactive component, a surfactant molecule, a... Agent: Patterson, Thuente, Skaar & Christensen, P.a.

20080220070 - Controlled release system and manufacturing method thereof: A controlled release system and manufacturing method thereof. The method comprises providing a first aqueous solution containing a hydrophilic drug and an alkaline agent, providing an organic solution containing a hydrophobic molecule, providing a second aqueous solution containing a hydrophilic surfactant, mixing the first hydrophilic solution with the organic solution... Agent: Joe Mckinney Muncy

20080220074 - Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same: Nanoparticulate compositions comprising docetaxel or a salt, derivative, conjugate or analogue thereof, wherein the compositions are terminally sterilized via gamma radiation, are described, as well as methods of making and using such compositions.... Agent: Fox Rothschild, LLP Elan Pharma International Limited

20080220069 - Long acting injectable crystal formulations of estradiol metabolites and methods of using same: The present invention provides sustained release formulations of estradiol metabolites whereby the in vivo pharmacokinetics are manipulated by a method selected from the group consisting of chemical modification, crystal packing formation, particle size or a combination thereof. Such compositions are useful in the long-term treatment of a wide variety of... Agent: The Mccallum Law Firm, P. C.

20080220077 - Microspheres for active embolization: The present invention relates to injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) for use in embolization drug therapy. The present invention further relates to methods of embolization gene therapy, particularly for the treatment of... Agent: Jones Day

20080220075 - Nanoparticulate compositions of angiogenesis inhibitors: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner

20080220073 - The treatment of respiratory diseases: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080220078 - Pharmaceutical formulations: A pharmaceutical formulation for delivery in aerosol or spray form, comprising a liquefied propellant gas, a solid particulate pharmaceutically active agent and a dispersing agent, wherein the dispersing agent is fused to the surface of particles of the pharmaceutically active agent.... Agent: Davidson, Davidson & Kappel, Llc

20080220079 - Sustained release compositions using wax-like materials: Sustained release spherical or non-spherical pellets comprising (a) an active ingredient (b) a wax-like agent, and (c) a spheronizing agent are provided. Oral dosage forms comprising said pellets and methods for preparing and using such pellets and dosage forms are also provided.... Agent: Seed Intellectual Property Law Group Pllc

20080220080 - Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release: The invention relates to a multiparticulate pharmaceutical form, comprising pellets with a multilayer structure for controlled active ingredient release, comprising a) a core layer comprising a substance having a modulating effect, b) an inner controlling layer which influences the delivery of the substance having a modulating effect, consisting of pharmaceutically... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080220081 - Water-dispersible xanthan gum containing composition: One aspect of the present invention relates to a readily water-dispersible particulate composition comprising by weight of dry matter at least 10% of xanthan gum and not more than 60% of starch, said composition being characterised in that the xanthan gum present in the composition can be dispersed completely within... Agent: Foley And Lardner LLP Suite 500

20080220082 - Compositions and methods for treating or preventing hair loss and processes for making the same: The present invention relates to composition useful in growing hair. The compositions are particularly suited for re-growing hair in subjects who have experienced hair loss due to any cause. The compositions comprise essentially the lipoidic fraction of mammalian bone marrow. Methods of using the compositions and processes of preparing the... Agent: Panacea Pharmaceuticals, Inc.

20080220083 - Pharmaceutical agent comprising blood components <10 kda and their use for prophylaxis and treatment of defects of the immune system: The invention relates to a composition of proteins, peptides and/or peptide components, a pharmaceutical agent comprising said composition, a method for the production of said composition and the use thereof in the prophylaxis or therapy of persons, animals and/or patients with pathogenic modifications and/or cellular immunodeficiencies, especially cancer, septicemia or... Agent: Joyce Von Natzmer Pequignot + Myers Llc

20080220084 - Combination therapy for alleviating pain-related conditions: The present invention provides compositions and methods for alleviating physical discomfort and/or pain-related conditions in a subject, comprising one or more ingredients that improve blood circulation, one or more ingredients that reduce pain and one or more ingredients that enhance bone health. The ingredients are selected from synthetic compounds, natural... Agent: Foley And Lardner LLP Suite 500

20080220085 - Production of neural protective and regenerative factors from stem cells and treatment of nervous system conditions therewith: A method for producing stem cell conditioned media for treatment of neurological insults is provided herein. By providing for the culture of adipose stem cells, and collecting the supernatants thereof, the supernatants have been shown to effect biological activity in preventing neural death when the supernatants are administered to a... Agent: Ice Miller LLP

20080220086 - Injectable composite material suitable for use as a bone substitute: The invention relates to a new injectable composite material suitable for use as a bone substitute. The composite material according to the invention comprises a reactive ceramic phase based on tricalcium phosphate and an organic phase comprising a polyvinyl alcohol hydrogel. By varying the concentration of the two phases it... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080220087 - Colon cleansing composition and method: A composition and method for cleansing a colon prior to endoscopic procedure. More particularly, a combination of bisacodyl, metoclopramide, sodium, and/or a phosphorus containing composition administered in sequential doses for preparing a colon prior to colonoscopy.... Agent: Hall, Vande Sande & Pequignot, LLP

20080220088 - Composition for treating wounds and burns: The invention discloses the use of a liquid composition, capable of promoting the growth of tissue cells at the site of a wound, a process that promotes regeneration of tissue and wound healing. More particularly, the present invention relates to the use of a liquid composition comprising a component (a)... Agent: Foley And Lardner LLP Suite 500

20080220089 - Medical agent for preventing or treating diseases resulting from one of inflammation and remodeling, and method for preventing or treating the diseases: An object of the present invention is to provide a medical agent that has an excellent effect on the diseases resulting from one of inflammation and remodeling and that can prevent or treat them in response to various mechanisms of onset and development of the diseases. Thus, the present invention... Agent: Kratz, Quintos & Hanson, LLP

20080220090 - Anti tumor compositions and methods of use: An anti-cancer composition having biocompatible materials, which can selectively exploit chemical variations between normal cells and cancer cells to inhibit or prevent the proliferation of cancerous cells and methods of use.... Agent: Alfred M. Walker

20080220091 - Reduction of reactive oxygen species in chronic wound management: Reactive oxygen species associated with a wound are modulated through treatment of the wound with a solution of metal ions selected from the group consisting of potassium ions, zinc ions, calcium ions and rubidium ions, at a pH of between about 5 and about 7. Preferably, citric acid is employed... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-1118

20080220092 - Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aid: Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the... Agent: Hogan & Hartson LLP

20080220093 - Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells: The present invention relates to a composite for the treatment of a variety of medical conditions, the composite comprising an oxidized gluthathione-based compound, which has a disulfide bond, and a metal material, in particular where the metal is either platinum or palladium. The oxidized glutathione-based compound and metal material can... Agent: Wolf Greenfield & Sacks, P.c.

20080220094 - Compositions and methods for the treatment and/or prevention of osteoporosis: The invention of this application relates to compositions and methods for the treatment and/or prevention of osteoporosis; improving and/or enhancing bone formation; and prevention and/or reducing bone mineral density loss. More particularly, the invention relates to a composition comprising vitamin K, in any form and betacryptoxanthin. A further aspect of... Agent: Wyeth Patent Law Group

20080220095 - Red blood cells loaded with s-nitrosothiol and uses therefor: Red blood cells can be loaded with low molecular weight nitrosylating agents, such as S-nitrosothiols, to act as a delivery system for NO+ groups to tissues. Loaded red blood cells can be used in methods of therapy for conditions which are characterized by abnormal O2 metabolism of tissues, oxygen-related toxicity,... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080220096 - Cynara scolymus extracts and compositions containing them: The present invention relates to a Cynara scolymus extract with a high caffeoylquinic acid content, obtainable by extraction from undried globe artichoke heads with alcohols having up to three carbon atoms.... Agent: Young & Thompson

20080220097 - Formulations containing cynara scolymus and phaseolus vulgaris extracts which are useful in the treatment of obesity: Said composition is useful in reducing obesity as it reduces cholesterol, triglycerides and blood glucose by sensitising the cells to insulin. This combination, when taken before meals, reduces the appetite, leading to a reduction in body weight. The extracts are preferably formulated in Oenothera biennis oil, fish oil, or oils... Agent: Young & Thompson

20080220098 - Formulations of alpha-amylase inhibitors with alpha-glucosidase innhibitors useful in the treatment of diabetes and obesity: This invention relates to the combination of α-amylase inhibitors prepared from Phaseolus vulgaris with α-glucosidase inhibitors obtained from Salacia oblonga and other species. The α-amylase inhibitor is accompanied by a quantity of lectins that reduces the amount of glucose originating from the starches present in the diet, and considerably reduces... Agent: Young & Thompson

20080220099 - Nutritional composition: A dietary supplement for dogs is disclosed. The composition is a blend of methyl sulfonyl methane, glucosamine sulfate, chondroitin sulfate, ascorbic acid, phylloquinone, yucca powder and stabilized rice bran. The composition may be added to a variety of meat products for dogs, preferably beef and/or beef by-products.... Agent: Thomas A. O'rourke Bodner & O'rourke

20080220101 - Compositions of extracts of aloe for oral administration: Compositions containing extracts of Aloe which are suitable for dietary supplements and/or functional food products are disclosed. The compositions which further comprise extracts of other plants are also disclosed. The compositions of extracts of Aloe in combination with chitosans, fatty acids, sterols and/or sterol esters are additionally disclosed. The compositions... Agent: Cognis Corporation Patent Department

20080220100 - Fermented panax notoginseng solution with anti-cancer effects and manufacture method thereof: This invention relates to a fermented Panax notoginseng solution and manufactured method thereof. The manufacture method comprises activating a Lactobacillus spp, fermenting a Panax notoginseng medium with the Lactobacillus spp. to form a fermented solution, and centrifuging the fermented solution to obtain a supernatant. The supernatant has anti-cancer effects.... Agent: Birch Stewart Kolasch & Birch

20080220102 - Solubilsation products of an active ingredient extract: The invention relates to a solubilizate of a phytoextract, which contains a physiological or pharmaceutical active ingredient, which solubilizate contains about 10% by weight to about 30% by weight of the phytoextract, about 4% by weight to about 35% by weight of water, which can be deionised, demineralised or distilled... Agent: Jacobson Holman Pllc

20080220103 - Method for treating/controlling/killing fungi and bacteria on living animals: Provided is a method of treating a fungal infection on an animal epidermis, nail or hair, or in an orifice of an animal. The method comprises contacting the fungus infection with a composition comprising an antifungal botanical.... Agent: Sonnenschein Nath & Rosenthal LLP

20080220104 - Compositions for producing satiety: Long term weight loss can be achieved and maintained with a formulation of over-the-counter life-enhancing dietary supplements. One or more supplements stimulate the release of serotonin within the brain and one or more supplements stimulate the release of cholecystokinin into the bloodstream. The combined potentiating effect of these two mechanisms... Agent: Lawrence J. Shurupoff

20080220105 - Composition containing lotus extract: For attaining effective utilization of lotus petals, receptacles, stem, leaves and husks having been discarded, there is provided a composition comprising an extract from at least one selected from among lotus petal, receptacle, stem, leaf and husk wherein anthocyanidin, various minerals and vitamins are contained in high proportion. Addition of... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080220106 - Otological solutions containing lapacho extracts: The present invention refers to otological solutions containing Lapacho extracts, and their preparation and uses.... Agent: Leydig Voit & Mayer, Ltd

20080220107 - Nasal spray apparatus: A nasal spray comprises a container holding a nasal preparation containing sesame oil and a spray pump dispenser mounted to close an opening of the container. A dip tube from the dispenser extends down into the nasal preparation. The pump body is provided with a mounting collar operable to create... Agent: O''shea Getz P.c.

20080220108 - Use of hop acids in fruit juices, fruit juice concentrates and other beverages to inhibit alicyclobacillus bacteria: An antimicrobial agent including hop acids is disclosed that inhibits the growth of acid-resistant and heat-resistant bacteria such as Alicyclobacillus acidoterrestris and Alicyclobacillus acidocaldarius in a medium such as fruit juice.... Agent: Quarles & Brady LLP

20080213165 - Methods and compositions for increasing patent tolerability during myocardial imaging methods: The present application discloses methods and compositions for increasing patient tolerability during myocardial imaging comprising the administration of doses of caffeine and one or more adenosine A2A receptor agonists to a mammal undergoing myocardial imaging.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080213170 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.A.

20080213171 - Cancerous disease modifying antibodies: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can... Agent: Mchale & Slavin, P.A.

20080213169 - Cytotoxicity mediation of cells evidencing surface expression of cd59: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a... Agent: Mchale & Slavin, P.A.

20080213166 - Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas: Isolated nucleic acids and proteins that are overexpressed in human cancers, and antibodies that specifically bind the proteins, which are useful diagnostic and therapeutic targets.... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20080213167 - Use of cd23 antagonists for the treatment of neoplastic disorders: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).... Agent: Pillsbury Winthrop Shaw Pittman LLP

20080213168 - Use of cd23 antagonists for the treatment of neoplastic disorders: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).... Agent: Pillsbury Winthrop Shaw Pittman LLP

20080213172 - Radioimaging moieties coupled to peptidease-binding moieties for imaging tissues and organs that express peptidases: Conjugates, methods and kits are described for imaging tissues and organs that express one or more peptidases. In a preferred embodiment of the invention, a series of di-(2-pyridylmethyl)amine (D) ligands, which can bind M(CO)3+ [M=Tc or Re], were coupled to lisinopril (L). Aliphatic tethers with varying number of methylene groups... Agent: Foley And Lardner LLP Suite 500

20080213173 - Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid: The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is substituted at the 2,3; 3,4; 4,5; 5,6 and other sequence positions of a fatty acid backbone. These novel fatty... Agent: Edwards Angell Palmer & Dodge LLP

20080213175 - Click chemistry-derived cyclic peptidomimetics as integrin markers: The present application is directed to radiolabeled cyclic peptidomimetics, pharmaceutical compositions comprising radiolabeled cyclic peptidomimetics, and methods of using the radiolabeled cyclic peptidomimetics. Such peptidomimetics can be used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).... Agent: Siemens Corporation Intellectual Property Department

20080213176 - Compositions for targeting amine oxidases in vivo: This invention relates to a diagnostic compositions for targeting an amine oxidase enzyme in vivo, said composition comprising a labelled peptide having the capability to bind to said enzyme. Further, the invention concerns a pharmaceutical composition for use to modulate the activity of an amine oxidase enzyme, said composition comprising... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080213174 - Radiolabelled insulin: The invention relates to in vivo imaging agents, specifically radiolabelled insulin derivatives of formula (III); wherein X is —CO—NH—, —NH—, —O—, —NHCONH—, or —NHCSNH—, and is preferably —CO—NH—, —NH— or —O—; Y is H, alkyl or aryl substituents; R* is a radiolabel moiety suitable for detection by SPECT or PET;... Agent: Ge Healthcare, Inc.

20080213177 - Nanoparticles comprising rna ligands: Materials and methods are provided for making nanoparticles having a core including metal and/or semiconductor atoms, which core is covalently linked to a plurality of ligands comprising a RNA ligand. The RNA ligands may include siRNA or miRNA. Also provided are uses of these nanoparticles in therapy and diagnosis.... Agent: Dann, Dorfman, Herrell & Skillman

20080213178 - Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid: The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is substituted at the 2,3; 3,4; 4,5; 5,6 and other sequence positions of a fatty acid backbone. These novel fatty... Agent: Edwards Angell Palmer & Dodge LLP

20080213180 - Ca ix-specific inhibitors: e

20080213179 - Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions: The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in brain microvascular endothelial cells undergoing early dynamic inflammation-induced changes in blood-brain barrier functionality. Such polypeptides are referred to as lipopolysaccharide-sensitive (LPSS) polypeptides herein. These nucleic acids and polypeptides may be useful in methods for... Agent: Mckenna Long & Aldridge LLP

20080213181 - Preparation of paramagnetic nanoparticles conjugated to leukotriene b4 (ltb4) receptor antagonists, and their use as mri contrast agents for the detection of infection and inflammation: Nanoparticle-based compositions and emulsions that are specifically targeted to leukotriene B4 (LTB4) receptors, and employing LTB4 receptor antagonist targeting agents, are set forth. In addition, there is provided the use of non-antibody based compositions for such targeting. The compositions of the invention are useful as imaging agents in diagnostic and... Agent: Louis J. Wille Bristol-myers Squibb Company

20080213183 - Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin: The use of the maximum tolerated dose (MTD) of individual drugs to determine appropriate administration ratios of drugs for combination therapy, wherein the ratios of drugs are fixed based on the same percentage of the MTD for each drug. Furthermore, antineoplastic compositions comprising liposomal encapsulated gemcitabine alone or in combination... Agent: Morrison & Foerster LLP

20080213182 - Methods and compositions for treatment of diseases associated with aberrant microsatellite expansion: The present invention provides methods and compositions for the treatment of diseases associated with aberrant microsatellite expansions. Methods of the present invention comprise the use of recombinant adeno-associated virus vectors containing a transgene encoding at least one muscleblind protein. The present invention also provides an animal model for a disease... Agent: Edwards Angell Palmer & Dodge LLP

20080213184 - Methods for modulating a drug-related effect or behavior: The present invention provides a method of reducing or preventing a drug-related effect or behavior in a subject by inhibiting N-type calcium channels. In addition, the invention provides a variety of prescreening and screening methods aimed at identifying agents that modulate a drug-related effect or behavior. These methods involve assaying... Agent: Jones Day

20080213186 - Method of producing a composition, composition and its use: The invention relates to a method of producing a composition comprising hyperpolarised 13-pyruvate, the composition and its use as an imaging agent for MR imaging.... Agent: Ge Healthcare, Inc.

20080213187 - Novel cascade polymer complexes, processes for their preparation and pharmaceutical compositions comprising them: with the proviso that the cascade polymer complexes comprise in the complexing agent residue K in total at least 4 ions of an element of atomic number 20 to 29, 39, 42 to 44 or 57 to 83 and comprise where appropriate cations of inorganic and/or organic bases, amino acids... Agent: Millen, White, Zelano & Branigan, P.C.

20080213185 - Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof: The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from Neisseria outer membrane proteins, such as Laz. The invention also provides synthetic... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20080213189 - Multifunctional metal-graphite nanocrystals: Disclosed are nanocrystals comprising metals and metal alloys, which are formed by a process that results in a layer of graphite in direct contact with the metallic core. The nanocrystals may be used in vivo as MRI contrast agents, X-ray contrast agents, near IR (NIR) heating agents, drug delivery, protein... Agent: Peters Verny , L.L.P.

20080213190 - Selective alfavbetas receptor peptide antagonist for therapeutic and diagnostic applications: The present invention is related to new peptide antagonists of αvβ3 receptor, designed on the basis of the crystal structure of integrin αvβ3 in complex with c(RGDf[NMe]V) and the NMR structure of echistatin. These peptides are potent and selective antagonists of the αvβ3 receptor and can be used as novel... Agent: Steinfl & Bruno

20080213188 - Novel ophthalmic compositions containing human recombinant lysozyme and use thereof for treating eye conditions and as contact lens solutions: An ophthalmic solution comprising: a) a human recombinant lysozyme; b) one or more natural lacrophyl substances; c) water; and d) optionally one or more therapeutic substances. The ophthalmic solution is useful to treat dry eye conditions and eye inflammation and also to condition and/or cleanse contact lenses. It is emphasized... Agent: Norris, Mclaughlin & Marcus, Pa

20080213191 - Composition and/or articles comprising cyclodextrin complexing material: Personal care products are provided. An exemplary personal care product includes a composition that is applied to the body or clothing, or an article applied against the body; a plurality of particles associated with the composition or a component of the article, the plurality of particles, at least some of... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080213192 - Aerosol lotion formulations: Non-foaming aqueous emulsion compositions; methylparaben-based preservative systems for aqueous aerosol compositions having a pH at or above a pH where methylparaben begins to hydrolyze; cosmetic, household, and human and veterinary pharmaceutical products containing these compositions.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080213193 - Foam skin cream, uses of the foam skin protection cream and a process for its preparation: n

20080213194 - Rhamnolipid-based formulations: The present invention relates to rhamnolipid-based formulations to clean, disinfect, deodorize, and act as an antimicrobial and antifungal agent for living and working environments. In addition, the present invention relates to the use of rhamnolipids to create a bio-film when applied to a surface, which prevents the growth of bacteria... Agent: Defillo & Associates, Inc.

20080213195 - Antibacterial dentifrice exhibiting antiplaque and breath freshening properties: A dual component antiplaque oral composition having antimalodor properties in which a first component contains an antibacterial agent and the second component contains a proteolytic enzyme, the first and second components are simultaneously combined for application to the teeth, the first and second components being physically segregated prior to use,... Agent: Colgate-palmolive Company

20080213196 - Enzyme containing composition, process of producing said composition and its use: The present invention relates to a composition comprising at least one biologically active protease and at least one biologically active glycosidase wherein the proteases and the glycosidases are present in an activity ratio of from 1,000,000:1 to 1:1,000,000 and wherein the composition has a total enzyme activity of at least... Agent: Mueting, Raasch & Gebhardt, P.A.

20080213197 - Agent for protection of tooth surfaces, in conjunction with conventional bleaching methods, by biomimetic deposition of fluorapatite: e

20080213199 - Amphoteric polysaccharide compounds containing aldehyde function(s), composition comprising them and cosmetic use thereof: The present invention relates to novel amphoteric polysaccharide compounds containing aldehyde function(s) corresponding to the formula (I): P—(O—(Y)p-CAT)m in which: P represents a polysaccharide chain, the said chain hearing one or more aldehyde functions and optionally one or more groups —COOV, this group possibly being obtained during the oxidation of... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080213202 - Composition for improving skin lipid barrier function: The invention relates to a composition for topical application to the skin comprising effective amounts of a protease inhibitor and a cell differentiation enhancer. The composition is useful in promoting skin lipid barrier repair and maintaining the integrity of the lipid barrier. In this regard, the compositions can be used... Agent: Estelle J. Tsevdos, Ph.d., J.d. Kenyon & Kenyon

20080213198 - Cosmetic or dermopharmaceutical composition comprising at least one udp glucuronosyl transferase (ugt) enzymes inducer: The invention relates to topical use of at least one UGT inducer for the preparation of a cosmetic or dermopharmaceutical composition comprising a dermatologically acceptable carrier to protect and/or enhance the state of the skin and prevent and/or treat imperfections of the skin.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080213200 - Micronized zinc oxide skin protector formulation: The invention provides a topical sunscreen comprising micronized zinc oxide, titanium oxide and iron oxide, and a hydrotrope and water. The sunscreen according to the invention protects against the harmful effects of UV, IR and visible irradiation.... Agent: Keown & Zucchero, LLP

20080213201 - Self-tanning composition, use of dha in combination with mineral oil, and a skin self-tanning method: The present invention relates to a cosmetic and/or dermatological self-tanning composition containing reduced DHA content and that uses the unexpected synergistic tanning effect of the joint use of DHA and mineral oil in obtaining an even tan, without stains and without producing skin dryness. The composition exhibits an improved stability... Agent: Philip S. Johnson Johnson & Johnson

20080213203 - Antiperspirant compositions comprising cyclodextrin complexing material: Antiperspirant compositions are provided. An exemplary composition includes a carrier material; an antiperspirant active in an amount from about 5% to less than 19%, by weight of the composition and on an anhydrous basis; and plurality of particles comprising a cyclodextrin complexing material and a fragrance material, wherein the percent... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080213204 - Antiperspirant compositions comprising cyclodextrin complexing material: Antiperspirant compositions are provided. An exemplary composition includes an anhydrous carrier; an antiperspirant active; a plurality of particles comprising a cyclodextrin complexing material and a first fragrance material, wherein the percent of the first fragrance material that is complexed with the cyclodextrin is greater than about 75%, so that the... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080213206 - Cosmetic composition comprising at least one fatty-chain polylysine, which is intended to improve the surface state of keratin fibers: The present invention relates to a cosmetic composition comprising, in a cosmetically acceptable medium, at least one fatty-chain polylysine. The composition of the invention enables to improve the surface state of keratin fibres. The invention also relates to methods for producing fatty-chain polylysines, as well as new compounds.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080213205 - Depilatory composition in emulsion form, process for preparation and use: Depilatory compositions comprising a depilatory agent, fatty alcohol and an oil-gelling agent provide improved resistance to rinsing of the compositions from the skin. The compositions provide for a method of depilation in wet conditions using a tool to apply and remove the compositions.... Agent: Traskbritt, P.C./reckitt Benckiser

20080213207 - Shaving preparation and method for shaving: Disclosed is a shaving preparation imparting durable lubricity. The shaving preparation has one or more silicone polyethers and one or more water-soluble polymers that associate with the one or more silicone polyethers in aqueous solution. The lubricity of the shaving preparation can be reactivated by wetting the skin after shaving... Agent: Avon Products, Inc.

20080213208 - Polyamino and/or polyammonium/polysiloxane copolymer compounds with polyalkylene oxide units in comb-shaped arrangement: The invention concerns polyamino and/or polyammonium/polysiloxane copolymer compounds with polyalkylene oxide units in comb-shaped arrangement, a method for producing said compounds and their use, in particular for treating textiles and other natural or synthetic textile materials.... Agent: Rankin, Hill & Clark LLP

20080213210 - Method to purify poly(vinyl alcohol): Disclosed herein is a process to produce a film comprising poly(vinyl alcohol), wherein the poly (vinyl alcohol) solution has been purified utilizing an ion exchange resin. An approximate 50 micrometer thick film produced from the purified aqueous poly(vinyl alcohol) solution has an APHA color value of 50 or less after... Agent: James J. Mullen M. Susan Spiering Celanese Ltd.

20080213209 - Process for producing cross-linked material of polylactic acid and cross-linked material of polylactic acid: A cross-linked material of polylactic acid produced by preparing a polylactic acid composition by mixing polylactic acid with at least a plasticizer containing either a rosin derivative or a dicarboxylic acid derivative and/or a glycerin derivative and cross-linking monomer, and kneading the resulting mixture; preparing a polylactic acid molded product... Agent: Mcdermott Will & Emery LLP

20080213211 - Compositions and methods for healthy pregnancy: Compositions, kits and methods for the prevention of, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure during assisted reproduction are provided. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure of... Agent: Morris Manning Martin LLP

20080213215 - Concentrated protein lyophilates, methods, and uses: The invention provides, among other things, lyophilized compositions of high surface area that comprise a protein and that reconstitute quickly and efficiently to solution of high protein concentration with minimal formation, if any, of foam, effervescence, bubbles, turbidity, or particulates that might be deleterious. The invention also provides, among other... Agent: Larry S. Millstein Holland & Knight LLP

20080213213 - Method for the treatment of myelodysplastic syndromes using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of treating, preventing and/or managing a myelodysplastic syndrome are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient, and/or blood or cells for transplantation therapy.... Agent: Jones Day

20080213212 - Sialoadhesin factor-2 antibodies: Monoclonal antibodies have been generated that bind to human sialoadhesion factor-2. These antibodies are useful as diagnostic and therapeutic reagents... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080213214 - Treating cardiovascular tissue: This document provides methods and materials for treating cardiovascular tissue. For example, stem cells, compositions containing stem cells, methods for obtaining stem cells, compositions for generating stem cells expressing particular markers, and methods for repairing cardiovascular tissue are provided.... Agent: Fish & Richardson P.C.

20080213216 - Methods of stimulating phagocytosis: The present invention relates, in general, to methods of stimulating phagocytosis and thereby combating infection and/or modulating immune complex disease, in particular, to methods of modulating the number and type of Fc receptors present on cells that normally possess such receptors, including monocytes and macrophages, as well as on cells... Agent: Nixon & Vanderhye, PC

20080213217 - Enantiomerically pure phosphoindoles as hiv inhibitors: 3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for their preparation, and... Agent: Jones Day

20080213218 - Method for treating hepatitis c virus infection in treatment failure patients: The present invention provides methods for treating individuals having a hepatitis C virus (HCV) infection, which individuals have failed to respond to therapy with an IFN-α other than consensus interferon (CIFN), or who, following cessation of therapy with an IFN-α other than CIFN, have suffered relaspe. The methods generally involve... Agent: Arent Fox LLP

20080213219 - Methods for treatment and management of macular degeneration using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione: Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery. Pharmaceutical compositions, single unit dosage forms, and kits... Agent: Jones Day

20080213220 - Cancer-targeted viral vectors: The present invention relates to viral vectors that are targeted to cancer cells. The viral vectors of the invention are adenoviruses having a PEG-3 promoter driving the expression of the viral genes E1A and E1B. The PEG-3 promoter exhibits increased activity in malignant cells. Adenoviruses of the invention show increased... Agent: Baker Botts L.L.P.

20080213221 - Compounds and methods to enhance raav transduction: Agents and methods to alter rAAV transduction are provided.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20080213224 - Immunoglobulin against helicobacter pylori: The present invention relates to materials and methods for prevention, treatment and diagnosing of infections caused by Helicobacter pylori (H. pylori). More specifically the present invention relates to new specific variable antibody regions, derivatives thereof and the fully human immunoglobulin, Abba3, which exhibit specific activity to the BabA antigen, expressed... Agent: Lynn E Barber

20080213222 - Methods and compositions for use in gene therapy for treatment of hemophilia: The invention includes a composition comprising a recombinant adeno-associated viral vector comprising at least two adeno-associated virus inverted terminal repeats, a promoter/regulatory sequence, isolated DNA encoding Factor IX and accompanying 5′ and 3′ untranslated regions and a transcription termination... Agent: Woodcock Washburn LLP

20080213223 - Systemic viral/ligand gene delivery system and gene therapy: The present invention relates to gene transfer and gene therapy technology. More specifically, the invention provides compositions and methods for targeted virus delivery. The method utilizes a method of mixing the virus, which may be a recombinant virus which will express a protein of interest or a nucleic acid of... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080213235 - Adipose tissue stem cells, perivascular cells and pericytes: The present invention provides methods for growing and inducing perivascular cell differentiation of adipose tissue-derived stromal cells. The invention further provides methods for administering such adipose tissue-derived cells to a subject. The cells of the invention are useful for treating diseases, disorders, conditions, and injuries requiring new or enhanced angiogenesis,... Agent: University Of Virginia Patent Foundation

20080213233 - Method of delivering nucleic acid molecules into embryonic stem cells using baculoviral vectors: There is provided a method of delivering a nucleic acid molecule to an embryonic stem cell, including a human embryonic stem cell, by infecting the embryonic stem cell with a baculoviral vector comprising the nucleic acid molecule. Embryonic stem cells transduced by this method are useful for treating a disease... Agent: Klarquist Sparkman, LLP

20080213232 - Radial glial cells promote nerve regeneration and functional recovery following spinal cord injury: An enriched population of radial glial cells has been isolated. These cells are nestin+, BLBP+, and non-tumorigenic. Furthermore, they are capable of exhibiting bipolar morphology, migrating and self-organizing in white matter, and supporting neuronal migration. These cells can be maintained by regeneration in culture. Therapeutic methods of use of these... Agent: Hoffmann & Baron, LLP

20080213234 - Use of osteopontin for the treatment and/or prevention of neurologic diseases: The invention relates to the use of osteopontin, or of an agonist of osteopontin activity, for treatment or prevention of a neurologic diseases.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080213226 - Compositions including ammonia oxidizing bacteria and methods of using same: A preparation and method for treating a subject how had developed or is at risk of developing at least one of high blood pressure, Alzheimer's Disease, obesity, and Diabetes Type II, Sickle Cell Anemia, Preeclampsia, Sudden Infant Death Syndrome, or Vascular disease comprising positioning ammonia oxidizing bacteria close proximity of... Agent: Lowrie, Lando & Anastasi, LLP

20080213225 - Sulfur-oxidizing plant growth promoting rhizobacteria for enhanced canola performance: Described herein is the isolation and identification of a number of sulfur oxidizing plant growth promoting rhizobacteria: RAY12, identified as Achromobacter piechaudii; RAY28, identified as Agrobacterium tumefaciens, RAY132, identified as Stenotrophomonas maltophilia; and RAY209, identified as Delftia acidovorans. The PGPR act to oxidize elemental sulfur which in turn provides sulfate... Agent: Ade & Company Inc.

20080213236 - Natural remedy-dietary supplement combination product: A natural remedy-dietary supplement combination product which comprises omega-3 fatty acids, α-tocopherol, ascorbic acid, selenium, Harpagophytum procumbens (devil's claw) and Boswellia serrata or carterii (frankincense), with the proviso that it does not comprise a plant or plant extract of the Saxifragaceae family, and a method of treating a chronic inflammatory... Agent: Greenblum & Bernstein, P.L.C

20080213230 - Enriched stem cell and progenitor cell populations, and methods of producing and using such populations: The present invention provides a novel method to isolate and expand pure progenitor/stem cells from a primary tissue explant, which produces a population enriched in multipotent functional progenitor/stem cells free of contaminating fibroblasts and other cell types. Cardiac progenitor/stem cells isolated by this method maintain their self-renewal and clonogenic character... Agent: Seed Intellectual Property Law Group PLLC

20080213229 - Fibrin contained semi-solid osteoblast composition for curing bone fracture and method for producing the same: A method for producing the fibrin contained semi-solid osteoblast composition has developed for treating the bone fracture. The method is comprised of: isolating osteoblasts from a bone tissue and culturing/proliferating the isolated osteoblasts in Dulbecco's Modified Eagle's Medium (DMEM) or Minimum Essential Medium, Alpha Modification (α-MEM) to prepare an osteoblast... Agent: Gwips Peter T. Kwon

20080213227 - Mesenchymal stem cells and uses therefor: Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.... Agent: Mcandrews Held & Malloy, Ltd

20080213228 - Methods and compositions for treatment of bone defects with placental cell populations: Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or... Agent: Jones Day

20080213231 - Pluripotent stem cell cloned from single cell derived from skeletal muscle tissue: Techniques are provided which can isolate pluripotent stem cells at high purity capable of differentiation into at least a myocardial cell to regenerate the cardiac muscle. The pluripotent stem cells at high purity capable of differentiation into at least a myocardial cell to regenerate the cardiac muscle can be isolated... Agent: Fitch, Even, Tabin & Flannery

20080213237 - Antigen specific lymphocytes, compositions thereof, and methods for isolation and preparation thereof: The invention relates to a method for the isolation of T cell lymphocyte, preferably, CD8+ cytotoxic T lymphocyte, which is capable of specifically recognizing an antigen related to a pathologic disorder. The method of the invention is base on ability of the CTL's to capture membrane from labeled target cells.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080213238 - Lyophilized platelet rich plasma for the use in wound healing (chronic or acute) and bone or tissue grafts or repair: This invention relates to an improved Lyophilized platelet rich plasma used to make a platelet gel wound healant, and methods of preparation and use thereof for healing wounds are disclosed. The improved wound healant comprises therapeutically effective amounts of activated growth factors, platelet ghost, plasma (know as the plasma back... Agent: Mcnair Law Firm, P.A.

20080213239 - Fatty acid formulations and methods of use thereof: The present invention provides dietary formulations comprising polyunsaturated fatty acids and vitamin E. The present invention further provides methods of treating various conditions, generally involving administering to an individual in need thereof an effective amount of a subject dietary formulation.... Agent: Bozicevic, Field & Francis LLP

20080213240 - Rac-pk as a therapeutic agent or in diagnostics, screening method for agents and process for activating rac-pk: The invention concerns RAC-PK and fragments thereof, as well as activators and inhibitors of RAC-PK for use as medicaments, particularly in the treatment of diseases concerned with abnormalities in processes modulated by insulin, such as cellular proliferation, insulin deficiency and/or excess blood sugar levels. Moreover, the invention provides RAC-PK for... Agent: Novartis Institutes For Biomedical Research, Inc.

20080213241 - Protease composition and method for treating a digestive disorder: There is provided methods, kits, combinations, and compositions comprising protease enzymes and a lipase enzyme for treating a digestive disorder in a subject in need thereof. The methods, kits, combinations, and compositions may also be used along with an agent (or combination of agents) for raising the gastric pH, a... Agent: Mayer Brown LLP

20080213242 - Composition and method for treating papilloma virus and equine sarcoids: A composition of lysozyme and a pharmaceutically acceptable carrier is active against the papilloma virus in both humans and animals. The composition can be used to treat women suffering from cervical cancer. The composition can also be used to treat cows and horses suffering sarcoids. It is emphasized that this... Agent: Norris, Mclaughlin & Marcus, Pa

20080213243 - Hemostatic materials and dressing: An adhesive material comprising gelatin and a non-toxic cross-linking material such as transglutaminase. The adhesive material is useful for medical purposes as hemostatic products. The hemostatic products are useful for the treatment of wounded tissue.... Agent: Staas & Halsey LLP

20080213245 - Enzyme treatment of foodstuffs for celiac sprue: Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.... Agent: Bozicevic, Field & Francis LLP Stanford University Office Of Technology Licensing

20080213244 - Glutamate receptor antagonists as neuroprotectives: The invention relates to the use of inhibiting agents of t-PA-mediated activation of the glutamate receptor, for example of the NMDA type, as neuroprotectives.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080213246 - Supplements for pain management: Dietary supplements, compositions and methods of administering the supplements to reduce pain, inflammation and stiffness in said mammal within a few hours. The supplements and compositions can include a combination of an amino acid, vitamins, herbs and enzymes. The composition/supplement can be put in capsule form and when administered to... Agent: Law Offices Of Brian S Steinberger

20080213254 - Bispecific molecules cross-linking itim and itam for therapy: The invention includes bispecific molecules capable of cross-linking ITAM and ITIM receptors on a cell in order to inhibit cell activation, as well as gene therapy approaches using nucleotides encoding such bispecific molecules for expression in vivo. One example of an ITAM/ITIM receptor pair is FcεRI and HM18, and another... Agent: Nikolaos C. George Jones Day

20080213253 - Combination therapy for the treatment of cancer: Disclosed are new methods for treatment of angiogenesis-related disorders. Angiogenesis-related disorders are treated by administration of a Tie1 ectodomain-binding agent and a vascular disrupting agent.... Agent: Lowrie, Lando & Anastasi, LLP

20080213255 - Determining and reducing immunoresistance to a botulinum toxin therapy using botulinum toxin b peptides: The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and... Agent: Dan G. Stathakis - T2-7h Allergan, Inc.

20080213251 - Hk1-binding proteins: The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.... Agent: Lowrie, Lando & Anastasi, LLP

20080213247 - Mbms as modifiers of branching morphogenesis and methods of use: Human MBM genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morphogenesis, comprising screening for agents that modulate the activity of MBM are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20080213248 - Methods and systems for treating asthma and other respiratory diseases: The subject invention provides methods for using TRPM8 receptors as a therapeutic target for identifying effective methods or compounds useful in the diagnosis or treatment of respiratory diseases or conditions. In certain embodiments, compositions that are identified using the methods of the invention are administered to a patient to diagnose... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080213252 - Methods of treating itch: The invention provides methods for preventing and/or treating itch in a subject in need thereof by administration of a protease-activated G-protein coupled Protease Activated Receptor 4 (PAR4) antagonist. The PAR4 antagonist can be combined with a PAR2 antagonist.... Agent: David S. Resnick

20080213250 - Use of eph receptor inhibitors for the treatment of neurodegenerative diseases: The present invention relates to methods for the screening of gamma secretase modulators, preferably inhibitors as well as to the use of Eph receptor inhibitors for the treatment of neurodegenerative diseases.... Agent: Clark & Elbing LLP

20080213249 - Use of retro-aldol reaction to generate reactive vinyl ketone for attachment to antibody molecules by michael addition reaction for use in immunostaining and immunotargeting: The present invention is directed to methods for formation of a chemically programmed antibody comprising the steps of: (1) reacting a conjugate comprising a signal module covalently linked to a proadapter with a catalytic moiety selected from the group consisting of a catalytic antibody and a Fab fragment of a... Agent: Catalyst Law Group, Apc

20080213264 - Compounds and methods for treatment and diagnosis of chlamydial infection: Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with... Agent: Seed Intellectual Property Law Group PLLC

20080213267 - Cytotoxicity mediation of cells evidencing surface expression of trop-2: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a... Agent: Mchale & Slavin, P.A.

20080213265 - Human cytomegalovirus neutralising antibodies and use thereof: The invention relates to neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes... Agent: Global Patent Group - Hmb Ms. Lavern Hall

20080213262 - Inhibition of islet amyloid polypeptide (iapp) aggregation for the treatment of type 2 diabetes: The present invention relates to the targeting and clearance of soluable unprocessed Islet Amyloid Polypeptide (hIAPP) in order to prevent the nucleation of hIAPP amyloidogenesis and to interfere with pancreatic cell death which is associated with the aggregation of hIAPP. Agents and methods for reducing hIAPP aggregation are provided herein... Agent: Klarquist Sparkman, LLP

20080213256 - Less immunogenic binding molecules: The present invention provides a bispecific binding molecule, wherein said molecule comprises or consists of at least two domains whereby one of said at least two domains specifically binds to/interacts with the human CD3 complex and said domain comprises an amino acid sequence of an antibody derived light chain, wherein... Agent: Foley And Lardner LLP Suite 500

20080213266 - Method for treating ccr4-related diseases: The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human CC chemokine receptor 4 (CCR4) and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine... Agent: Nixon & Vanderhye, PC

20080213258 - Method of predicting and reducing risk of metastasis of breast cancer to lung: A signature for breast cancer tissue derived from a patient is established that is indicative of the virulence and risk of lung metastasis by determining the expression levels to define a sample signature, and comparing this sample signature to a reference signature. The reference signature defines a standard expression level... Agent: Marina Larson & Associates LLC Re: Msk

20080213263 - Methods and compositions for treatment of immune dysfunction disorders: Methods and compositions are disclosed for modulating the immune system of animals. Applicants have identified that oral administration of immunoglobulin or plasma fractions purified from animal serum can modulate serum IgG and/or TNF-α levels for treatment of autoimmune disorders, potentiation of vaccination protocols, and improvement of overall health and weight... Agent: Schwegman, Lundberg & Woessner, P.A.

20080213259 - Methods for treating autoimmune and chronic inflammatory conditions using antagonists of cd30 or cd30l: The invention provides methods of treating autoimmnune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNFα inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering... Agent: Immunex Corporation Law Department

20080213257 - Methods for treating il-18 mediated disorders: The invention pertains to methods for treating medical disorders characterized by elevated levels or abnormal expression of IL-18 by administering an IL-18 antagonist, such as soluble IL-18 receptor, a soluble IL-18 binding protein and/or an antibody.... Agent: Immunex Corporation Law Department

20080213261 - Transdiscal administration of specific inhibitors of pro-inflammatory cytokines: The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080213260 - Use of cd23 antagonists for the treatment of neoplastic disorders: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).... Agent: Pillsbury Winthrop Shaw Pittman LLP

20080213268 - Neuropilin antagonists: Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications.... Agent: Genentech, Inc.

20080213269 - Preventive and/or treating agent for cancer: A compound or salt thereof that inhibits the activity of a protein that has an amino acid sequence that is the same or substantially the same as the amino acid sequence shown by SEQ ID NO: 1, a compound or salt thereof that inhibits the expression of the gene for... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080213271 - Compositions and methods for modulating dopamine nerutransmission: The present invention provides for diagnosis or treatment of neurological or neuropsyciatric disorders involving abnormal dopamine neurotransmission. Methods and agents are provided for modulating dopamine transporter activity and modulating dopaminergic neurotransmission. Agents of the present invention include fragments of D2 receptor or dopamine transporter (DAT) that can disrupt D2-DAT coupling.... Agent: Winston & Strawn LLP Patent Department

20080213270 - Neurotensin as a marker and therapeutic target for sepsis: Sepsis is a complex, incompletely understood and often fatal disorder, typically accompanied by hypotension, that is considered to represent a dysregulated host response to an infection. Neurotensin (NT) is 13-amino-acid peptide that, among its multiple effects, induces hypotension. It is shown herein that plasma concentrations of NT are increased in... Agent: Bozicevic, Field & Francis LLP

20080213272 - Vegf-related protein: A human VEGF-related protein (VRP) has been identified and isolated that binds to, and stimulates the phosphorylation of, the receptor tyrosine kinase Flt4. The VRP is postulated to be a third member of the VEGF protein family. Also provided are antibodies that bind to VRP and neutralize a biological activity... Agent: Genentech, Inc. Attn: Wendy M. Lee

20080213274 - Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye: The present invention relates to compositions and methods for prevention and treatment of ocular diseases and conditions characterized by aberrant fibrogenesis or scarring, inflammation and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against bioactive lipids and which are capable... Agent: Biotechnology Law Group C/o Portfolioip

20080213277 - Hepcidin, hepcidin antagonists and methods of use: The invention relates to purified, correctly folded hepcidin, antibodies that bind hepcidin, and methods of making and using such materials. Also provide are methods of treated hepcidin-related disorders.... Agent: Marshall, Gerstein & Borun LLP

20080213276 - Modulation of neural stem cells and neural progenitor cells: The invention relates generally to methods of influencing central nervous system cells to produce progeny useful in the treatment of CNS disorders. More specifically, the invention includes methods of exposing a patient suffering from such a disorder to a reagent that modulates the proliferation, migration, differentiation and survival of central... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080213273 - Single dose use of cd20-specific binding molecules: The present invention provides materials and methods for treatment of diseases involving aberrant B-cell activity using a single dose of CD20-specific binding molecule.... Agent: Marshall, Gerstein & Borun LLP

20080213275 - Use of mtki 1 for treating or preventing bone cancer: The present invention is concerned with the finding that the macrocyclic quinazoline derivative 4,6-ethanediylidenepyrimido[4,5-b][6,1,12]benzoxadiazacyclo-pentadecine, 17-bromo-8,9,10,11,12,13,14,19-octahydro-20-methoxy-13-methyl-, described as compound 22 in PCT publication WO2004/105765, is useful in the manufacture of a medicament for the treatment or prevention of bone cancers and methods for killing bone cancer cells, including osteosarcomas, chondrosarcomas, myeloma... Agent: Philip S. Johnson Johnson & Johnson

20080213278 - Method of treating disorders using compositions comprising zotarolimus and paclitaxel: A system and compositions including zotarolimus and paclitaxel are disclosed, as well as methods of delivery, wherein the drugs have effects that complement each other. Medical devices are disclosed which include supporting structures that include at least one pharmaceutically acceptable carrier or excipient, which carrier or excipient can include one... Agent: Squire, Sanders & Dempsey L.L.P.

20080213279 - Blocking leukocyte emigration and inflammation by interfering with cd99l2: The present invention provides methods and compositions for modulating transendothelial migration (TEM) of leukocytes. In particular, inhibition of TEM can provide a potent therapeutic approach to treating inflammatory conditions. The invention specifically relates to the discovery that the adhesion molecule CD99L2 mediates TEM of leukocytes. CD99L2 is present on endothelial... Agent: Darby & Darby P.C.

20080213280 - Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor: The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNFα-inhibitor.... Agent: Genentech, Inc.

20080213281 - Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents: The invention provides a butyrylchinesterase variant, a method of converting a camptothecin derivative to a topoisomerase inhibitor by contacting the camptothecin derivative with a butyrylcholinesterase variant and a method of treating cancer by administering to an individual an effective amount a butyrylcholinesterase variant exhibiting increased capability to convert a camptothecin... Agent: Eli Lilly & Company

20080213282 - Formulations: The invention provides a formulation comprising a buffer with a pH from about 4.0 to about 6.0, proline and an effective amount of a polypeptide. The polypeptide can be an antibody. The specification also provides methods of preparing the formulation, a kit containing the formulation and methods of using the... Agent: Amgen Inc.

20080213283 - Use of certain drugs for treating nerve root injury: The present invention relates to a method for treating nerve disorders in a mammal or a vertebrate by administering a TNF-alpha inhibitor. The invention also relates to the use of a TNF-alpha inhibitor in the preparation of pharmaceutical compositions for the treatment of nerve root injury and other nerve disorder.... Agent: Fish & Richardson P.C.

20080213284 - Receptor binding polypeptides: Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating... Agent: Occhiuti Rohlicek & Tsao, LLP

20080213285 - Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof: The present invention relates to secreted Chlamydia polypeptides, which may be expressed by a Gram-negative bacterial strain and secreted by the type III secretion pathway of said bacterial strain. The present invention also relates to polynucleotides coding for these polypeptides, as well as to the therapeutic and vaccination uses of... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080213288 - Combined use of a modulator of cd3 and a glp-1 compound: Methods and uses for the prevention and intervention of Type 1 diabetes comprising administration of a modulator of CD3 and a GLP-1 compound.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080213286 - Mam domain containing protein: This invention relates to a novel protein, termed INSP152, herein identified as a secreted protein, in particular, as a MAM domain containing protein and to the use of this protein and nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080213287 - Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell: A method of inhibiting infection by Flaviviridae viruses including HCV, GBC/HGV, and BVD in addition to VSV and any other virus capable of forming a complex with a lipoprotein strategies: preventing formation of a complex should one form, altering the conformation of such a complex to prevent its interaction with... Agent: David Silverstein Andover-ip-law

20080213289 - Recombinant anti-cd30 antibodies and uses thereof: The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the... Agent: Seattle Genetics, Inc.

20080213290 - Hepatitis c virus codon optimized non-structural ns3/4a fusion gene: Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions... Agent: Knobbe Martens Olson & Bear LLP

20080213291 - Malaria vaccines: The invention provides isolated placental P. falciparum polypeptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:1-4 and 6-24, and immunogenic derivatives thereof. The invention also provides isolated nucleic acid molecules encoding the placental P. falciparum polypeptides of the invention, compositions comprising one or more... Agent: Seattle Biomedical Research Institute Attn: Karen Blochlinger

20080213292 - Soluble and stabilized trimeric form of gp41 polypeptides: The present invention concerns a modified polypeptide containing at least an immunodominant region and the connecting loop between N- and C-helices of gp41 ectodomain of HIV-1, wherein the connecting loop includes at least a linker fragment having: —a size convenient for keeping the native conformation of the interaction between N-... Agent: Oliff & Berridge, PLC

20080213293 - Prevention and treatment of recurrent respiratory papillomatosis: Juvenile-onset recurrent respiratory papillomatosis is treated using active vaccination or passive immune therapy of neutralizing antibodies against HPV L2 neutralizing epitopes.... Agent: Stites & Harbison, PLLC

20080213294 - Immunization of dairy cattle with gapc protein against streptococcus infection: The GapC plasmin binding protein genes of Streptococcus dysgalactiae (S. dysgalactiae), Streptococcus agalactiae (S. agalactiae), Streptococcus uberis (S. uberis), Streptococcus parauberis (S. parauberis), and Streptococcus iniae (S. iniae) are described, as well as the recombinant production of the GapC proteins therefrom. Also described is the use of the GapC proteins... Agent: Robins & Pasternak

20080213295 - Her-2/neu fusion proteins: The present invention is generally directed to HER-2/neu fusion proteins, nucleic acid molecules encoding HER-2/neu fusion proteins, viral vectors expressing HER-2/neu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the HER-2/neu fusion proteins and/or nucleic acid molecules encoding the HER-2/neu fusion proteins. The present invention is also directed to methods... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080213296 - Immunogen: The present invention relates, in general, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.... Agent: Nixon & Vanderhye, PC

20080213297 - Method of producing conjugate vaccines: The present invention relates to a method of production of a hydrazide modified sugar comprising a step of reacting a sugar with a hydrazide in a reaction solvent at a pH of between 3 and 5.5, wherein the solvent comprises an aqueous based solvent and an optional polar organic co-solvent.... Agent: Edwards Angell Palmer & Dodge LLP

20080213298 - Herbal therapy for the treatment of asthma: The present invention provides herbal formulas, and compositions thereof, that can treat or reduce the severity, intensity, or duration of asthma and asthma-related symptoms. The compositions may optionally include one or more adjuvants, cytokines, encapsulating materials, or pharmaceutically acceptable carriers or excipients, and may be administered prior to, during, or... Agent: Choate, Hall & Stewart LLP

20080213300 - Compositions for juice-based treatment serums: The disclosure herein is directed to organic skin-based products that comprise an excess of 70% organic ingredients. The skin care products described herein are composed of a plurality of organic juices and other organic materials.... Agent: Baker & Mckenzie LLP Patent Department

20080213299 - Silver-ionized plant extraction liquid and use thereof: The present invention relates to a silver-ionized plant extraction liquid and the use thereof. Particularly, there are provided herein a silver-ionized liquid extraction liquid prepared by ionizing silver in a plant extraction liquid used as an electrolyte and an antimicrobial composition comprising the same.... Agent: Intellectual Property Law Group LLP

20080213301 - Compositions and methods for healthy pregnancy: Compositions, kits and methods for the prevention of, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure during assisted reproduction are provided. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure of... Agent: Morris Manning Martin LLP

20080213302 - Methods for treating cancer with mva: The invention relates to compositions, kits, and methods for cancer therapy using recombinant MVA viruses encoding a tumor-associated antigen, such as HER-2, particularly in combination with taxanes. The taxanes can be administered prior to, at the same time as, or after the recombinant MVA virus.... Agent: Law Office Of Salvatore Arrigo

20080213303 - Mutant forms of cholera holotoxin as an adjuvant: Mutant cholera holotoxins comprising a cholera toxin subunit A having single amino acid substitutions in the amino acid positions 16 or 72 or a double amino acid substitution in the amino acid positions 16 and 68 or 68 and 72 have reduced toxicity compared to the wild-type cholera holotoxin. The... Agent: Howson And Howson

20080213304 - Methods of treating and preventing neurological symptons caused by avian reovirus and novel associated characteristics: Embodiments of the present invention generally relate to novel methods for the treatment and/or prevention of neurological symptoms caused by an avian reovirus, enteric reovirus strain (ERS), and associated characteristics. Other embodiments generally comprise and immunogenic composition or vaccine comprising an ERS for the treatment and/or prevention of neurological symptoms.... Agent: Intervet/schering-plough Animal Health Patent Department

20080213305 - Vaccine for periodontitis and methods of use: The present invention is directed to an immunogenic composition for inducing an immune response against lysine decarboxylase for treating or preventing periodontitis in a subject. The present invention is also directed to methods for inducing an immunogenic response in a subject by administering such immunogenic composition.... Agent: Dunlap Codding & Rogers, P.C.

20080213306 - Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines: The invention provides adjuvants, immunogenic compositions, and methods useful for polynucleotide-based vaccination and immune response. In particular, the invention provides an adjuvant of cytofectin:co-lipid mixture wherein cytofectin is GAP-DMORIE.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080213307 - Monoparamunity inducers based on attenuated rabbit myxomaviruses: The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and... Agent: Law Office Of Salvatore Arrigo

20080213308 - Imidazoquinoline compounds: The invention provides novel compositions comprising imidazoquinoline compounds. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an)other agent(s).... Agent: Novartis Vaccines And Diagnostics Inc.

20080213309 - Multi-antigenic alphavirus replicon particles and methods: Viral replicon selected nucleic acid expression libraries are useful for analyzing multiple antigens associated with a parasite, pathogen or neoplasia or for preparing immunogenic compositions for generating immune responses specific for the parasite, pathogen or neoplasia. Alphavirus replicon particles representative of the nucleic acid expression library are preferred. The nucleic... Agent: Greenlee Winner And Sullivan P C

20080213310 - Use of lytic toxins and toxin conjugates: Agents are provided which are capable of inhibiting the cell division cycle in a target cell of interest. The agents comprise first and second components, wherein the first component is a targeting moiety which is capable of directing the second component to the target cell of interest. The second component... Agent: Morris Manning Martin LLP

20080213312 - Botulinum toxin treatments: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.... Agent: Allergan, Inc.

20080213313 - Botulinum toxin treatments: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.... Agent: Allergan, Inc.

20080213311 - Clostridial toxin derivatives and methods for treating pain: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting... Agent: Dean G. Stathakis (t2-7h) Allergan, Inc.

20080213315 - Clostridial toxin pharmaceutical compositions: A botulinum toxin pharmaceutical formulation free of animal derived proteins, comprising a botulinum toxin and a recombinant albumin, suitable for therapeutic administration to a human patient, and methods for treating patients with various diseases and afflictions with the formulation.... Agent: Allergan, Inc.

20080213314 - Combined dna vaccine and biological modifiers for cancer therapy: The present invention relates to the combination of a DNA vaccination strategy that makes use of a nucleic acid encoding an immunogenic polypeptide, with a non-immunosuppressive inducer of tumor cell differentiation and/or apoptosis or a tumor cell modifier, useful for cancer therapy. Vaccine compositions and kits are provided, as well... Agent: Stites & Harbison PLLC

20080213316 - Destruction of spores through glycoconjugate enhanced phagocytosis: Methods for enhancing destruction and killing of bacterial spores via phagocytosis, where phagocytosis of bacterial spores is enhanced by using a glycoconjugate. In one embodiment, the method includes the steps of modifying a surface of a bacterial spore to increase adherence to a phagocyte; and ingesting the adherence-increased spore with... Agent: Morris Manning Martin LLP

20080213317 - Avian e. coli vaccine for protection against colibacillosis: A genetic deletion mutant live E. coli vaccine suitable for mass application to poultry, including chickens, is provided. Also provided is a safe and effective method to protect poultry against the ravages of Escherichia coli bacillosis infection and disease in which a live mutant aroA-gene deleted E. coli immunogen is... Agent: Wyeth Patent Law Group

20080213318 - Malaria msp-1 c-terminal enhanced subunit vaccine: A vaccine or immunogenic composition is described that contains recombinantly produced, secreted, forms of malaria MSP-1 C-terminal subunit proteins from any of the Plasmodium falciparum strains as active ingredients combined with one or more adjuvants. The immunogenic compositions that result in a protective response are based on the use of... Agent: George E. Darby

20080213319 - Chemorepulsion of cells: The present invention provides compositions and methods of controlling the direction and/or movement of migratory cells. Specifically, the invention is directed to the identification of novel chemorepellents and unimodal fugetaxins, their agonists and antagonists which alter or affect the movement of cells involved in immune, inflammatory or cancerous phenotypes.... Agent: Elmore Patent Law Group, PC

20080213320 - Compositions for treatment of gastro-esophageal reflux disorders: The present invention provides compositions for treatment of gastro-esophageal reflux disorders. The compositions include at least two of the following: (i) one or more digestive enzymes; (ii) one or more probiotics; and (iii) stevia. Also provided are processes for preparing the compositions useful for treatment of gastro-esophageal reflux disorders, and... Agent: Brinks Hofer Gilson & Lione

20080213321 - Dermabrasion devices and systems: In general, the invention relates to the design and fabrication of devices and systems suitable for dermabrasion.... Agent: Pearl Cohen Zedek Latzer, LLP

20080213324 - Amphiphilic or lipophilic polar functionalized fullerenes and their uses: Described herein are synthetically modified fullerene molecules, wherein the fullerene is preferably ellipsoid in shape with an equatorial band and two opposing poles, comprising an adduct at one or both poles, at least one adduct being a hydrophobic chemical moiety capable of anchoring the fullerene on or in a lipid... Agent: Buchanan, Ingersoll & Rooney PC

20080213322 - Method for the hydrophobic treatment of pigment particles and the personal care compositions comprising said pigment particles: The present invention provides a method for the hydrophobic treatment of pigment particles comprising contacting said pigment particles with one or more silicone-based materials, that are substantially free of silicon-hydrogen bonds and fluorine, producing hydrophobic, non-covalently bound, modified pigment particles. Additionally, the present invention provides personal care compositions comprising said... Agent: Joann Villamizar Ciba Corporation/patent Department

20080213325 - Powder mixture consisting of titanium dioxide, zinc oxide and zinc/titanium mixed oxide: e

20080213323 - Use of active principles which are capable of enhancing the content of ceramides, as protective agent for delicate lips:

20080213326 - Method for producing aqueous active substance compositions of active substances that are hardly soluble in water: c) emulsion polymerization of a second monomer composition M2 in an aqueous dispersion of the polymer/active compound particles obtained in step b), where the monomer composition M2 comprises at least 60% by weight, based on its total weight, of at least one neutral, monoethylenically unsaturated monomer M2.1 having a solubility... Agent: Birch Stewart Kolasch & Birch

20080213327 - Method of deparasitizing and parasiticidal powder: Method using a parasiticidal powder typically comprising from 1 to 15% by weight of silica and from 85 to 99% of alkali metal bicarbonate.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080213328 - Nanosilver-containing preservation articles, and the preparation process and the uses thereof: A preservation article is provided which includes nanosilver-containing anti-bacterial granules blended with plastic materials. The granules blended with the plastic materials are present in the plastic materials in an amount of 0.1 to 0.8 weight percentage based on the weight of the plastic materials.... Agent: Rosenberg, Klein & Lee

20080213329 - Method of delivering a biologically active agent: A method of delivering a biologically active agent to a target site comprising exposing a surface of a non-target carrier organism to a carrier comprising at least one biologically active agent, wherein the non-target carrier organism delivers the biologically active agent to the target site.... Agent: Senniger Powers LLP

20080213331 - Methods and devices for renal nerve blocking: A method and apparatus for treatment of cardiac and renal diseases associated with the elevated sympathetic renal nerve activity by implanting a device to block the renal nerve signals to and from the kidney. The device can be a drug pump or a drug eluding implant for targeted delivery of... Agent: Perkins Coie LLP Patent-sea

20080213330 - Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons: A liquid pharmaceutical composition comprising a biodegradable polymer, polyethylene glycol having a molecular weight of less than 600 Daltons, a pharmaceutically active agent and less than 0.5% of an biologically acceptable organic solvent.... Agent: Novartis Corporate Intellectual Property

20080213332 - Cells isolated from placenta, device for isolating same, and uses thereof: A method of processing an organ is disclosed. The method comprises: (a) placing an organ in a sealable container; (b) disrupting the structure of said organ to yield a cell suspension; and (c) transferring said cell suspension to a sealable cell-suspension storage container, thereby isolating cells of said organ, wherein... Agent: Martin D. Moynihan Prtsi

20080213337 - Drug implant carrier for drug delivery: The present invention relates to ceramic precursor material exhibiting injectability arid properties that make the material suitable as a carrier material used in drug delivery. According to the invention this is accomplished by selecting a microstructure based on pre-reacted phases and after injection established phases, which contain anti-infective and/or anti-inflammatory... Agent: Young & Thompson

20080213335 - Graft prosthesis, materials and methods: A graft prostheses (11), materials and method for implanting, transplanting, replacing, or repairing a part of a patient. The graft prosthesis includes a purified, collagen-based matrix structure removed from a submucosa tissue source. The submucosa tissue source is purified by disinfection and removal steps to deactivate and remove contaminants, thereby... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20080213338 - Implant stent with a retinoid for improved biocompatibility: An implant device is provided which incorporates a retinoid for improving the biocompatibility of the device in tissue. The device may be bioerodible for the purpose of systemically or locally releasing a therapeutic agent in tissue or it may be a permanent implant which includes a surface treated with a... Agent: Walter A. Hackler

20080213333 - Methods and compositions for fostering and preserving bone growth: A method for augmenting bone in a subject in need thereof including installing within an interior portion of a bone located in the subject a sufficient amount of a biocompatible material to form a scaffold within the bone interior, wherein the scaffold serves as a support for the formation of... Agent: Ostrolenk Faber Gerb & Soffen

20080213334 - Polyelectrolyte media for bioactive agent delivery: The invention provides polyelectrolyte hydrogels, blends, and multilayers for the controlled release of bioactive agents from implantable medical devices coated with or containing such media.... Agent: Surmodics, Inc.

20080213336 - Polymethylmethacrylate revision bone cement: The invention relates to a PMMA revision bone cement having powder and liquid component, in which the powder component contains two or more granular antibiotics whose grain size distribution is equal in that the main screening fraction each of the individual antibiotics is in the same grain size range, in... Agent: Norris, Mclaughlin & Marcus, Pa

20080213339 - Pharmaceutical composition containing indometacin and/or acemetacin: The invention relates to a pharmaceutically active composition or pharmaceutical form of administering that contains at least one of the active ingredients indomethacin or acemetacin and optionally other adjuvants, the composition containing the active ingredient, or a mixture of the active ingredients, in micronized form, preferably mixed with at least... Agent: Hammer & Associates, P.C.

20080213341 - Butyric acid esters of carbohydrates and carbohydrate polyols: The invention relates to butyric acid esters or butyrate esters of carbohydrates and carbohydrate polyols and their use as a butyrate carrier and butyrate source for the gastrointestinal tract, in particular for the prevention and treatment of diseases of the gastrointestinal tract, especially of the large intestine.... Agent: Ostrolenk Faber Gerb & Soffen

20080213340 - Transformed plant cell expressing tandem repeats of beta-amyloid gene and plant produced by the same: The present invention relates to a transformed plant cell expressing β-amyloid gene, which is known as a causal substance of senile dementia in human, a transformed plant and a preparation method of the same, more particularly, to a transformed plant cell expressing tandem repeats of β-amyloid gene, a transformed plant... Agent: Licata & Tyrrell

20080213342 - Hop acids as a replacement for antibiotics in animal feed: A method of using hop acids for increasing food and energy uptake from feed by livestock is described which includes delivering the hop acids for oral ingestion to the animals by mixing the acids with livestock feed. The acids are mixed with the feed in an amount to inhibit certain... Agent: Edwards Angell Palmer & Dodge LLP

20080213343 - Oral, quickly disintegrating film, which cannot be spit out, for an antiemetic or antimigraine agent: Film-form, single-layered, cavity-free preparation free of surfactants, effervescent additive and taste masker and comprising one or more film former(s), one or more gel former(s) and one or more active ingredient(s) from the group of anti-emetics and anti-migraine agents.... Agent: Licata & Tyrrell P.C.

20080213344 - Wound dressing and method for controlling severe, life-threatening bleeding: This invention is directed to advanced hemorrhage control wound dressings, and methods of using and producing same. The subject wound dressing is constructed from a non-mammalian material for control of severe 5 bleeding. The wound dressing for controlling severe bleeding is formed of a biomaterial comprising chitosan, a hydrophilic polymer,... Agent: Ryan Kromholz & Manion, S.c.

20080213348 - Agents for gene therapy of cerebrovascular disorders: The present invention provides novel methods for treating cerebrovascular disorders, in which HGF is overexpressed by introducing an HGF gene. The methods of this invention using an HGF gene enable active treatment of cerebrovascular disorders, such as cerebral infarction, by gene transfer, and enable the maintenance of neuronal function and... Agent: Klarquist Sparkman, LLP

20080213351 - Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease: The present invention relates to pharmaceutical compositions comprising liposomes and methods of using such liposomes to prevent, treat, or manage a variety of diseases and/or bodily conditions. The liposomes may comprise large unilamellar vesicles (LUVs) alone or in combination with multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or other therapeutics.... Agent: Jones Day

20080213345 - Delivering iron to an animal: The invention provides a method for delivery iron to an animal. This invention further provides a method for treating iron deficiency in an animal.... Agent: Viksnins Harris & Padys Pllp

20080213350 - Encapsulation of nucleic acids in liposomes: Complexes of nucleic acid and cationic polymer, which are encapsulated in liposomes for the purpose of delivering nucleic acid and methods for producing encapsulated complexes.... Agent: Jackson Walker LLP

20080213352 - Liposome carriers for in vivo delivery of fullerenes: Described herein are pharmaceutically acceptable compositions comprising fullerene molecules dispersed in vesicles comprising phosphatidylcholine (PC) phospholipid molecules and non-PC phospholipid molecules suspended in aqueous solution. In preferred embodiments, the phospholipid molecules are substantially uniformly organized into vesicles composed of one or more lipid bilayers and the fullerene molecules are substantially... Agent: Buchanan, Ingersoll & Rooney PC

20080213349 - Liposome complexes containing pharmaceutical agents and methods: Liposome complexes are provided for site-specific delivery of pharmaceutical agents with improved targeting efficiency. The liposome complexes include a pharmaceutical agent associated with the liposome; a sialic acid-containing molecule associated with the liposome; and optionally a targeting agent attached to the sialic acid-containing molecule. The invention also provides methods of... Agent: Medtronic, Inc.

20080213353 - Method for preparing liposome formulations with a predefined release profile: The present invention provides a novel tool for designing a release profile of an active agent from a liposome in to which it is loaded. According to the invention, a method is provided for preparing a liposomal formulation for delivery of an active agent to a target, the release of... Agent: Nath & Associates

20080213347 - Novel ligand antagonists of rar receptors and pharmaceutical/cosmetic applications thereof: e

20080213346 - Preparation of nanoliposome-encapsulating proteins and protein-encapsulated nanoliposome: Preparing a nanoliposome for encapsulating a protein includes preparing a dispersion by dispersing a phospholipid in an aqueous solution containing the protein, applying a shearing force to the dispersion; adding an additional amount of the phospholipid to the result of the step of applying the shearing force to the dispersion... Agent: The Rafferty Patent Law Firm

20080213356 - pharmaceutical composition containing hmg-coa reductase inhibitor and method for the preparation thereof: The present invention relates to the formulation of solid dosage forms comprising a therapeutically effective amount of an HMG-CoA reductase inhibitor, and especially Fluvastatin or Atorvastatin or salts thereof, in combination with inorganic silica polymer such as Dimethicone, and a process for the preparation thereof by direct compression.... Agent: Akc Patents

20080213355 - Method and system for in vivo drug delivery: A system and method for polymeric drug delivery vehicles activated by ultrasound is disclosed herein. The system and method include polymeric particles, partially filled with a gas or a gas precursor, and partially filled with a liquid containing a drug. The drug is then released locally by application of ultrasound.... Agent: Philips Intellectual Property & Standards